Identifying FoxA1 Interacting Partners: Insight into Androgen Regulated Prostatic Genes by Sun, Qian
IDENTIFYING FOXA1 INTERACTING PARTNERS: INSIGHT INTO 
ANDROGEN REGULATED PROSTATIC GENES 
 
By 
 
QIAN SUN 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements 
for the degree of 
DOCTOR OF PHILOSOPHY 
in 
Cancer Biology 
May, 2010 
Nashville, Tennessee
 
Approved: 
Professor Sarki A. Abdulkadir 
Professor Robert J. Matusik 
Professor Jennifer A. Pietenpol 
Professor David L. Hachey
CANCER BIOLOGY 
 
IDENTIFYING FOXA1 INTERACTING PARTNERS: INSIGHT INTO  
ANDROGEN REGULATED PROSTATIC GENES 
 
QIAN SUN 
 
Dissertation completed under the direction of Dr. Robert Matusik, PhD 
This research project is to identify FoxA1 interacting partners. In this study, a 
potential FoxA1 binding partner, Upstream Stimulatory Factor 2 (USF2), has been 
examined; its DNA binding activity was determined and the function of USF2 was 
monitored in USF2 knockdown LNCaP cells. FLAG-6His-FoxA1 stable expressing 
LNCaP cell lines were established. The FoxA1 protein complex from LNCaP 
tagged-FoxA1 cells was purified and analyzed by Liquid Chromatography Tandem Mass 
Spectrometry. 
 
 USF2 has been confirmed to interact with FoxA1 using ImmunoPrecipitation and 
glutathione-S-transferase pull-down assays. Our study also indicates, as FoxA1, USF2 
binds to prostatic specific gene promoters such as probasin promoter, Spermine Binding 
Protein promoter, and the Prostate Specific Antigen core enhancer. PSA mRNA levels 
were increased in USF2 knocked down LNCaP cells compared with control LNCaP cells 
when the LNCaP cells were treated with DHT (10-8 M).  
 
Using LC-MS/MS analysis, a total of 16 proteins that appear to interact with Foxa1 
have been identified and eight of them have been previously reported as AR interacting 
proteins. Further work is needed to confirm the binding between FoxA1 and these 
identified proteins and to perform functional studies of the confirmed FoxA1 binding 
partners. 
 
This study has identified FoxA1 interacting partners which helps unravel the critical 
transcription factors that control cell type specific gene expression and to further 
understand the role of FoxA1 during prostate development. This work gives us an insight 
into the essential mechanism of androgen regulation of the prostate gland and of 
hormonal regulation of prostate cancer. 
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CHAPTER I 
 
INTRODUCTION 
 
Prostate Overview 
A. Prostate Structure and Function 
The prostate is an accessory gland of the male reproductive system. The gland is 
slightly larger than a walnut and it surrounds the urethra as it leaves the bladder 
(Aumueller et al., 1994). The prostate consists of glandular tissue and muscle tissue. The 
glandular tissue produce about 20% of seminal fluid and other substances including 
proteins such as proteolytic enzymes, prostatic acid phosphatase, prostate-specific 
antigen and a high concentration of zinc (Aumuller and Seitz, 1990). Although those 
secretions are necessary for fertility, many of the functions of these proteins are unknown 
(Aumuller and Seitz, 1990). The muscle tissue in the prostate help expel the prostatic 
fluid in ducts. 
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Figure 1. The adult prostate structures. The prostate is below the bladder and wraps 
around the urethra. The three zones of prostate are central zone, transitional zone, and 
peripheral zone. Image taken from  
http://www.prostate-cancer.org/education/sidefx/Hai_PhotoselectiveVaporization.html
 
 
The prostate can be divided into three zones based upon anatomy and histology: 
peripheral zone, central zone, and transition zone (Figure 1) (Kumar and Majumder, 
1995). The peripheral zone is a large area of the prostate gland that is located in the back 
of the prostate gland and surrounds the distal urethra (Kumar and Majumder, 1995). More 
than 50% prostate cancer, specifically prostatic adenocarcinoma, develops in this area. 
The central zone is located in the base right beneath the bladder and surrounds the 
ejaculatory ducts (Kumar and Majumder, 1995). Prostate cancer in this zone tends to be 
more aggressive even through the chance of developing prostate cancer in this zone is 
very low. The transition zone is a small area that is located in the internal part of the 
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prostate; it surrounds the proximal urethra (Kumar and Majumder, 1995). Prostate cancer 
can also occur in this zone and over growth of this zone as well as the central zone can 
lead to the disease of benign prostatic hyperplasia. 
 
B. Prostate Diseases 
Prostatitis. Prostatitis is an inflammation of the prostate gland that can cause pain in 
the groin, painful and difficult urination (De Marzo et al., 2007). Some forms of 
prostatitis that are related to bacterial infections are well studied and can be treated 
effectively. Most forms of prostatitis are not well understood and are difficult to diagnose 
and treat. There are mainly four categories of prostatitis: 1. acute prostatitis, 2. chronic 
bacterial prostatitis, 3. chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), and 4. 
asymptomatic inflammatory prostatitis (Hua and Schaeffer, 2004; Rivero et al., 2007; 
Simardi et al., 2004). Acute prostatitis and chronic bacterial prostatitis are both due to 
bacterial infection of prostate gland (De Marzo et al., 2007). More than 90% prostatitis 
patients are diagnosed as CP/CPPS, also known as chronic nonbacterial prostatitis with 
pelvic pain. Asymptomatic inflammatory prostatitis patients usually have leukocytosis 
symptoms, but barely have genitourinary pain (Simardi et al., 2004). 
 
BPH (Benign Prostatic Hyperplasia). When males are in their 50’s the prostate gland 
may start to enlarge. Studies show that about 50% of the men over 50 have an enlarged 
prostate. The benign overgrowth of the prostatic stromal and epithelial cells is so called 
Benign Prostatic Hyperplasia. When the prostate grows continuously, eventually the 
gland can no longer grow outwardly due to being restricted by the layer of tissue that 
surrounds the gland, so the gland will grow inwardly, pinching the urethra. When the 
 4
urethra is pinched, the flow of urine is obstructed, and the bladder experiences back 
pressure, which would cause the bladder wall to become thicker and more irritable. The 
bladder will start contracting more frequently (frequent urge to urinate), and eventually, 
the bladder is weakened substantially and unable to empty all its content. 
 
The cause for BPH is not known, but many potential factors are thought to contribute 
to BPH (Isaacs and Coffey, 1989). Androgen is considered to be a passive factor in 
causing BPH, since BPH cannot occur in the absence of androgen and applying extra 
androgen does not aggravate the symptoms of BPH. In particular, dihydrotestosterone 
(DHT), a substance derived from testosterone in the prostate, is thought to play a main 
role in BPH (Isaacs and Coffey, 1989). Even as testosterone drops in older men, DHT can 
continue to be produced and stored substantially in the prostate. DHT can encourage cell 
growth in the prostate (Isaacs and Coffey, 1989).  It has been observed that older men 
that do not produce DHT do not develop BPH. 
 
Prostate Cancer. The most common prostate cancer is adenocarcinoma. At the 
beginning cancer grows in the interior of the prostate. Early stage prostate cancer is not 
lethal and can usually be treated successfully. The cancer cells can spread to surrounding 
tissues, such as the seminal vesicles and bladder and may metastasize to other parts of the 
body, particularly the bones and lymph node (Coffey and Pienta, 1987). The metastasized 
tumors are often lethal. Prostate cancer is the most common cancer in men and is the 
second leading cause of cancer death and the leading type of new cancer in American 
males. Although the causes of prostate cancer are not completely understood, several 
factors may contribute to prostate cancer: 
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1. Age. Overall, cancer is an aging disease, so age is the strongest risk factor associated 
with prostate cancer (Greenlee et al., 2001). Most prostate cancers are found after age 
50 and the onset of cancer increases rapidly as the age increases. 
 
2. Race. Studies have found that the possibility of getting prostate cancer is different in 
different races. Lower incidence of prostate cancer is found in Asian and 
Hispanic/Latino men than in non-Hispanic whites (Gann, 2002). African-American 
men have the highest risk of being diagnosed with prostate cancer and are more likely 
to die of prostate cancer. The reasons for the racial differences are not clear. 
 
3. Family history. Like most cancers, inherited genes have been found and seem to be 
related to prostate cancer risk. These genes or genetic factors can be inherited, so a 
man having a father or brother or other relatives with prostate cancer may have a high 
risk of developing this disease (Gann, 2002). For example, MSMB, a gene coding for 
beta-microseminoprotein, and POU5F1P1, a processed pseudogene homologous to 
the pluripotency factor OCT4 have been identified recently as candidate susceptibility 
genes for prostate cancer in genome-wide association studies (Kote-Jarai et al., 2010). 
The over-expression of these genes in prostatic carcinoma in addition to their 
genomic location and the putative function of their gene products render them good 
candidates to harbour functional genetic variants which modulate prostatic cancer 
susceptibility. 
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4. Diet. Studies have found that Asian men are less likely of getting prostate cancer than 
American men, but for American born Asian the risk of getting prostate cancer is the 
same as American men within several generations (Lee et al., 2007). The facts 
indicate that diet may be one of the risk factor for prostate cancer. Men who eat more 
red meat or high-fat dairy products appear to have a higher chance of getting the 
disease. 
 
5. Inflammation and infection. Studies have found that inflammation is often observed 
in the prostate tissues that are cancerous. Even though the link between the two is not 
very clear, some evidence suggests that inflammation of the prostate gland may be 
considered as a risk factor of prostate cancer. Sexually transmitted infections may 
also increase the risk of prostate cancer, like gonorrhea or chlamydia, which can 
cause prostate inflammation.  
 
 
Figure 2. Human prostate cancer progression pathway. Progression stages of 
prostate cancer are correlated with specific gene changes. (Abate-Shen and Shen, 
2000) 
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It is not clear how prostate cancer initiates. More research has been done to 
understand how the cancer progresses and to analyze chromosomal alterations during the 
progression. Stages of the progression are correlated with losses and/or gains of specific 
chromosome regions (Figure 2). Studies have found that loss of chromosomes 6q, 7q, 8p, 
10q, 13q, 16q, 17p, and 18q are frequently identified in prostate cancer patients, which 
may correlate with the loss of candidate tumor suppressor genes (Latil et al., 1994; 
Zenklusen et al., 1994; Takahashi et al., 1995; Cooney et al., 1996; Cunningham et al., 
1996; Elo et al., 1995; Latil et al., 1997; Saric et al., 1999).  
 
At the early stage of prostate cancer, when carcinoma is limited in the prostate 
capsule, surgery and radiation therapy are routinely used. Localized disease usually has a 
high survival rate. Prostate cancer can develop to more aggressive stages characterized by 
local invasion of the seminal vesicles and even metastasis to the bone or lymph nodes. 
Androgen ablation is the therapeutic choice for these advanced diseases. Prostate cancer 
always progresses to androgen independent disease after hormone ablation therapy and 
become more aggressive and results in lethality. 
 
Prostate Development and Hormone Regulation 
A. Prostate Development 
The urogenital sinus develops from endodermal cells to form the prostate. Several 
glandular and non-glandular components tightly fused within a capsule to form the adult 
prostate gland, which develops from the condensation of mesenchyme, urethra and 
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Wolffian ducts. At the early weeks of human fetal development, the male and female 
urogenital systems are identical. During the 9th week of the embryonic development, the 
wall of the proximal portion of the male urethra represents the prostate glands. At week 
10, the epithelial buds in the presumptive prostatic urethra are induced by the androgen 
responsive urogenital sinus mesenchyme. Initially, solid epithelial cell develop into buds 
and grows into the surrounding mesoderm, this presents the presumptive peripheral 
glandular area. Later, the budding gives rise to the internal glandular area and keeps 
extending and branching under mesodermal control. Lumens starts to form within the 
epithelial cords and cellular end buds form primitive acini by the 11th week. 
Mesenchymal cells differentiate into smooth muscle, fibroblasts and blood vessels. 
During the 12th week, the epithelium continues to grow and proliferate and the stroma of 
the gland becomes thinner while the ducts and acini expand. At week 13~15, the 
embryonic testosterone level have reached its peak, the cuboidal epithelial cells start to 
differentiate by interacting with androgen mediated mesenchyme. At first, the proximal 
regions of the large ducts progress distally. At the end of the 15th week, the secretory 
cells are functional; the basal cells have developed and scattered neuroendocrine cells are 
present. The gland keeps developing and matures as the embryonic testosterone levels 
elevate. When the testosterone levels fall during the third trimester, the gland enters a 
quiescent state. 
 
The quiescent state lasts until puberty, when the testosterone levels increase again 
and epithelium proliferates and gives rise to the complex folding in the mature gland. The 
prostate size will double in size during puberty and the epithelial cells will express 
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androgen regulated factors and the gland will reach its full secretory state. By 45 to 50 
years, the testosterone levels drop again and the prostate undergoes a period of mild 
involution. 
 
 
 
 
 
Figure 3. The male endocrine pathway. The hypothalamus releases LHRH, which 
stimulates the pituitary to generate LH and ACTH. LH stimulates the testis to produce 
testosterone, while ACTH stimulates adrenal glands to synthesize adrenal androgens. 
Both testosterone and adrenal androgens can target the prostate. In addition, androgens 
also function as a negative feedback to the pituitary and the hypothalamus to control 
hormone production. (Krongrad and Droller, 1993) 
 
  
B. Prostate Hormone regulation 
Androgen plays an important role in prostate development. The maturation of 
prostate is stimulated by androgens (testosterone) that are primarily secreted by the testis 
and a small amount that is secreted by adrenal glands (referred to as the adrenal 
androgens). The endocrine pathway that ultimately results in synthesis of androgen 
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begins in the hypothalamus. The hypothalamus synthesizes and releases Lutenizing 
Hormone Releasing Hormone (LHRH), which stimulates the pituitary to secret 
Lutenizing Hormone (LH) and Adrenocorticotropic Hormone (ACTH). LH stimulates the 
testis to release testosterone and ACTH stimulates the adrenal glands to produce the 
adrenal androgens such as testosterone, dihydroepiandrosterone (DHEA), DHEA sulfate, 
and androstenedione. Both the testicular and adrenal androgens stimulate the prostate, but 
testosterone is responsible for the primary effects (Figure 3). Testosterone circulates in 
the blood either bound to albumin or sex-hormone binding globulin or freely by itself. 
The free testosterone can cross the plasma membrane and reach the prostate by diffusion. 
The testosterone will be converted to DHT by the enzyme 5 alpha-reductase. DHT is the 
most active androgen that can bind the androgen receptor (AR). AR is part of the 
superfamily of nuclear receptors which functions by binding small cytoplasmic steroid or 
non-steroid ligands. AR contains a DNA binding domain, a hinge region, a hormone 
binding domain, and a N-terminal variable domain. When AR is inactive, it is associated 
with heat shock proteins and located in cytoplasm. When DHT binds to the androgen 
receptor, the heat shock proteins are released. The ligand-binding AR dimerizes and 
translocates to the nucleus to bind androgen responsive elements in DNA and thus to 
activate transcription of target genes which involved in the growth and survival of the cell 
(Figure 4). 
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Figure 4. AR action in the prostate. DHT binds AR and causes the release of 
heat shock protein. Ligand binding induces receptor dimerization followed by 
translocation to the nucleus. Dimerized AR and AR coactivator together bind to 
androgen-response element in the promoter region of androgen-regulated genes 
to active the genes and lead to biological responses. (Debes and Tindall, 2004) 
 
 
Androgen and AR are critical for prostate development and normal prostate function 
(Abate-Shen and Shen, 2000; Heinlein and Chang, 2004; Cunha et al., 1987; Roy et al., 
1999; Yeh et al., 2002). In AR knockout mice or testicular feminized mice or mice with 
inactivating mutations of AR, the prostate does not develop (Heinlein and Chang, 2004; 
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Cunha et al., 1987; Yeh et al., 2002; Quigley et al., 1995; Lyon and Hawkes, 1970). In the 
mature prostate, the proliferation and differentiation of the prostatic epithelial cells is 
mainly regulated by androgens (Feldman and Feldman, 2001; Heinlein and Chang, 2004; 
Cunha et al., 1987). Androgens promote cell survival and inhibit apoptosis (Feldman and 
Feldman, 2001; Heinlein and Chang, 2004). To maintain the normal size of the prostate 
gland, the number of cells that undergo proliferation and apoptosis have to be kept in 
balance. 
 
AR is required for normal prostate function and is expressed in PIN and early 
carcinoma, advanced carcinoma, and metastatic carcinoma. Androgens regulate the 
proliferation rate of epithelial cells, which become the adenocarcinoma. So androgens 
that increase AR activity may result in uncontrolled cell proliferation of the cancer.  
PSA, an androgen regulated gene, can be monitored in the bloodstream as a marker for 
prostate cancer. 
 
Initially, the prostate cancer growth is dependent on androgens; when androgens are 
removed, the tumor undergoes apoptosis and regression. When Clarence V. Hodges and 
Charles B. Huggins reported this observation in 1941, androgen ablation therapy was 
used to treat prostate cancer patients and it was very effective for a certain period of time 
(Huggins and Hodges, 1941; Taplin et al., 1995; Brewster and Simons, 1994). However, 
most of the tumors eventually become refractory to androgen ablation and develop into 
androgen-independent tumors. The mechanisms behind this progression is still not very 
clear, it appears to vary from patient to patient and has been difficult to study. 
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The mechanisms for the development of Castration Resistant Prostate Cancer (CRPC) 
can be divided into main two pathways: one involves the androgen receptor and another 
bypasses the androgen receptor (Figure 5) (Grossmann et al., 2001; Debes and Tindall, 
2004). When the androgen receptor remains involved in prostate cancer cells survival, 
then AR amplification, AR mutations, alteration of AR coactivators or deregulation of 
growth factors/cytokines may occur (Feldman and Feldman, 2001): 
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Figure 5. Androgen-Independent Progression of Prostate Cancer. Multiple 
mechanisms for a cancer cell to escape androgen deprivation therapy and become 
androgen independent. (Debes and Tindall, 2004) 
 
 
1. Amplification of AR functions to enhance the AR response to low levels androgen. 
Androgen receptor gene amplification is observed in about a third of patients with CRPC, 
but not in hormone dependent prostate cancer patients. The AR gene amplification causes 
the overexpression of the androgen receptor and the receptors can response to low levels 
of androgens (See review by Debes and Tindall (Debes and Tindall, 2004)). Interestingly, 
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studies have found that the CRPC patients with amplification of the androgen receptor 
gene survive longer than patients without amplification of the gene (Debes and Tindall, 
2004). 
 
2. Mutation of AR results in its binding of other ligands or antiandrogens. The 
androgen receptor gene in androgen-independent tumors may have mutations, which can 
increase the number of ligands that can activate the receptor (Debes and Tindall, 2004). 
In normal prostate cells AR is activated by DHT, when it is mutated AR can respond to 
other steroids or antiandrogens which could activate the downstream gene expression 
(Debes and Tindall, 2004). This mechanism accounts for failure to respond to therapy in a 
small portion of CRPC patients. 
 
3. Overexpress of AR coactivators. The AR action pathway in prostate involves 
different coactivators, growth factors or cytokines which could facilitate the activation of 
androgen receptor. In some CRPC patients, several growth factors such as insulin-like 
growth factor I or cytokines such as interleukin-6 or other activators have been found to 
be overexpressed (Debes and Tindall, 2004). 
 
Another type of pathways that androgen-dependent prostate cancer cells use to 
survive is to completely bypass the androgen receptor. There are two subtypes: 
1. Neuroendocrine cells. In androgen-independent prostate cancer neuroendocrine 
cells are more widespread compared to androgen-dependent prostate cancer. 
Neuroendocrine cells have a higher survival rate than epithelial cells during most 
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chemotherapy, endocrine and radiation treatments due to their low proliferation rate. The 
proliferation of cancer cells that surrounding the neuroendocrine cells is stimulated by the 
neuropeptides secreted by the neuroendocrine cells (Debes and Tindall, 2004). 
 
2. Deregulation of apoptotic genes. The tumor suppressor gene PTEN and the 
antiapoptotic gene Bcl-2 play critical roles in androgen-independent prostate cancer. In 
normal prostate cells, PTEN inhibits the phosphatidylinositol 3-kinase pathway and 
allows cells to undergo apoptosis. Loss of PTEN function is always found in 
androgen-independent prostate cancer patients and the inactivation of PTEN increases 
Akt activity to block apoptosis (Debes and Tindall, 2004). Studies have shown that 
androgen ablation can cause the overexpression of Bcl-2, which increases cells survival 
(Debes and Tindall, 2004). 
 
Tissue-specific gene expression 
 The development of a complex eukaryote requires differential transcription of over 
20,000 genes in precise spatial and temporal patterns (Carey, 1998). How could an 
organism have such diversity while simultaneously maintaining cell specificity and 
responding dynamically to its environment? In 1974 Gierer proposed the paradigm of 
combinational gene control which assumes that the regulatory protein added to each new 
cell must be self-perpetuating, giving that cell a memory (Gierer, 1974; Alberts et al., 
1994). The regulatory proteins added during development need not initially change gene 
expression but may await the expression of a final regulatory protein which then 
dispatches the cell to its final transformation. This cascade can account for cell 
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determination where the cell is assigned a developmental fate, and subsequently cell 
differentiation where the assigned cell now emerges with its own unique character. As 
few as twenty-five regulatory proteins can potentially specify 10,000 different cell types 
(Alberts et al., 1994). Thus, the regulatory proteins need not be unique. Rather, they must 
appear in the proper combination of multiple factors to result in tissue-specific expression 
(Gierer, 1974). This view has evolved through our understanding transcriptional synergy 
(Figure 6) (Carey, 1998; Brivanlou and Darnell, Jr., 2002; Fry and Peterson, 2002). A 
rough estimation suggests that 2000-3000 transcription factors exist in mammals. They 
are: 1) general transcription factors that are ubiquitously distributed and constitutively 
important for most genes; 2) conditional transcription factors that are signal-dependent, 
such as steroid receptors; 3) cell specific factors that are restrictively distributed and 
expressed in certain cell types during development (Brivanlou and Darnell, Jr., 2002). 
Combinatory use of these factors could lead to an exponentially large number of 
regulatory decisions, ensuring that each gene is expressed in the right place and at the 
right time under a unique regulation (Carey, 1998). 
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Figure 6. Positive-acting transcription factors. (Matusik et al., 2008) 
 
  
In the regulatory regions of some well characterized genes, multiple proteins are 
required to act on the same “enhanceosome” for optimal and specific gene expression. 
The underlying mechanisms for cell specific gene expression are currently under active 
studies. Several transcription factors that are specific for pituitary (Sornson et al., 1996), 
muscle (Arnold and Winter, 1998), testis (Xu et al., 1994), mammary gland (Wakao et al., 
1992), and prostate (Bieberich et al., 1996; Oettgen et al., 2000) have been described. For 
example, the rat prolactin (rPRL) gene promoter has been well characterized. The 
expression of rPRL gene, which is restricted to the pituitary glandular cells, is under a 
stringent tissue-specific control. The rPRL gene expression is cell-specific and 
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hormone-dependent, which result from the regulation of both cell-specific and ubiquitous 
transcription factors (Gourdji and Laverriere, 1994). Pituitary-specific transcription factor 
Pit-1 and LSF-1 together with ubiquitous TFs Oct-1, BTF, F2F, and ER are binding at the 
distal enhancer and/or proximal promoter of rPRL gene to regulate the gene expression 
(Bodner et al., 1988; Jackson et al., 1992; Gutierrez-Hartmann et al., 1987; Ingraham et 
al., 1988; Maurer and Notides, 1987; Waterman et al., 1988; Day and Maurer, 1989). 
When the minimal DNA promoter elements necessary to control tissue specificity have 
been defined in species ranging from drosophila to man, the complete cascade will appear 
to require four to eight regulatory proteins, with the mean being only five regulatory 
proteins (Arnone and Davidson, 1997). 
 
Cell determination for the reproductive glands occurs in the embryo but the final 
stages of cell differentiation take place after birth and during sexual maturation. For 
example, androgen resistance prevents normal embryonic and pubertal development of 
the genotypic male. Mutations in the androgen receptor result in androgen insensitivity 
syndrome (AIS, formerly termed Tfm) where patients are genotypic males but the 
resulting phenotype is female or they may appear with ambiguous external genitalia 
(Kazemi-Esfarjani et al., 1993; Pinsky et al., 1992; Brown et al., 1990; Wiener et al., 
1997). In Tfm mice, the Wolffian ducts degenerate and a female-like urethra, a shortened 
vagina, and external female genitalia develop in the male. The Tfm mice never develop 
prostates. Clearly, the androgen receptor plays a vital role in the development of the male 
reproductive tract (Sugimura et al., 1986). The role differs in mesenchymal and epithelial 
cells. Since the Tfm mouse reflects the AIS human phenotype, the mouse model permits a 
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dissection of the critical role that the mesenchymal-epithelial cell interactions play in 
organogenesis (Philip et al., 1994; Cunha, 1994). Cunha’s seminal work showed that Tfm 
mesenchymal cells, when recombined with wild type epithelial cells from the urogenital 
sinus (UGS) and implanted into the kidney capsule, would histologically develop into an 
organ that was vaginal-like whereas wild type UGS mesenchymal cells combined with 
Tfm epithelial cells would result in a differentiated prostate (Cunha and Lung, 1978). 
Cunha went on to prove that female vaginal stroma could direct epithelium to form a 
prostate in response to androgens but that these vaginal stromal cells increasingly lost this 
ability when the newborn mouse reached 20 days of age. However, vaginal epithelium 
could always be converted to a ductal prostate structure by UGS mesenchymal cells in 
the presence of androgens (Cunha et al., 1980). Therefore, the androgen receptor is a 
critical trigger in the mesenchymal cells (UGS or newborn vaginal) to induce prostatic 
ductal growth and epithelium differentiation (Hayashi et al., 1993; Donjacour and Cunha, 
1993). However, AR must function with other TFs to determine prostate function since 
many organs contain AR but do not express prostatic genes. This process is completed 
during sexual maturation (Cunha et al., 1987). 
 
Prostatic cell determination during prostate development involves the establishment 
of unique regulatory programs that eventually lead to cell differentiation resulting in 
prostate-specific gene expression. Several genes, such as prostate specific antigen (PSA), 
PB, prostatic steroid-binding protein gene C3 (1), prostate-specific membrane antigen 
(PSMA), human glandular kallikrein 2 (hKLK2), prostate-specific transglutaminase gene, 
and prostatic acid phosphatase (PAP) are almost exclusively expressed in prostate. These 
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genes provide unique insight to prostate specific gene expression. Schuur et al first 
described three regions located at the upstream enhancer (-4.8kb to -3.8kb) of PSA gene 
that showed prostate-specific binding (Schuur ER et al., 1996). The core enhancer region 
(-4168 to -3801bp) of PSA was further characterized as a highly AR-responsive and 
prostate-specific element (Cleutjens et al., 1997; Huang et al., 1999). Farmer et al. 
showed that this element interacts with a prostate-specific factor and is essential for 
maximal activation of PSA in transient transfection assays (Farmer et al., 2001). Similarly, 
using in vitro protein-DNA interaction analyses, Celis et al. found that an unidentified 
prostate-specific factor bound to an A/T rich DNA element in the first intron of PBP C3 
(1) subunit gene (Celis et al., 1993). These observations indicated the existence of factors 
that are involved in prostate-specific regulation although the corresponding factors have 
not yet been identified. These early results are supported by several recent discoveries. 
The prostate derived ets factor (PDEF) was recently described as a novel prostate-specific 
transcription factor that activates PSA gene expression (Oettgen et al., 2000). However, 
more recent observations pointed out that PDEF is also overexpressed in human breast 
tumors (Ghadersohi and Sood, 2001). Nkx-3.1, a homeobox gene, serves a negative role 
(Bhatia-Gaur et al., 1999). Phenotypic analyses of Nkx-3.1 knockout mice demonstrated 
prostate epithelial hyperproliferation (Bhatia-Gaur et al., 1999). A more recent yeast two 
hybrid screen surprisingly showed that Nkx-3.1 interacts with PDEF and regulates PSA 
promoter antagonistically (Chen et al., 2002). These findings provide promising 
prospects for identifying factors contributing to tissue specificity (See review by Matusik 
et al. (Matusik et al., 2008)). 
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Prostate Specific Gene Expression 
A. Probasin and probasin promoter. 
Probasin (PB: PROstatic BASic protein) was identified in the rat dorsolateral 
prostate lobes as a protein of 177 amino acids with an isoelectric point of 11.5. It is 
specifically expressed in prostatic epithelial cells (Matuo et al., 1982; Yamamoto et al., 
1989). The PB gene contains 7 exons (Kasper and Matusik, 2000) and the alternative use 
of an initiation codon can produce either a secreted protein with a signal peptide or a 
nuclear protein without the signal peptide (Spence et al., 1989). The PB protein belongs 
to the lipocalin superfamily of proteins, it shares the lipocalin conserved motifs such as 
the glycine-X-tryptophan (G-X-W) sequence, the C-X-X-X-C sequence (Newcomer, 
1995; Du and Prestwich, 1995), and two conserved cysteines. It most closely shares the 
similar amino acid sequence and tertiary structure of the lipocalins that include 
aphrodisin, rat odorant binding protein, rat alpha2 urinary globulin, mouse major urinary 
globulin, retinol binding protein and bovine beta-lactoglobulin (Kasper and Matusik, 
2000). All of the lipocalin proteins have eight antiparallel beta-sheets with a beta-barrel 
core binding the hydrophobic ligands. Since aphrodisin, OBP, rat alpha2 urinary globulin 
and MUP are pheromone carriers, it is reasonable to postulate that PB may be a 
pheromone carrier as well, although the ligand of PB is still unknown (Kasper and 
Matusik, 2000). 
 
Although the protein function of PB is unknown, the promoter of the PB gene has 
been well studied and the prostate-specificity of this gene promoter can be used as a tool 
to direct gene expression to the prostate. The Chloramphenicol Acetyltransferase (CAT) 
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reporter gene driven by a -426PB promoter showed specific and high expression in 
human prostate cell lines (LNCaP and PC-3), but negligible expression in non-prostate 
cell lines (HepG2, MCF-7, CHO, BL13) by in vitro experiments (Brookes et al., 1998). 
In vivo experiments indicate that the large PB promoter fragment (~12 kb or the artificial 
promoter) (Yan et al., 1997), the small 5’-flanking PB fragment (-426/+28) (Greenberg et 
al., 1994), and the ARR2PB promoter (Zhang et al., 2000) all targeted gene expression in 
the prostate in transgenic mice. In the ARR2PB promoter construct, an Androgen 
Responsive Region, ARR, (-244 to -96 bp of the PB promoter) serves as enhancer that is 
repeated in front of -286/+28 bp PB promoter. Experiments also confirmed that the 
-286/+28 bp fragment of PB promoter is sufficient to target the prostate in transgenic 
mice (Zhang et al., 2000). 
 
Different genes have been targeted to mouse or human prostate using the PB 
promoters. SV40 early region has been targeted into mouse prostate to create the TRAMP 
mouse by using the -426/+28 PB promoter; the large T antigen (a deletion removes the 
small t antigen) has been targeted into the mouse to create the LADY mouse models 
(Greenberg et al., 1995; Kasper et al., 1998). Additionally, therapeutic genes were 
targeted to the prostate tumor cells for gene therapy purposes: Adenoviral delivery of 
pro-apoptotic Bax gene directed by ARR2PB promoter induces apoptosis in LNCaP 
prostate cancer cells (Lowe et al., 2001; Andriani et al., 2001); Spencer et al. took 
advantage of the ARR2PB-direted death switch protein caspase-9 to elicit prostate cancer 
cell suicide (Xie et al., 2001); and Handerson et al. reported that, a novel adenovirus 
CV787, with the rat PB promoter driving the adenovirus type 5 E1A gene, destroys 
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prostate cancer cells 10,000 times more efficiently than non-prostate cells and has 
powerful therapeutic efficiency for human metastatic prostate cancer which is always 
intractable for surgical treatment (Yu et al., 1999). 
 
The probasin promoter has become the promoter to target genes to prostate epithelial 
cells in transgenic mice and to be used in gene therapy constructs to target therapeutic 
genes to prostate cancer cells. 
 
B. Probasin promoter is regulated by androgen receptor and other transcription 
factors (TF). 
Studies show that PB mRNA level dramatically drops below detection limits in 
castrated animals, but after androgen treatment of the castrated animals PB mRNA level 
was found to restore to the pre-castration level (Greenberg et al., 1994; Yan et al., 1997). 
In transgenic mice, the expression level of the PB promoter directed CAT transgene 
increased consistently with the increasing serum androgen level during animal maturation, 
and CAT expression reached a peak when the animal reached sexual maturity at six week 
of age (Yan et al., 1997). These facts suggest that the expression of the rat PB transgene 
in transgenic mice was specifically androgen-regulated. Two Androgen Responsive 
Elements (ARE) were identified within the -426 to +28bp of PB 5’ flanking region by 
DNase I footprinting and Electrophoretic Mobility Shift Assays (EMSA) (Rennie et al., 
1993; Kasper et al., 1994; Kasper et al., 1999). The two sites were named as Androgen 
Receptor Binding Site 1 (ARBS1) and ARBS2. They are located at -236 to -223bp and 
-140 to -117bp, respectively. A single point mutation in either binding site can 
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dramatically reduce AR binding on both sites and it would cause more than 95% loss of 
CAT transgene expression (Rennie et al., 1993). These experiments confirmed the 
dependence of PB promoter activity on AR. Both in vivo and in vitro experiments showed 
that this hormone regulatory effect is specific for AR. Therefore, the region of -244 to 
-96bp designated as being responsible for the full androgen induced activity of the PB 
promoter. This fragment was named Androgen Responsive Region (ARR). By making 
deletion constructs over a 10kb fragment of the upstream region of the PB gene, two 
additional ARBSs (ARBS3 and ARBS4) between -700 to -400 bp have been identified. 
These sites cooperate with ARBS1 and ARBS2 to confer a potent androgen induced 
activity (Zhang J-F et al., 2010). AR is expressed not only in prostate tissues, but in 
non-prostate tissues such as liver, kidney, testis, bladder, seminal vesicle as well, which 
do not express probasin and AREs are also found in promoters of genes which are 
expressed in non-prostate cells; thus it is not possible for AR alone to dictate the tissue 
selectivity of PB. 
 
 In order to identify other DNA binding elements within the -286/+28 bp PB promoter, 
DNA sequences were mutated every ten base pairs to cover the -286 to +28 promoter 
region resulting in 31 continuous link-mutation constructs (Zhang J-F et al., 2010). 
Besides ARBS1, ARBS2, and the TATA box, five additional cis-acting elements were 
identified as key regulatory sites (Zhang J-F et al., 2010) (Gao et al., 2003). Three of the 
five elements are occupied by ubiquitous TFs: NF-1, c-jun, and Oct-1. When these sites 
were mutated individually, they reduced the bioactivity of the PB promoter in both 
prostatic and non-prostatic cell lines (Figure 7). The binding of NF-1, c-jun, and Oct-1 to 
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the PB promoter has been confirmed by EMSA, antibody supershift, and consensus TF 
site competition (Zhang J-F et al., 2010). 
 
 
 
Figure 7. PB promoter. PB proximal promoter region (-286 to +28) linker scanning 
mutagenesis disclosed five additional key cis-acting elements including two tissue 
specific elements (TS1 and TS2). 
 
 
Two elements were referred to as TS1 and TS2 (Tissue Specific). When TS sites are 
mutated, the bioactivity is reduced only in prostatic cells lines, but not in non-prostatic 
cells (Gao et al., 2003). TS1 is immediately upstream to ARBS1 and TS2 is immediately 
downstream to ARBS2 (Gao et al., 2003). DNA alignment of TS1 and TS2 revealed 
sequence similarity, EMSA and nuclear protein fractionation revealed nearly identical 
protein binding patterns of TS1 and TS2 (Gao et al., 2003). Southwestern and EMSA 
disclosed that both TS1 and TS2 harbor a FoxA1 binding sites (Gao et al., 2003). The 
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FoxA1 binding sites are confirmed to be essential for maximum induction by androgens 
since point mutations in FoxA1 binding sites block activation of the PB promoter (Gao et 
al., 2003). Further, southwestern analyses mapped at least two small proteins bound to 
TS2 at 52 kDa (FoxA1) and 46 kDa (unknown at the time but identified in this thesis as 
USF2) as well as the large protein at 113 kDa identified as AR plus additional weaker 
bands (Gao et al., 2003).  The FoxA1 and AR bands have been confirmed (Gao et al., 
2003). Mutation of the FoxA1 site prevents expression in transgenic mice. Our data 
strongly suggests that FoxA1 functions as a critical component in a TF complex that 
controls androgen regulated and prostate-specific expression of PB.  
 
FoxA 
Originally the FoxA proteins were called Hepatocyte Nuclear Factor 3 (HNF3). 
HNF3 proteins were discovered as liver-enriched factors because of their ability to bind 
the transthyretin gene promoter (Lai et al., 1991; Lai et al., 1990). The three FoxA 
proteins, FoxA1 (HNF3alpha), FoxA2 (HNF3beta) and FoxA3 (HNF3gamma), are 
encoded by different genes on different chromosomes (Kaestner et al., 1994), yet they 
share about 85% sequence identity in the DNA-binding domain (Lai et al., 1991), which 
exhibits 82% similarity with the Drosophila forkhead protein (Weigel and Jackle, 1990). 
The FoxA proteins bind to the same consensus binding site but each exhibit different 
affinity. The forkhead domain (FH) displays a novel protein folding called “winged 
helix”, which contains three alpha-helices flanked by two loops, or “wings” (Clark et al., 
1993). Helix 3 makes primary contacts with the DNA major groove and wing 2 makes 
contacts with the minor groove (Clark et al., 1993). In mouse, FoxA2 is first expressed in 
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the anterior of the early primitive streak and later in the definitive endoderm, the 
notochord and the floor plate of the neural tube (Sasaki and Hogan, 1993); FoxA1 is first 
expressed in the definitive endoderm at the late primitive streak stage(Kaestner et al., 
1999); FoxA3 is first expressed in the endoderm after the formation of the gut. 
Homozygous FoxA2 knockout mice die at embryonic day 10 due to foregut defects and 
failure to form notochord; homozygous inactivation of FoxA1 results in perinatal 
lethality (Kaestner et al., 1999); inactivation of FoxA3 is not lethal (Kaestner et al., 1998). 
Three FoxA proteins are involved in endoderm differentiation, but FoxA2 is important 
for both formation and maintenance of endoderm. FoxA binding sites were found in 
numerous liver-expressed gene promoters (Zaret, 1999), and the consensus binding sites 
5’-(G/A)(T/C)(C/A)AA(C/T)A-3’ were extracted from these reported binding sites 
(Kaufmann and Knochel, 1996). The FoxA proteins also regulate gene transcription in 
other gut endoderm-derived lineages, such as lung, pancreas, intestine and thyroid 
(Kaufmann and Knochel, 1996). To date, nearly 200 FH members have been discovered 
in a variety of species (Kaestner et al., 2000). 
 
The molecular mechanisms by which FoxA proteins control transcription have only 
been partially characterized. Three dimensional structure of the FH domain mimics the 
structure of linker histones H1 and H5, which help to compact chromatin and inhibit 
transcription (Clark et al., 1993; Zhou et al., 1998). FoxA proteins activate transcription 
by displacing linker histones from nucleosomes and opening chromatin, making the local 
DNA region more accessible for other transcription factors (Cirillo et al., 1998). For 
example, FoxA2 facilitates the binding of glucocorticoid receptor to the 
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phosphoenolpyruvate carboxykinase gene promoter (Wang et al., 1996; Stafford et al., 
2001); while on the vitellogenin B1 gene promoter, FoxA establishes promoter 
environment favorable to transactivation by estrogen receptor (Robyr et al., 2000). Both 
amino-terminal and carboxyl-terminal ends of FoxA show transactivation activities (Pani 
et al., 1992); however, little information exists on co-operative co-regulators that mediate 
the crosstalk with general transcription machinery. Overproduction of a truncated FoxA 
protein without both N- and C-terminal domains inhibited the expression of several 
liver-specific genes (Vallet et al., 1995). Beside its DNA-binding ability, the FH domain 
also contains a nuclear localization signal (Qian and Costa, 1995). A phosphorylation site 
for casein kinase was reported for FoxA2 protein, but this phosphorylation event does not 
affect transcription activity (Qian and Costa, 1995). Direct and indirect evidence point 
out the cross talk between FoxA transactivation activity and protein kinase A, B, and C 
pathways. For example, PKA activation improves the recruitment of FoxA to a 
glucocorticoid responsive element on the tyrosine aminotransferase promoter (Espinas et 
al., 1995); PKB directly phosphorylates three FH members AFX, FKHR and FKHRL1 to 
inactivate them (Kops and Burgering, 1999). FoxA1 translocation from nucleus to 
cytoplasm and inactivation could be caused by TGFbeta treatment; however this effect 
was abolished by PKC inhibitor (Kumar et al., 2000). Curiously, no report so far could be 
found about screening for coregulators for FoxA proteins, such as using yeast two hybrid 
system. Two different groups have identified a novel interaction between estrogen 
receptor (ER) and a different forkhead member, FKHR, by using ER as a bait in yeast 
two hybrid screen (Zhao et al., 2001; Schuur et al., 2001). It has been reported that Small 
Heterodimer Partner (SHP; NR0B2), an atypical orphan nuclear receptor that acts as a 
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coregulator of various nuclear receptors, physically interacted with FoxA (Kim et al., 
2004). Also, FoxA1 is essential for ERalpha binding to the prototypic gene TFF1 as 
determined by using a combination of genome-wide location, genetic analyses, and 
functional assays. Furthermore, FoxA1 is required for E2-induced reentry of quiescent 
breast cancer cells into the cell cycle (Laganiere et al., 2005). Developmental studies 
showed that FoxA proteins are expressed at a very early stage of mouse embryo 
development, and in vivo foot printing studies indicated that FoxA is among the first to 
bind silent genes in early development (Zaret, 1999), Ken Zaret suggested FoxA proteins 
are “genetic potentiators”, which could enhance the activation of genes by facilitating the 
binding of other TFs during development and differentiation (Zaret, 1999). In conclusion, 
the expression patterns of FoxA proteins in the early embryo developmental stage and the 
ability to access as well as to modify compacted chromatin indicate that FoxA proteins 
are important positive acting TFs that regulate organ differentiation and cell specific gene 
expression.  
 
Our study shows that FoxA1 is involved in androgen-regulated prostate-specific gene 
expression. FoxA1 is expressed constitutively in prostate, and prostates rescued from 
FoxA1-deficient mice displayed basal-like cell hyperplasia (Gao et al., 2003; Gao et al., 
2005a). FoxA2 is only expressed in budding prostate during development between E18 to 
D1 and is dramatically reduced in the adult prostate tissue to barely detectable levels 
(Mirosevich et al., 2005b). However, FoxA2 is expressed in both normal and cancerous 
prostate neuroendocrine (NE) cells.  Surprisingly, FoxA2 can convert the 
androgen-dependent PSA promoter to function in an androgen-independent manner 
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(Mirosevich et al., 2005a). This suggests that FoxA2, or a closely related forkhead 
protein, may represent a common mechanism by which prostate cancer can progress from 
androgen-dependent to androgen-independent disease. FoxA2 can regulate 
androgen-dependent prostatic genes in an androgen-independent fashion, FoxA2 but not 
FoxA1 is expressed in the epididymis. Furthermore, FoxA2 interacts with the AR to 
regulate the mouse epididymal retinoic acid binding protein (mE-RABP) gene, an 
epididymis-specific gene (Yu et al., 2005). Glutathione-S-transferase (GST) pull-down 
assays determined that both FoxA1 and FoxA2 physically interact with the DNA binding 
domain of the AR (Gao et al., 2003; Yu et al., 2005). (See review by DeGraff et al. 
(DeGraff et al., 2009))  
 
USF2 
The upstream stimulatory transcription factor (USF) was originally identified as a 
cellular transcription factor that is critical for maximal expression of the major late 
promoter of adenovirus both in vivo and in vitro (Sawadogo and Roeder, 1985; Carthew 
et al., 1985; Miyamoto et al., 1985). Two different polypeptides of USF were first 
purified from HeLa cell nuclei with molecular weight of 43 kDa and 44 kDa (Sawadogo 
et al., 1988). From both human and mouse, USF cDNA clones were isolated and 
indicated the 43 kDa (USF1) and 44 kDa (USF2) polypeptides were the products of two 
different genes (Gregor et al., 1990; Sirito et al., 1992; Sirito et al., 1994). Both USF1 
and USF2 are expressed in different cell types and they can either form homodimers or 
heterodimers (Sirito et al., 1994). The DNA consensus sequence of USF is identified by 
the presence of a central CACGTG motif, which includes the canonical CANNTG that 
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are recognized by the helix-loop-helix transcription factors (Sawadogo and Roeder, 1985; 
Murre et al., 1989). Studies have found that USF binding sites exist in a variety of 
cellular and viral genes (Carthew et al., 1987; Chodosh et al., 1987; Lemaigre et al., 1989; 
Chang et al., 1989; Scotto et al., 1989; Sato et al., 1990; Greaves and O'Hare, 1991; 
Potter et al., 1991; Zwartkruis et al., 1991; Bungert et al., 1992; Riccio et al., 1992; 
Reisman and Rotter, 1993). Interestingly, most USF binding sites are also recognized by 
other transcription factors, such as Myc (Blackwell et al., 1990; Prendergast and Ziff, 
1991; Halazonetis and Kandil, 1991), MAX/Myn (Blackwood and Eisenman, 1991; 
Prendergast et al., 1991), Mad/Mxi (Ayer et al., 1993; Zervos et al., 1993), and 
TFE3/TFEB (Beckmann et al., 1990; Carr and Sharp, 1990).  
 
USF2 binds to the conserved E-box (CANNTG) site and belongs to the 
basic-helix-loop-helix-leucine-zipper (bHLH-zip) family of transcription factors (Gregor 
et al., 1990; Sirito et al., 1992). USF2 has been confirmed to occupy the same binding 
site as FoxA1 on the PB promoter (Kivinen et al., 2004). USF2 has a weak interaction 
with AR together with other proteins that bind to the same site to enhance the 
transactivation function of AR (Kivinen et al., 2004). Western blot analysis has revealed 
that USF2 expression is decreased in androgen-independent prostate cancer cell lines, 
PC-3, DU145, and M12 (Chen et al., 2006). Overexpression of USF2 in PC-3 cells could 
inhibit anchorage-independent growth and the tumorigenicity of PC-3 cells (Chen et al., 
2006). USF2 can inhibit Myc-dependent transformation in rat embryo fibroblast (Luo and 
Sawadogo, 1996). USF2 knockout mice demonstrated prostate hyperplasia suggesting 
that USF2 may play an important role in prostate differentiation and prostate 
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carcinogenesis (Chen et al., 2006).  
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Hypothesis 
In summary, we believe that FoxA1 and its binding partners form a protein complex 
with AR and other TFs which is capable of directing prostate-specific gene expression 
and that this or a similar complex plays a critical role in the androgen regulation of tumor 
growth. Purification and identification of the interacting partners of FoxA1 will facilitate 
our understanding of how these TFs/AR interactions regulate tumor growth. 
 
The overall hypothesis is that the FoxA1, AR, and other FoxA1 interacting partners 
co-operate together to direct androgen regulated gene expressions.  
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Cell Culture 
The human prostate carcinoma cell line LNCaP was obtained from American Type 
Culture Collection. LNCaP cells were cultured in complete RPMI 1640 medium 
(Invitrogen, Carlsbad, CA) supplemented with 5% fetal bovine serum.  
NeoTag cell line was generated by our lab. The androgen-regulated probasin 
promoter linked to the neomycin phosphotransferase (Neo) gene was used to generate the 
ARR2PBneo transgenic mouse model. All six ARR2PBneo transgenic founder lines 
expressed the Neo gene in a prostate-specific manner. Line C, which expressed high 
levels of neo, was crossbred to LPB-Tag 12T-7f transgenic mice (in which the SV40 large 
T antigen (Tag) was targeted to the prostate by the large probasin (LPB) promoter). Three 
bigenic males (carrying both Neo and Tag transgenes) were identified. Three separate 
NeoTag epithelial cell strains were established from three bigenic mice. G418 selection 
was used to obtain immortalized epithelial cells in culture. Selected cells expressed both 
the Neo and Tag transgenes, cytokeratins 8 and 18, and were androgen responsive for 
growth (Wang et al., 2006). 
 
Expression Vectors and Reporter Plasmids 
A. Expression Vectors 
Mammalian FoxA1 (HNF-3α) expression vector pRB-HNF-3α was kindly provided 
 36
by Dr. Kenneth S. Zaret (Fox Chase Cancer Center, Philadelphia, PA). Full-length wild 
type and FoxA1 subdomain fragments were PCR amplified and directionally cloned into 
pcDNA3.1D/V5/His-TOPO expression vector (Invitrogen Carlsbad, CA),  in frame with 
the carboxy-terminal V5 epitope and 6╳His Tag by Dr. Nan Gao (a previous graduate 
student in Dr. Matusik’s lab) (Gao et al., 2003).  
pSG5-mUSF2 (containing wild type mouse USF2), pSG5-U2d(7-178) (containing 
USF2 with 7-178 a.a. deletion), and pSG5-U2dE5 (containing USF2 with exon 5 deletion) 
vectors were kindly provided by Dr. N Chen (Department of Molecular Genetics, U.T. 
M.D. Anderson Cancer Center). USF2 (a.a.1-a.a. 235) (USF2 amino acid 1 to 235) was 
cloned by PCR using pSG5-mUSF2 as a template. All four USF2 sequences were cloned 
into pGEX-4T-1 to express GST-USF2 fusion proteins: GST-USF2, GST-USF2-ΔE5, 
GST-USF2-ΔN (Aa 7-178 deletion), and GST-USF2-ΔC (Aa 1- 235). pGEX-4T-1 vector 
was kindly provided by Dr. Guanglei Zhuang from Dr. Jin Chen’s lab (Cancer Biology 
department, Vanderbilt University Medical Center). 
 
B. Luciferase Reporter Plasmids 
ARR2PB-Luc reporter (ARR is the androgen response region of PB promoter) 
contains an additional androgen response region (-244 to -96 bp of PB promoter) fused 
upstream of the -286 to +28 bp of PB promoter to enhance the androgen response (Zhang 
et al., 2000). 
A 621 bp fragment of PSA minimal promoter (-610 to +11 nt) was amplified by PCR 
and cloned at the Smal and Xhol sites of pGL3-basic luciferase vector (Promega Corp., 
Madison, WI), thus a 823 bp upstream enhancer fragment (-4758 to -3935 bp) containing 
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the PSA core enhancer region was obtained by PCR and inserted upstream of the PSA 
promoter at SacI and SmaI sites, resulting in PSA-Luc reporter construct. 
 
Electrophoretic Mobility Shift Assays (EMSA) 
Nuclear extract for LNCaP cells was prepared as described previously CITE. All 
nuclear extracts and purified proteins were stored in buffers containing 1x concentration 
of Complete Protease Inhibitor Cocktail (Roche Molecular Biochemicals, Indianapolis, 
IN). All oligonucleotides for EMSAs were purchased from Integrated DNA Technologies 
(Coralville, IA). Probes were end labeled with [γ-32P]ATP (Amersham Pharmacia 
Biotech, Pittsburgh, PA) using T4 polynucleotide kinase (New England Biolabs, Ipswich, 
MA), and purified by 15% PAGE. A typical binding reaction involved a 10-min 
preincubation with 10 µg of nuclear extract, 1 µg of the nonspecific competitor poly 
(dI-dC), and buffer D [20 mM HEPES-NaOH (pH 7.9); 100 mM KCl; 0.2 mM EDTA; 
1.5 mM MgCl2; 1 mM dithiothreitol; 20% glycerol; and 1 mM phenylmethylsulfonyl 
fluoride (PMSF)], followed by a 15 min incubation with 200,000 cpm of radiolabeled 
probe in a total volume of 20 µl. For supershift analysis, antibodies were added after the 
binding reaction and incubated for an additional 20 min on ice before electrophoresis. All 
supershift antibodies [USF2 ((N-18)X sc-861X), USF1 ((H-86)X sc-8983X), GATA-3 
((H-48)X sc-9009)] were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, 
CA). The concentration of antibody in each EMSA reaction was 0.2 µg/µl. Complexes 
were resolved by electrophoresis for 2.5 h at 160 V on a 5% native polyacrylamide gel, 
which was later dried and processed for autoradiography. 
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Western Blotting 
For Western blotting analysis, cell pellets were collected, and sonicated in cold lysis 
buffer [0.01 M Tris-HCl (pH 7.4), 0.01 M NaCl, 1 mM EDTA, in 1x concentration of 
Complete Protease Inhibitor Cocktail], followed by centrifugation at 14,000 rpm.  
Samples were loaded onto a 4%-12% Sodium Dodecyl Sulfate-polyacrylamide Gel 
Electrophoresis (SDS-PAGE) gel and separated at 120 volts for 2.5 hours and transfered 
to polyvinylidine difluoride membrane (Invitrogen, Carlsbad, CA). Membranes were 
blocked in Tris-buffered saline containing 0.1% Tween 20 and 5% non-fat dry milk, and 
incubated with primary antibodies [1:1000 dilution: anti-FoxA1 (sc-6553), 1:10000 
anti-USF2 (Santa Cruz Biotechnology, Santa Cruz, CA)] for 1 hour at room temperature. 
Membranes were incubated with secondary antibody (anti-rabbit IgG, GE Healthcare 
Piscataway, NJ), or anti-goat IgG, Santa Cruz Biotechnology, Santa Cruz, CA) for 1 hour 
at room temperature. In cases where anti-V5-horseradish peroxidase antibody (Invitrogen, 
Carlsbad, CA) was used to detect the recombinant V5-tagged FoxA1 proteins, a dilution 
of 1:5000 was used. The signal was visualized by enhanced chemiluminescence assay 
(Amersham Pharmacia Biotech, Pittsburgh, PA). 
 
Chromatin Immunoprecipitation (ChIP) 
The procedure and PCR primers used in this study is listed in Table 1. 
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Table 1. Primers Used in ChIP 
 
Name Sequence 
PB-F TCCCAGTTGGCAGTTGTA 
PB-R CACCAACATCTATCTGATTGGAG 
PBdis-F TTCTATTGGTGCCCAACGAGGCTA 
PBdis-R AGGTCAATGCTAGCAGCAAACCAC 
SBP-F GCCCCTACTGACCCAGTATAGA 
SBP-R GAACTTTGTTTTCTGCTTATCCCTCAG 
SBPdis-F TGCCTGTTTCAATAGGACGAGGGT 
SBPdis-R GATGGCTCAGAAGATGGGAATTGCTG 
PSA-F ACAGACCTACTCTGGAGGAA 
PSA-R AAGACAGCAACACCTTTTTTTTTC 
PSAdis-F GATGGTGTTTCACCGTGTTG 
PSAdis-R AGAGTGCAGTGAGCCGAGAT 
PSA-RTPCR-F CTGCCCACTGCATCAGGAACAAA 
PSF-RTPCR-R AGCTGTGGCTGACCTGAAATACCT 
hGAPDHf TGCACCACCAACTGCTTAGC 
hGAPDHr GGCATGGACTGTGGTCATGAG 
 
 
ChIP assays were performed according to manufacturer’s protocol (Millipore, 
Billerica, MA).  Briefly, LNCaP cells were serum starved for 24 hours in RPMI 1640 
with 5% charcoal/dextran-treated fetal bovine serum (HyClone, Logan, UT), and cells 
were subsequently treated in the presence or absence of 10-8 M DHT for 12 hours and 
then washed with PBS and cross-linked with 1% formaldehyde at 37oC for 10 minutes. 
Cells were scraped into conical tube, centrifuged for 4 min at 2000 rpm at 4oC, and 
resuspended in SDS lysis buffer [1% SDS, 10 mM EDTA, 50 mM Tris-HCl (pH 8.1), 1x 
proteinase inhibitor cocktail] at a concentration of 500,000 cells/100 µl., after which cells 
were sonicated 10 times for 10 seconds pulses at an output level 2-3 (Fisher Sonic 
Dismembrator, model 50; Fisher Scientific, Pittsburgh, PA). Cells were centrifuged, and 
supernatants were collected and diluted in ChIP dilution buffer [0.01% SDS, 1.1% Triton 
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X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl (pH 8.1), 167 mM NaCl], followed by 
preclearing for 30 min with 3 µg of sonicated salmon sperm DNA with protein A agarose 
(80 µl of 50% slurry in 10 mM Tris-HCl, 1 mM EDTA). Immunoprecipitation (IP) was 
performed overnight at 4oC with specific antibodies (anti-AR, anti-FoxA1, anti-USF2, 
anti-FoxA3 antibodies were used for IP, water was used as negative control). Protein A 
agarose with salmon sperm DNA was then added and incubated for 1 hour to collect 
immune complexes. Beads were then sequentially washed in low-salt wash buffer (0.1% 
SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, 150 mM NaCl), high-salt wash 
buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, 500 mM NaCl), 
LiCl wash buffer (0.25 M LiCl, 1% Nonidet P-40, 1% deoxycholate, 1 mM EDTA, 10 
mM Tris-HCl) and twice with TE buffer (10 mM Tris-HCl, 1 mM EDTA). The complex 
was eluted twice with 250 µl of elution buffer (1% SDS, 0.1 M NaHCO3) and eluates 
were pooled. Formaldehyde cross-linking was then reversed by adding 20 µl 5 M NaCl 
and incubating for 8 hours at 65oC. Eluates were incubated for an additional 1 hour at 
45oC with Proteinase K. DNA was extracted using QIAquick Spin Column (Qiagen Inc., 
Valencia, CA) and used for PCR amplification. The amplified region of PB promoter 
(-359 bp / -106 bp) includes ARBS-1, ARBS-2, and two FoxA1 binding sites. The 
amplified region of Spermine Binding Protein (SBP) promoter (-538 bp / -285 bp) 
includes two ARE and two FoxA1 binding sites (Gao et al., 2005a). The amplified region 
of PSA core enhancer (-4131 bp / -3938 bp) includes AREIII, and two FoxA1 binding 
sites (Gao et al., 2003). For each PCR, a distal region was amplified as a negative control. 
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SYBR green real-time PCR 
Real-time PCR and data analysis were performed in a total volume of 25 μl using 
96-well microwell plates and MyiQ Single Color Real-time PCR Detection System 
(BIO-RAD, Hercules, CA). 5 ul of purified DNA sample from ChIP assay, 12.5 μl SYBR 
green I PCR Master Mix (Applied BioSystems, Foster City, CA), and 500 nM of each 
primer pair (Table 1) were added to each microwell. To reach a total volume of 25 μl per 
well, DNase-RNase-free distilled water (Sigma-Aldrich, St. Louis, MO) was added. 
Following a pre-incubation of reaction mix at 95oC for 10 minutes, the following 
parameters were used for 40 cycles: 95o C for 45 seconds, 56o C (PB) / 56o C (SBP) / 52o 
C (PSA) for 1 minute, 72o C for 30 seconds, and an extension phase of 1 cycle at 72o C 
for 7 minutes. All reactions were performed in triplicate. The amount of DNA in each 
sample was calculated based on a standard curve, then each DNA sample amount was 
divided by input DNA amount and graphical data is depicted as the average of the 
normalized data from three individual reactions. cDNA from USF2 knockdown and 
control LNCaP cells were used for real time PCR following the same procedure as above. 
The amount of DNA in each sample was normalized relative to GAPDH. The DNA 
amount from control LNCaP cells was set as 1 and that of the USF2 knockdown samples 
were compared with the control.  
 
Co-Immunoprecipitation (Co-IP) 
LNCaP cells were washed three times with cold 1x PBS and lysed with 1 ml of 
nondenaturing lysis buffer (50 mM Tris, 150 mM NaCl, 10 mM EDTA, 0.02% NaN3, 50 
mM NaF, 1 mM Na3VO4, 1% NP-40, 1 mM PMSF, 0.5 mM dithiothreitol, and 1x 
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concentration of protease inhibitor cocktail). After sonication and centrifugation, 1 mg of 
total cell lysate for each reaction was incubated at 4o C for 3 h with 20 µl (dry volume) 
protein G-Sepharose beads (Amersham Pharmacia Biotech, Pittsburgh, PA), which were 
pre-conjugated with 1 µg of experimental antibody (anti-HNF-3α/β (C-20)X, Santa Cruz 
Biotechnology, Santa Cruz, CA) or goat serum negative control).  Beads were washed 
four times with lysis buffer and once with PBS for 5 minutes, followed by Western 
blotting analysis for USF2 (Santa Cruz Biotechnology, Santa Cruz, CA). Reciprocal IP 
was also performed.  For Co-IP experiments using ethidium bromide (EB) to disrupt 
DNA-protein interactions, 25 ug/ml and 100 ug/ml was used. 
 
GST-USF2 fusion proteins expression, in Vitro Translation of FoxA1 Proteins, and 
GST Pull Down assay 
GST-USF2 fusion proteins were produced by expressing USF2 fusion 
protein-encoding vectors in the BL21-CodonPlus(DE3)-RIL strain, which allows the 
inducible expression of transformed vectors by Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) addition.  Following IPTG treatment, bacterial cells were harvested and 
resuspend in lysis buffer (1x PBS, 1% Triton X-100, 1x protease inhibitor), cells were 
sonicated 3 times for 1-3 minutes at an output level of 3-4. Samples were then 
centrifuged and the supernatant was transferred to pre-equilibrated glutathione agarose 
beads, followed by washing (1x PBS, 1x concentration of complete protease inhibitor 
cocktail), and stored at -80 oC without elution. 
Recombinant FoxA1s and LacZ proteins labeled with a C-terminal V5-epitope were 
synthesized in vitro using the TNT T7 Quick Coupled Transcription/Translation System 
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(Promega Corp., Madison, WI) 
For GST pull-assays, glutathione agarose beads conjugated GST or GST-USF2 
fusion proteins (each contains 20 ug protein) were equilibrated with PBS-T binding 
buffer [1x PBS (pH 7.4), 1% Tween 20, and protease inhibitors] and incubated for 2 
hours at 4oC with 10 ul products from the TNT reactions. Complexes were washed four 
times with 1.5 ml of cold binding buffer, heated for 10 min at 70 oC in 1X LDS loading 
buffer, and separated by SDS-PAGE. Western blotting analysis with V5-horseradish 
peroxidase antibody or USF2 was used to detect the domain that involved in interaction. 
 
USF2 Knockdown 
LNCaP cells treated in the presence or absence of DHT for over night were 
transiently transfected with either ON-TARGET Plus SMART pool human USF2 siRNA 
or ON-TARGET Plus Non-targeting siRNA #2 (DHARMACON RNAi Technologies, 
Chicago, IL) at a working concentration of 100 nM. Western blotting was performed 48 h 
and 72 h post transfection to detect verify USF2 knockdown. 
 
Transfection Assays 
Transient transfection assays were performed using lipofectamine 2000 for LNCaP 
cells. The pRL-CMV containing the Renilla luciferase reporter gene (Promega Corp., 
Madison, WI) was used to optimize transfection efficiencies for each cell line. LNCaP 
cells were planted in 24-well plates in a density of 8-10 X 104/well at the first day. Cells 
were transfected with plasmid DNA and lipofectamine 2000 in Opti-MEM I reduced 
Serum Medium (Gibco) at the second day. All samples received 12.5 ng/well of 
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pRL-CMV and the total amount of plasmid DNA was 0.8ug/well. After 6 hours of 
transfection, the medium was replaced by Minimum Essential Medium (Gibco) with 5% 
Charcoal/Dextran Treated Fetal Bovine Serum (HyClone, Logan, UT) in the presence or 
absence of 10-8 M of DHT (same amount of 100% alcohol as control). Cells were 
harvested and lysed with passive lysis buffers after 24 hours of incubation. 
 
Luciferase Assay 
The luciferase activity was determined by using the dual luciferase reporter assay 
systerm (Promega Corp., Madison, WI) and LUMIstar (BMG lab Technologies Durham, 
NC). Background activity of the cell lysate with no DNA transfection was subtracted 
from the activities obtained from experimental group. All values were normalized by 
Renilla activity to correct for the transfection efficiency. Results are presented as relative 
luciferase activities. Each experiment was at least repeated three separate times. 
 
RNA extraction and Reverse Transcriptase PCR 
RNA extracted from LNCaP cells (USF2 knockdown LNCaP cells and control 
LNCaP cells) using RNeasy Mini Kit (Qiagen Inc., Valencia, CA). 2 ug RNA of each 
sample were reverse transcribed into cDNA using Superscript Reverse Transcriptase 
(Invitrogen, Carlsbad, CA). cDNA used for real time PCR analysis. 
 
Enzyme-linked Immunosorbent Assays (ELISA) 
The DSL-10-9700 ACTIVE PSA ELISA kit (Diagnostic Systems Laboratories, Inc. 
Webster, TX) was used to examine the PSA level in LNCaP cells medium supernatant. 96 
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microtitration wells are coated with anti-PSA antibody. Protein-based (BSA) buffer with 
a non-mercury preservative contains 0 ng/ml PSA is used as negative control, and Level I 
and II protein-based (BSA) buffer with a non-mercury preservative contain low and high 
concentration of PSA served as positive controls. The PSA standard curve was made by 
using protein-based (BSA) buffer contain 1.0, 2.0, 10.0, 25.0, 50.0, 100.0 ng/ml PSA. 
Samples from the LNCaP cells medium supernatant was dilute 10 times. 25 ul of the 
samples, standards, and controls are incubated in the 96 microtitration wells on an orbital 
microplate shaker for 1 hour at room temperature. After 5 times wash each well with 
Wash Solution using an automatic microplate washer, blot dry by inverting the plate on 
absorbent material. Then the wells were treated with another anti-PSA detection antibody 
labeled with the enzyme horseradish peroxidase by adding 100 ul of the 
Antibody-Enzyme Conjugate Solution to each well. Incubate the wells for 10 min at 
room temperature. After the washing steps, the wells were incubated with the substrate 
tetramethylbenzidine. An acidic stopping solution is then added and the degree of 
enzymatic turnover of the substrate is determined by dual wavelength absorbance 
measurement at 450 nm.  
The absorbance measured is directly proportional to the concentration of PSA present 
in the samples. A set of PSA standards is used to plot a standard curve of absorbance 
versus PSA concentration from which the PSA concentrations in the samples can be 
calculated. 
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Establish HeLa-FoxA1 / HeLa-E (empty) HeLa AR-FoxA1/HeLa AR-E and 
LNCaP-FoxA1 / LNCaP-E cell lines 
One FLAG adjacent to 6 X His tag was added in the N-terminal of human FoxA1 
cDNA by PCR. The PCR products were cloned into pCR-TOPO 2.1 vector (Invitrogen, 
Carlsbad, CA). The sequence of tagged FoxA1 was confirmed by DNA sequencing. The 
retro-virus vector pLPCX (Clontech, Mountain View, CA) was kindly provided by Dr. 
David Cortez’s lab (Biochemistry Department, Vanderbilt University Medical Center). 
Both pCR-TOPO 2.1-tagged-FoxA1 and pLPCX were digested with Xho I and Hind III, 
and the tagged FoxA1 was inserted into the pLPCX vector at Xho I/Hind III site. The 
Phoenix A cells were transfected with the pLPCX-FoxA1 or pLPCX empty vector to 
generate active viral particles. LNCaP, HeLa and HeLa AR cells were infected by the 
viruses that were generated by the Phoenix A cells. Selection of the infected LNCaP, 
HeLa and HeLa AR cells was performed by growing cells in the medium that contains 
puromycin. The puromycin concentration was increased from 1 ng/ml to 5 ng/ml for 
LNCaP FoxA1 / LNCaP E cells and 10 ng / ml for HeLa FoxA1 / HeLa E / HeLa AR 
FoxA1 / HeLa AR E cells. 
 
Nuclear Extract Preparation 
Twenty five 150 mm plates each of LNCaP FoxA1 and LNCaP E cells were grown to 
90% confluency and were used for a single nuclear extraction experiment. Cell pellet 
volume (CPV) was measured and pellet was washed with 5 X CPV volume of cold 1 X 
PBS, and then centrifuged for 5 min at 2000 rpm at 4o C. cells were resuspended in 2 X 
CPV volume of Buffer A [10mM HEPES (pH 7.9), 1.5mM MgCl2, 10mM NaCl, 1mM 
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DTT, Protease Inhibitor]. Cells were broken with 10 strokes using pestle “A” (loose), 
spin for 15 min at 3000 rpm. Supernatant was decanted and spin 20 min at 12,500 rpm. 
Pellet was resuspended in Buffer C [20mM HEPES (pH 7.9), 1.5mM MgCl2, 420mM 
NaCl, 25% (v/v) glycerol, 0.2mM EDTA, 1mM PMSF, 1mM DTT, Protease Inhibitor] in 
2 X CPV volume/109 cells. The nucleus was broken with 10 strokes using pestle “B” 
(tight), and mixed end-over-end on a rotator for 30 min at 4o C. Spin 30 min at 25,000 g. 
supernatant was then collected. Dialysis tube was heated with water until boiling. 
Supernatant was dialyzed in 50 time volume of the Buffer D [20mM HEPES (pH 7.9), 
100mM NaCl, 20% (v/v) glycerol, 0.2mM EDTA, 1mM PMSF, 1mM DTT, Protease 
Inhibitor] for 2 hours per change of buffer, with total 3 changes. After dialysis, samples 
were spun at 25,000 g for 15 min. The supernatant, which is the nuclear extract, was 
stored at -80o C. 
 
Tandem Affinity Purification 
The nuclear extracts from 109 LNCaP FoxA1 cells / LNCaP E cells were mixed to 
pre-equilibrated TALON Metal Affinity Resins (Clontech, Mountain View, CA), 1 ml of 
nuclear extract loads to 250 ul TALON resin (dry volume). Gently agitate the mixture at 
4o C degree for 4 hours, and then spin at 700 g for 5 min. Carefully remove the 
supernatant without disturbing the pellet and wash the resin using 10-20 volumes 1 X 
equilibration/wash buffer (protease inhibitors added) for 2 times. Remove and discard the 
supernatant after a spin in the centrifuge. Add one bed volume of the 1 X 
equilibration/wash buffer to the resin and resuspended by vortexing. Transfer the resin to 
a 2 ml gravity flow column (with end cap in place). Allow buffer to drain until it reaches 
 48
the top of the resin bed, making sure no air bubbles are trapped in the resin bed. Wash the 
column once with 5 bed volumes of quilibration/wash buffer. Elute the polyhistidine 
tagged protein by adding 2 X 0.5 ml (pH 7) + 100 mM imidazole elution buffer to the 
column. Collect the eluate and add to 200 ul pre-equilibrated ANTI-FLAG M2 Affinty 
Gel (dry volume) (Sigma, Saint Louis, MI) and agitate gently for overnight. Centrifuge 
the sample next morning for 30 seconds at 5000 g. Remove the supernatant with a 
syringe carefully and wash the resin for 4 times with 1 ml 1 X PBS (protease inhibitors 
added). The tagged protein complex was eluted by boiling in Laemmli sample buffer. 
 
Mass Spectrometry Analysis 
The eluate from the tandem affinity purification were subject to 10% SDS-PAGE 
followed by Collioidal Blue staining according to the manufacturer’s instruction. Protein 
bands were visualized by Colloidal Blue staining. The gel was divided into sections for 
the LNCaP FoxA1 cells. The gel sections that were excised were then subjected to in-gel 
trypsin digestion with trypsin protease. The corresponding area in the gel of the LNCaP E 
cells was also processed as negative controls to identify any non-specific proteins bound 
during the purification. Protein bands of interest were excised and cut into 1 mm cubes 
and equilibrated in 100 mM NH4HCO3. Proteins were then reduced within the gel pieces 
with DTT (1/10 volume 45 mM DTT, 50°C for 20 min) followed by alkylation with 
iodoacetamide (1/10 volume 100 mM iodoacetamide, dark at room temperature for 20 
minutes). The gel pieces were then dehydrated with acetonitrile and rehydrated with 15 
mL 12.5 mM NH4HCO3 containing 0.01 mg/mL trypsin (Trypsin Gold, Promega), and 
trypsin digestion was carried out for >2 h at 37°C. Peptides were extracted with 60% 
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acetonitrile, 0.1% formic acid, dried by vacuum centrifugation and reconstituted in 15mL 
0.1% formic acid. 5mL of peptide hydrosylate were analyzed by C18 reverse-phase 
LC-MS/MS using a Thermo LTQ ion trap mass spectrometer equipped with a Thermo 
MicroAS autosampler and Thermo Surveyor HPLC pump system, nanospray source, and 
Xcalibur 2.0 instrument control using standard data-dependent methods. Tandem MS data 
were analyzed with the Sequest algorithm against the IPI human database (135,674 
entries, October 2007 release) including a concatenated reverse database for calculating 
false-discovery rate. 
 
Computational model of AR, FoxA1, and USF2 binding to PB promoter 
The x-ray crystal structure of AR binding to AR consensus DNA sequence (1R4I.pdb) 
is obtained from the protein data bank (http://www.rcsb.org). The only existing crystal 
structure of FoxA is for the FoxA3 protein and its DNA binding sequence (pdt013), 
which came from the Nucleic Acid Database (http://ndbserver.rutgers.edu). Since the 
forkhead domain (DNA binding domain) of FoxA proteins are highly conserved, the 
FoxA3 crystal structure is used for this study. The USF2 X-ray crystal structure has not 
been published.  An X-ray crystal structure of USF1 and its binding DNA sequence 
(1AN4.pdb), which is obtained from the protein data bank (http://www.rcsb.org), was 
substituted since USF2 and USF1 have highly conserved DNA binding domains. The 
DNA structure of PB promoter is based upon James Stroud’s make-na server that uses 
David Case’s program NAB (http://structure.usc.edu/make-na/server.html) (Macke et al., 
1998). The 3-D model is assembled manually by optimal 3-D alignment of the DNA 
oligos from the crystal structure (AR, FoxA3, and USF1) with the NAB-generated 
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structure of the PB promoter region using the molecular visualization program called 
UCSF Chimera (http://www.cgl.ucsf.edu/chimera) (Pettersen et al., 2004). This 3-D 
model can mimic the binding of AR, FoxA1, and USF2 to PB promoter. 
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CHAPTER III 
 
Upstream Stimulatory Factor 2 Interacts with FoxA1 and is Involved in Prostate 
Specific Gene Expression 
 
Introduction 
The prostate is a male accessory reproductive gland in mammals. Human prostatic 
secretions are rich in PSA, acid phosphatase, and citric acid components that are found in 
semen. Androgen plays a key role in the normal development and physiology of the 
prostate. However, little is known about the basic molecular events that are required for 
organ determination and cell differentiation of the prostate. Our previous studies show 
that a member of the forkhead family, FoxA1, interacts with the AR, and that this 
interaction is required for the expression of prostate specific proteins such as the rodent 
probasin, Spermine Binding Protein and human PSA (Gao et al., 2003). Prostate tissue 
rescued from FoxA1 knockout mice exhibits abnormal prostate development, typified by 
the absence of differentiation markers and the inability to engage in secretion (Gao et al., 
2005b). Recent studies have confirmed that FoxA1 and AR binding sites are frequently 
found adjacent to each other on multiple genes (Wang et al., 2007; Jia et al., 2008; Yu et 
al., 2005; Yu et al., 2006). Taken together, these studies indicate that FoxA1 plays an 
essential role in expression of androgen regulated and prostate-specific genes, as well as 
the normal differentiation of the prostate gland.  
 
Originally the FoxA proteins were termed Hepatocyte Nuclear Factor 3 (HNF3) and 
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were discovered as liver-enriched factors because of their ability to bind the transthyretin 
gene promoter (Lai et al., 1990).  There are three FoxA proteins, FoxA1 (HNF3α), 
FoxA2 (HNF3β) and FoxA3 (HNF3γ), which are encoded by different genes on different 
chromosomes (Kaestner et al., 1994). The FoxA proteins are involved in endoderm 
differentiation and also regulate gene transcription in various other endoderm-derived 
organs, including the lungs, pancreas, intestines and thyroid (Kaufmann and Knochel, 
1996). Developmental studies have shown that FoxA proteins are expressed at a very 
early stage of mouse embryo development (Zaret, 1999; Sasaki and Hogan, 1993; Sasaki 
and Hogan, 1993) For these reasons, FoxA proteins have been referred to as “genetic 
potentiators”, which act to enhance the activation of gene expression by facilitating the 
binding of other transcription factors during developmental and differentiation-associated 
events (Zaret, 1999). Thus, the temporal and spatial expression patterns of FoxA proteins 
and the ability of FoxA proteins to access and modify compacted chromatin indicate that 
FoxA proteins are important positive acting transcription factors that regulate organ 
differentiation and cell specific gene expression. 
 
Probasin is a prostate specific protein that was first identified in rat dorsolateral 
prostate epithelial cells (Matuo et al., 1982; Yamamoto et al., 1989). Although the 
function of probasin is unknown, the prostate-specificity of this promoter (Greenberg et 
al., 1994) has resulted in the further development of a potent androgen and prostate 
specific promoter (Zhang J et al., 2000) that has been extensively characterized and 
utilized as a tool to target gene expression to the prostate (Wen et al., 2003; Ellwood-Yen 
et al., 2003; Klezovitch et al., 2004). In our previous study, two FoxA1 binding sites were 
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identified, which are immediately adjacent to functional AR binding sites in the PB 
promoter (Gao et al., 2003). A similar organization of the androgen response element 
adjacent to functional FoxA1 binding sites in Spermine Binding Protein (SBP), prostatic 
acid phosphatase, C3, and PSA gene core enhancer also were observed (Gao et al., 2003; 
DeGraff et al., 2009), and the close association between FoxA1 and AR binding sites has 
been subsequently verified at a larger scale (Jia et al., 2008). However, limited 
information still exists regarding corresponding co-regulators that mediate the crosstalk 
of the FoxA1/steroid receptor complex with the general transcription machinery. This is 
noteworthy because while signal dependent steroid receptors can regulate genes in a 
tissue-specific manner, specificity is not regulated by the steroid receptor alone. Rather, a 
unique complex of transcription factors must act with the receptor to restrict expression 
to a specific cell type (Matusik et al., 2008). 
 
Southwestern analysis, using the androgen receptor binding site 2 of the PB promoter, 
identified the AR and FoxA1 as well as a third unknown 44 kDa protein binding to this 
DNA sequence (Gao et al., 2003). We have identified this 44 kDa protein as the Upstream 
Stimulatory Factor 2, an E-box binding transcription factor of the 
basic-helix-loop-helix-leucine-zipper (bHLH-zip) family (Sirito et al., 1992). USF2 has a 
weak interaction with AR, as well as with other proteins that bind to the same site to 
enhance the transactivation function of AR on the PB promoter (Kivinen et al., 2004). 
The present study reveals 1) that USF2 binds not only to the PB promoter, but also other 
prostate specific promoters including the SBP promoter and PSA core enhancer; 2) that a 
physical interaction between USF2 and FoxA1 is mediated via the DNA binding domain 
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of USF2 and the forkhead DNA binding domain of FoxA1; 3) that the consensus DNA 
sequence for the binding sites of FoxA1 and USF2 overlaps critical base pairs permitting 
binding to the DNA suggesting a direct interaction between these proteins at the same site; 
and, 4) that FoxA1 and USF2 are bound to the promoters prior to androgenic activation 
of AR. This data shows USF2 interacts with FoxA1 in a complex with AR to control 
androgen regulation of prostate specific gene expression. 
 
Results 
Analysis of USF2 expression across a panel of cell lines. 
The expression level of USF2 was detected in different human prostate cancer cell 
lines (LNCaP, PC3, and DU145) and in mouse prostate cancer cell lines (NeoTag1, 
NeoTag2, and NeoTag3) and also in HeLa cells by Western Blot analysis. Figure 8 
indicates that USF2 was expressed in all these cell lines. Beta-actin was used as a loading 
control. The expression of USF2 in LNCaP cells and NeoTag cells allows us to perform 
further studies of USF2 in those cells. LNCaP cells are used to study the binding of USF2 
to human PSA core enhancer, and function studies of USF2 are performed in USF2 
knockdown LNCaP cells. NeoTag1 cells are used to study the binding of USF2 to mouse 
PB and SBP promoters. The expression level of USF2 was reported to have a 
dramatically decrease in androgen-independent prostate cancer cell lines, PC3 and 
DU145, compared with androgen-dependent cell line, LNCaP (Chen et al., 2006). From 
our data, no obvious different of the USF2 expression level is observed among these cell 
lines (Figure 8). The western experiments have been repeated several times. The different 
results may be caused by the cell lines alteration after long-term culture. 
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Figure 8. The expression level of USF2 protein in different cell lines by 
western blot analysis. 1: LNCaP; 2: PC3; 3: DU145; 4: NeoTag1; 5: 
NeoTag2; 6: NeoTag3; 7: HeLa. Westen blot was used to examine the USF2 
expression level in human prostate cancer cells (1, 2, 3), mouse prostate 
tumor cells (4, 5, 6), and non-prostate cells (7) by using USF2 antibody, and 
beta-actin antibody was used in western blot as a loading control. 
 
 
USF2 Binds to PB and SBP Promoters and the PSA Core Enhancer. 
EMSA has shown that USF2 is associated with GAAAATATGATA element in 
prostate. This region is also a FoxA1 binding site (Gao et al., 2003). Previous studies 
have identified multiple FoxA1 binding sites in prostate specific gene promoters and 
enhancers including the PSA core enhancer and SBP promoter (Gao et al., 2003), so it is 
very likely that there exists an USF2 binding site in prostate specific gene enhancers and 
promoters. The probe PSA1 (Figure 9A) used in our EMSA experiments encompasses 
sequence located at -4122/-4109 bp of the PSA gene core enhancer, which contains an 
AR binding site and a FoxA1 binding site (Gao et al., 2003). Figure 9B shows an EMSA 
using LNCaP human prostate cancer cells nuclear extract, which expresses USF2. When 
the USF2 antibody was incubated with PSA1 probe and LNCaP cell nuclear extract, a 
band was supershifted when compared with the PSA1 probe and LNCaP cell nuclear 
USF2 
1   2   3   4   5   6   7 
Beta-actin 
 56
extract alone. However, no visible effect was observed when the USF1 antibody or 
GATA3 antibody was used. These results indicate USF2 binds the PSA core enhancer in 
vitro, while USF1 does not bind the PSA1 sequence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 57
 
 
Figure 9. Identification of USF2 binding site in PSA core 
enhancer. A, PSA1 EMSA probe. The probe PSA1 used in our 
EMSA experiments encompasses sequence located at -4122/-4109 
bp of the PSA gene core enhancer, inclusive of ARE III and a 
FoxA1 binding site, which also contains the USF2 binding site. B, 
EMSA. LNCaP nuclear extracts were incubated with radiolabeled 
PSA1 probe. Strong complexes formed in lane 2-5. The very top 
complex was shifted by USF2 antibody (lane 4), but not USF1 or 
GATA3 antibodies (lane 3 and 5). 
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To investigate the association of USF2 with a prostate specific gene promoter in 
cultured cells, Chromatin Immunoprecipitation (ChIP) assays were performed. Because 
the Neotag1 mouse cell line express the endogenous mouse PB and SBP genes, and 
LNCaP cells express endogenous human PSA gene, both Neotag1 and LNCaP cells were 
used for ChIP assays. Figure 10A is a schematic diagram of the PB, SBP, and PSA 
regulatory regions. Since USF2 binds to the same region as FoxA1, the regions that cover 
the USF2/FoxA1 binding sequences were tested in the experiments. A distal region of 
each promoter/enhancer (negative controls) was also tested (Figure 11). NeoTag1 and 
LNCaP cells were either treated with 10-8 M dihydrotestosterone (DHT) or maintained in 
androgen-depleted medium to determine the occupancy of USF2 on transcriptionally 
active vs. inactive PB/SBP/PSA chromatin via ChIP. As expected, DHT results in the 
recruitment of AR to responsive regions (Figure 10B, 10C, 10D). USF2, in contrast, was 
constantly bound to the promoter/enhancer as was FoxA1 (see Figure 11 for a gel of the 
PCR products). Only a small change in USF2 binding occurred with the binding of AR, 
thus the in vivo evidence for the binding of USF2 with PB and the SBP promoter and the 
PSA core enhancer shows that the binding of both USF2 and FoxA1 are largely 
independent of DHT treatment and AR binding. The PSA promoter contains relatively 
low level of USF2 as measured by real-time PCR (Fig. 10D) and the binding can be seen 
in the Figure 11D where a USF2 band shows up after 31 PCR cycles in the absence of 
androgens. 
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Figure 10. USF2 occupies PB promoter, SBP promoter, and PSA enhancer in vivo. 
A: Schematic diagram of the 5’ upstream regions of PB, SBP, and PSA genes. The 
diagram shows the amplified regions including distal regions (negative controls) and the 
USF2 binding regions. B, C, D: ChIP. After an overnight IP with indicated antibodies, 
formaldehyde cross-linking was reversed, and DNA fragments were extracted, followed 
by real-time PCR amplification. The y-axis unit is relative DNA enrichment. The amont 
of DNA pulled down by antibody was normalized with the amont of input DNA. 
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Figure 11. USF2 occupies PB promoter, SBP promoter, and PSA 
enhancer in vivo. A, Schematic diagram of the 5’ upstream regions of PB, 
SBP, and PSA genes. The diagram shows the amplified regions including 
distal regions (negative controls) and the USF2 binding regions. B, ChIP. 
After an overnight IP with specific antibodies, formaldehyde cross-linking 
was reversed, and DNA fragments were extracted, followed by PCR 
amplification (“+” or “–” represents cells with or without DHT treatment). 
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USF2 Physically Interacts with FoxA1 
The observation that overlapping binding sites for FoxA1 and USF2 exist at the 
androgen response regions of the PB, SBP, and PSA regulatory elements prompted us to 
determine if FoxA1 and USF2 physically interact. As LNCaP cells express both FoxA1 
and USF2, we used this cell line to perform co-immunoprecipitations. Cell lysates 
immunoprecipitated with anti-FoxA1 conjugated protein G-sepharose beads followed by 
western blotting for USF2 (Figure 12A) indicate FoxA1 and USF2 interact. Reciprocal 
immunoprecipitations using anti-USF2 conjugated protein G-Sepharose beads in the 
presence of ethidium bromide followed by western blotting for FoxA1 confirm the 
FoxA1 and USF2 interaction and also indicate this interaction does not require the 
presence of DNA (Figure 12B). Although we previously reported a physical interaction 
between FoxA1 and AR (Gao et al., 2003), we did not detect an interaction between 
USF2 and AR (data not shown). Taken together, these results demonstrate that FoxA1 
and USF2 interact.  
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Figure 12. IP. A: LNCaP cell lysates were immunoprecipitated with FoxA1 
antibody (lane 3). Water (lane 1) and goat serum (lane 2) were used as 
negative controls. LNCaP cell lysate (Input) served as a positive control. 
Western blotting was performed using USF2 antibody. B: LNCaP cell lysates 
were immunoprecipitated with USF2 antibody (lane 3, lane 4, and lane 5), 
water (lane 1), and rabbit IgG (lane 2, negative control). LNCaP cell lysate 
(Input) served as a positive control. Ethidium bromide (EB) was added to 
remove the influence of DNA presence on observed protein-protein 
interactions (0ug/ml EB in lane 3, 50 ug/ml EB in lane 4, 100ug/ml EB in 
lane 5). Western blot was performed using FoxA1 antibody. 
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Responsible Domains for USF2/FoxA1 Interaction 
To further confirm the interaction between FoxA1 and USF2, as well as to determine 
the responsible domains for the USF2/FoxA1 interaction, in vitro GST pull-down assays 
was performed. Full-length FoxA1 and FoxA1 subdomain (V-5 epitope on the C-terminal) 
expression vectors with a T7 promoter were transcribed and translated in vitro using the 
TNT T7 Quick Coupled Transcription/Translation System (Promega Corp., Madison, WI). 
(Figure 13A), and four GST-USF2 fusion proteins with different subdomains deletion 
were synthesized and purified (Figure 13B). In vitro synthesized FoxA1s and LacZ 
proteins labeled with a C-terminal V5-epitope were shown by western blot using anti-V5 
antibody (Figure 13C) and used to map the USF2 binding regions of FoxA1. In Figure 
13D, the FH domain of FoxA1 alone was sufficient to mediate binding to USF2. 
Furthermore, the N-terminal and C-terminal domains of FoxA1 alone did not bind to 
USF2. Figure 13E shows that the USF2 DNA binding domain, but not the transcription 
activation domain, is involved in the FoxA1/USF2 interaction. These results indicate that 
the C-terminal DNA binding region of USF2 and the FH domain of FoxA1 are the 
respective responsible regions for the interaction between USF2 and FoxA1. 
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Figure 13. GST pull-down assays. A and B: Schematic diagrams showing a series of 
FoxA1 and USF2 subdomains used in vitro GST pull-down assays. The FoxA1 FH 
domain and USF2 transcription activation domain are highlighted in black. Two 
conserved FoxA1 C-terminal domains designated as region 2 and 3 are in grey boxes. 
C: Western blot using anti-V5 antibody shows eight in vitro synthesized V5-labled 
FoxA1 subdomains and a V5-labled LacZ protein. D: Eight V5-labeled FoxA1 
subdomains as well as a LacZ protein were synthesized in vitro and incubated with the 
GST-bound USF2 to identify the USF2-interacting region in FoxA1. E: Four purified 
truncated GST-USF2 fusion protein were bound to glutathione agarose beads, 
followed by incubation with V5-labeled FoxA1 protein synthesized in vitro. Western 
blot was performed to identify the FoxA1-interacting domain in USF2. 
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USF2 Knockdown modestly increases PSA expression at mRNA and protein level in 
LNCaP human prostate cancer cells 
To further examine USF2 function, USF2 was knocked down in LNCaP cells. PSA 
expression was evaluated at the RNA level both for USF2 knockdown LNCaP cells and 
control LNCaP cells. USF2 levels were decreased by 90% in LNCaP cells following 72 
hours siRNA treatment (Figure 14A). Real-time PCR results (Figure 14B) indicate the 
PSA mRNA levels slightly increased in USF2 knocked down LNCaP cells compared with 
control LNCaP cells when the LNCaP cells were treated with DHT (10-8 M), but the 
change was not statistically significant. The PSA level change was very minor when the 
LNCaP cells were under DHT depletion condition. 
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Figure 14. PSA level in USF2 knockdown LNCaP cells. A: USF2 knockdown in 
LNCaP cells. Western blotting shows a ~50% decrease in USF2 expression following 
48 hours knockdown, and a ~95% decrease following 72 hours knockdown. B: 
Steady-state levels of PSA mRNA were determined following USF2 knockdown in 
LNCaP cells by quantitative real-time PCR. Total RNA was extracted from USF2 
knockdown LNCaP cells and control LNCaP cells treated in the presence and absence 
of DHT. The unit of y-axis is relative fold change of PSA. Cycle number for each 
sample was normalized by GAPDH, and the cycle number difference between control 
samples and USF2 knocked down samples was converted as fold change. 
 
 
 
Experiments were also done to examine the secreted PSA level in LNCaP cells 
(USF2 knockdown or control cells) medium. At intervals of 24 hours, conditioned 
medium was collected from control and USF2 knockdown LNCaP cells, and replenished 
with fresh medium allowing for the analysis of PSA levels via Enzyme-linked 
Immunosorbent Assays (ELISA). USF2 knockdown resulted in a significant (p<0.05) 
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increase in the amount of secreted PSA (Figure 15). The result indicated that USF2 could 
suppress the activity of PSA gene and negatively regulate the PSA expression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. USF2 knockdown resulted in an increase in the amount 
of secreted PSA. A, USF2 knockdown in LNCaP cells. Western 
blotting shows a ~50% decrease in USF2 expression following 48 
hours knockdown, and a ~95% decrease following 72 hours 
knockdown. B, The secreted PSA protein level in LNCaP cells medium 
following USF2 knockdown was examined by ELISA. The P value for 
48 hours is 0.006269 (highly significant); P value for 72 hours is 
0.003223 (highly significant). 
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USF2 knockdown does not cause a dramatic change in the promoters (ARR2PB Luc 
and PSA Luc) activity 
ARR2PB-Luc or PSA-Luc reporter construct was transient transfected into USF2 
knockdown LNCaP cells and control LNCaP cells. Luciferase assay indicate that the 
activity of the promoters in USF2 knockdown cells almost in a same level as in the 
control cells (Figure 16). This indicates USF2 is constitutively bound to important 
prostate cis regulatory sequences. 
 
 
Figure 16. USF2 knockdown (72 hr) in LNCaP cells does not cause a dramatic 
change in the transient transfected ARR2PB promoter or PSA promoter 
directed Luciferase. A, 95% USF2 has been knockdown in 72 hours by siRNA 
compared with the control. B and C, The change of ARR2PB / PSA promoter activity 
is very minor in USF2 knockdown (72 hr) LNCaP cells compared with the control 
LNCaP cells (Luciferase units expressed as Raw Luciferase Values/ mg protein/ 4 
seconds).  
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CHAPTER IV 
 
Identifying FoxA1 Interacting Partners 
 
Introduction 
Hormone ablation therapy is commonly used for most localized and metastatic 
prostate cancer. However, some cancer cells survive the treatment and develop into 
androgen-independent prostate cancer. One major reason causing this progression is due 
to the alteration in androgen receptor function or localization (Debes and Tindall, 2004). 
The molecular mechanisms of this progression are not very clear. Transcription factors 
that are involved in the AR activation pathway may play important roles in the 
development of androgen-independent cancer (Debes and Tindall, 2004). Studies on the 
transcription factor networks involved in androgen receptor action will help us to 
understand how castrate resistant prostate cancer (CRPC) develops. 
 
AR activity is dependent on ligand binding, nuclear translocation, and association 
with AR coactivators or corepressors. In CRPC tumor cells, AR may contain mutations 
that cause the receptor to response to lower levels of androgens or antiandrogens which 
now enables the tumor to regrow (Feldman and Feldman, 2001). In some CRPC patient, 
nuclear AR levels are increased (Debes and Tindall, 2004). AR coactivators and 
corepressors may be implicated in all of these processes (Debes and Tindall, 2004). 
Studies have found that AR coregulators can increase AR sensitivity to weak androgens 
or antiandrogens (Debes and Tindall, 2004). AR coactivators may enhance 
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ligand-induced transcription of the AR by general mechanisms such as controlling 
nuclear translocation, bridging the AR with the basal transcriptional machinery, 
facilitating ligand binding, recruiting chromatin-modifying complexes, and/or enhancing 
DNA binding (Debes and Tindall, 2004). Thus, AR is the central factor in the progression 
to CRPC. Identifying AR coregulators can help us to explain how androgen-independent 
tumors cells develop. Targeting the transcription factors that interact with AR by 
inhibiting the protein-protein interaction can become a new treatment to the patients who 
fail hormone ablation therapy. Understanding the interaction between AR and its binding 
partners can provide a foundation for the development of next generation drugs. 
 
We have reported that the forkhead protein, FoxA1, is critical for androgen 
regulation of prostate-specific promoters, such as human Prostate Specific Antigen, 
rodent probasin, and human/rodent Prostatic Acid Phosphatase (Gao et al., 2003). Our 
study shows that: 
1. FoxA1 binding sites exist in the PB promoter. Two elements were referred to as 
TS1 and TS2 (Tissue Specific) (Zhang J-F et al., 2010). When TS sites are mutated, the 
bioactivity is reduced only in prostatic cells lines, but not in non-prostatic cells (Gao et al., 
2003). DNA alignment of TS1 and TS2 revealed sequence similarity, EMSA and nuclear 
protein fractionation revealed nearly identical protein binding patterns of TS1 and TS2 
(Gao et al., 2003). Southwestern and EMSA disclosed that both TS1 and TS2 harbor a 
FoxA1 binding sites (Gao et al., 2003). The FoxA1 binding sites are confirmed to be 
essential for maximum induction by androgens since point mutations in FoxA1 binding 
sites block activation of the PB promoter (Gao et al., 2003). Further, southwestern 
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analyses mapped at least two small proteins bound to TS2 as 52 kDa (FoxA1) and 46 kDa 
(USF2) as well as the large protein at 113 kDa identified as AR plus additional weaker 
bands (Gao et al., 2003).  The FoxA1 and AR bands have been confirmed (Gao et al., 
2003). Mutation of the FoxA1 site prevents expression in transgenic mice (Zhang J-F et 
al., 2010). Further, the PB constructs tested in transgenic mice reveal that the fragment of 
DNA between -244 to -96 bp contains sufficient information to specifically target 
prostatic epithelium (Zhang J-F et al., 2010). This fragment of DNA contains the TS1 and 
TS2 elements which bind FoxA1. Our data strongly suggests that FoxA1 functions as a 
critical component in a TF complex that controls androgen regulated and prostate-specific 
expression of PB.  
 
2. Androgen receptor interacts with FoxA1. IP was carried out using LNCaP total 
lysate that contained endogenous AR and FoxA1 (FoxA1 has been confirmed to present 
in LNCaP, and PC-3 cells). Immunoprecipitating one antigen, AR or FoxA1, with its 
corresponding antibody simultaneously precipitated the other factor, which was detected 
by western blot. Further, the same results were obtained with GST-AR and FoxA1 (Gao 
et al., 2003).  
 
3. FoxA1 binding sites have been identified on other prostate specific gene 
promoter/enhancers. TF string search and EMSA using in vitro synthesized FoxA1 
protein identified two FoxA1 binding sites on the PSA core enhancer region reported as 
the Prostate Specific Enhancer (PSE) (Cleutjens et al., 1997; Huang et al., 1999; Schuur 
ER et al., 1996; Wu et al., 2001) and one on the PAP proximal promoter (Virkkunen et al., 
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1994). Importantly, all of three FoxA1 sites are immediately adjacent to a functional 
androgen response element and the PSA and PAP FoxA1 sites have been confirmed as 
being functional within the promoters (Gao et al., 2003). 
 
4. FoxA1 regulates prostate development. FoxA1 is expressed throughout prostate 
development and maturation and is broadly expressed in almost all epithelium 
(Mirosevich et al., 2005b). From our FoxA1 knock-out study, we observed that 
structurally aberrant epithelial ducts demonstrate a hyperproliferative feature reminiscent 
of solid primitive epithelial cords that are surrounded by thick stromal layer. The 
abnormal ductal phenotype of FoxA1-deficent prostate is accompanied by a series of 
alterations in some early signaling molecules (Gao et al., 2005a). We confirmed that the 
activation of Sonic hedgehog (Shh) and elevated FoxA2 and Notch1 in FoxA1-deficient 
prostate (Gao et al., 2005a). The prostatic protein Nkx3.1 was down regulated in the null 
epithelium (Gao et al., 2005a). Further, the siRNA to FoxA1 in LNCaP cell will cause 
LNCaP cells to die (unpublished data from our laboratory). 
 
These data show that FoxA1 plays a pivotal role in controlling prostate 
morphogenesis, cell differentiation, and proliferation. Here I propose to identify other 
transcription factors that interact with FoxA1 and function in a complex with androgen 
receptor. Androgen activates the androgen receptor to increase transcription. In order to 
do so, the spatial order and the temporal addition of proteins to the promoter must occur 
to create the TF complex. Through protein-protein and protein-DNA interactions, the 
complex is stabilized permitting the initiation of transcription. Using yeast two-hybrid 
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system, extensive research has been conducted to identify TFs that interact with the AR 
(Yeh and Chang, 1996; Fujimoto et al., 1999; Kang et al., 1999; Wang et al., 2001). 
However, by this method, no one has ever detected the interaction between FoxA1 and 
AR, indicating that this approach has missed an important TF involved in steroid receptor 
action. Since our publication on AR/FoxA1 interactions (Gao et al., 2003), others have 
implicated FoxA1 with estrogen receptor action (Carroll et al., 2005) and confirmed our 
findings with AR (Jia et al., 2008; Lupien and Brown, 2009). Recently, an estrogen 
receptor (ER) negative subset of breast cancer cells was shown to be androgen responsive 
and FoxA1 positive (Doane et al., 2006). These data suggest that FoxA1 and its binding 
partners play a significant role in hormonal regulation of not only prostate but also breast 
cancer. Thus, understanding the essential mechanism of androgen regulation can give 
insights into hormonal regulation of both prostate and breast cancer. 
 
In summary, we believe that FoxA1 and its binding partners form a protein complex 
with AR and other TFs that now direct prostate-specific gene expression. We believe that 
the same TFs complex with the AR to control PSA also will play a critical role in the 
androgen regulation of tumor growth. Purification and identification of the interacting 
partners of FoxA1 will facilitate our understanding of the role of these TFs to interact 
with the AR to regulate tumor growth. 
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Results 
Cloning of FLAG, 6His tagged human FoxA1 into retroviral vector pLPCX. 
A FLAG-6His tag was added to human FoxA1 N-terminal by PCR. The PCR 
products were cloned into pCR-TOPO 2.1 vector, then the tagged-FoxA1 was inserted 
into retroviral vector-pLPCX in frame using restriction enzymes. The sequence was 
confirmed by DNA sequencing (Figure 17). 
Figure 17. The procedure of cloning tagged-FoxA1 into a retroviral vector-pLPCX. A 
FLAG tag and 6 Histidine tag were cloned in the N-terminal of human FoxA1 cDNA by 
PCR. The PCR products were inserted into pCR-TOPO 2.1 vector (Invitrogen, Carlsbad, 
CA) and then cloned into retroviral vector pLPCX in frame (Clontech, Mountain View, 
CA). 
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Transiently Transfect HeLa cells with pLPCX-FoxA1 
pLPCX-FoxA1 was first transiently transfected into HeLa cells. HeLa cells do not 
expression endogenous FoxA1. A western blot using anti-FoxA1 antibody was done to 
examine whether tagged Foxa1 can be properly expressed in HeLa cells. LNCaP cells 
were used as a positive control (Figure 18). The result ensures that tagged FoxA1 is 
inserted in the vector in frame and can be expressed. The quantitative expression level of 
tagged FoxA1 is measured in Figure 20. 
 
 
Figure 18. The expression of tagged-FoxA1 in HeLa cells. Western blot using 
FoxA1 antibody to confirm the tagged-FoxA1 expression in transient transfected 
pLPCX-FoxA1 HeLa cells. HeLa cells do not contain endogenous FoxA1; LNCaP 
cells have endogenous FoxA1 served as positive control. 
 
 
Establish FLAG-6His FoxA1 stably expressing LNCaP, HeLa, and HeLa AR cell 
lines and determining the level of expression. 
HeLa, HeLa AR, and LNCaP cell lines were infected with pLPCX-FoxA1 vector or 
pLPCX empty vector that would serve as the control cells. Cells were first selected by 1 
ug/ml puromycin. The concentration of puromycin was then increased to a final 
 76
contraction 10 ug/ml for HeLa and HeLa AR cells, 5 ug/ml for LNCaP cells (Figure 19). 
 
 
Figure 19. The process of establishing the stable tagged FoxA1 expression cells 
lines. pLPCX-FoxA1 or empty pLPXC vectors are used to transfect Phoenix A cells to 
generate active FoxA1 or empty viral particles which are used to infect HeLa, HeLa 
AR, and LNCaP cells to generate tagged FoxA1 stable expressing cell lines and control 
cell lines. Each cell line was grown under puromycin selection. 
 
 
The expression level of tagged FoxA1 in each cell line was examined by a Western 
blot using both FoxA1 antibody and Anti-His antibody. The tagged FoxA1 level in 
LNCaP FoxA1 cell line is much higher than the endogenous FoxA1 level in LNCaP with 
empty pLPCX vector (Figure 20). Since the high level of tagged FoxA1 expression may 
not reflect the true FoxA1 level in biological system, some false positive binding partners 
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may be identified due to the high level expression of tagged FoxA1. To avoid the false 
positive binding, the identified FoxA1 binding proteins need to be subjected for further 
studies, such as IP or GST-pull down, to confirm the binding with FoxA1. HeLa FoxA1 
and HeLa cells with both AR and FoxA1 always had very low levels of FoxA1 
expression even after repeating the infection multiple times. The reasons for the low level 
of FoxA1 expression in HeLa and HeLa AR cells are unknown. 
 
                 LNCaP      LNCaP 
              Empty Vector    FoxA1 
 
 
 
 
Figure 20. The tagged FoxA1 expression level in LNCap FoxA1 
and control cell lines. In both LNCaP FoxA1 and LNCaP control 
cell lines, FoxA1 antibody was used to indicate the expression level 
of FoxA1, anti-Histidine antibody was used to indicate the 
expression of tagged FoxA1 in western blot. Beta-actin antibody 
was used as a loading control. 
 
 
Tandem Affinity Purification of tagged-FoxA1 protein complex from LNCaP FoxA1 
and LNCaP E cells. 
We have established FLAG-6His-FoxA1 stably expressing LNCaP cell line and a 
LNCaP cell line with the empty vector as the control. Both the cells were harvested at 
about 1х109 cells. Harvested cells were lysated and the nuclear extracts were prepared for 
Beta-actin Ab 
FoxA1 Ab 
Anti-His Ab 
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tandem purification. The BD TALON Single Step Column, which binds the His-tagged 
protein, was used to perform the first step purification. In the second step, ANTI-FLAG 
M2 Affinity Gel, which specifically binds to FLAG fusion proteins, was used to further 
purify the eluate from the first step (Figure 21).  
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Figure 21. The process of the Tandem Affinity Purification of tagged-FoxA1 protein 
complex from LNCaP FoxA1 and LNCaP E cell lysates. Total cells (LNCaP FoxA1 
cells and LNCaP control cells) of 109 were harvested and nuclear extract of the cells 
were prepared. The nuclear extracts were purified by using TALON column and 
anti-FLAG M2 affinity gel column respectively. The final eluated from the purification 
were collected for LC-MS/MS analysis. 
 
 
Examination of the tagged-FoxA1 expression level in the elutes of LNCaP FoxA1 
cells and LNCaP E cells. 
During tandem affinity purification, each portion from every purification step was 
collected for western blot analysis. Tagged-FoxA1 expression levels need to be examined 
in the final elutes before the liquid chromatography and tandem mass spectrometry 
analysis. In Figure 22, the flow through from the first step purification (TALON column) 
is named as “supernatant from TALON”; the flow through from the second step 
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purification (FLAG affinity gel) is named as “supernatant from Flag”. Western blot 
results indicate the flow through of LNCaP E cells from TALON column contains more 
FoxA1 than that of LNCaP FoxA1 cells, because the tagged-FoxA1 from LNCaP FoxA1 
cells is bound to the TALON column. There is no His tag detected in the first step flow 
through from both LNCaP E and LNCaP FoxA cells. The flow through of LNCaP E and 
LNCaP FoxA1 cells from the second step does not contain FoxA1, but both contain His 
tag. The final elute of LNCaP FoxA1 cells contains both high level FoxA1 and His Tag, 
but the eluate from LNCaP E cells contains neither of them. The western blot confirms 
the high level of tagged-FoxA1 in LNCaP FoxA1 cells eluate, but not in the control 
LNCaP E cells eluate. 
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Figure 22. Western blot analysis for each portion from the tandem affinity 
purification. Western blot using FoxA1 antibody to detect the expression of FoxA1 and 
using anti-Histidine antibody to detect the expression of tagged FoxA1. The lanes in A 
are the flow through of LNCaP FoxA1 cells and control cells from the first step 
purification. The lanes in B are the flow through of LNCaP FoxA1 cells and control cells 
from the second step purification. The lanes in C are the final eluate from LNCaP FoxA1 
cells and control cells. 
 
 
AR is identified in the final elute of LNCaP FoxA1 cells by western blot 
An earlier study has shown FoxA1 and AR can physically interact with each other, so 
AR can serve as a positive control during identifying the FoxA1 binding partner. AR is 
detected in the LNCaP FoxA1 cell final elute, but not in the control LNCaP E cell elute 
by western blot using AR antibody (Figure 23). The results tell us that AR can be pulled 
down together with tagged-FoxA1 during the purification. 
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Figure 23. Western blot using AR antibody indicates that AR is pulled 
down together with tagged-FoxA1 from the LNCaP FoxA1 cells. Final 
eluates from LNCaP Foxa1 cells and control cells were subject for a 
SDS-PAGE gel and using AR antibody to detect whether AR was pulled 
down together with tagged FoxA1. 
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The SDS-PAGE analysis for the final elutes following with Colloidal Blue staining 
In Figure 25, the elutes from the second step purification of both LNCaP FoxA1 cells 
and LNCaP E cells were subject to SDS-PAGE and colloidal blue staining. Select protein 
bands from the LNCaP FoxA1 eluate as well as the same region of the control gel were 
cut from the gel and the protein digested with trypsin (Figure 24). Peptide hydrosylate 
were analyzed by C18 reverse-phase LC-MS/MS using a Thermo LTQ ion trap mass 
spectrometer equipped with a Thermo MicroAS autosampler and Thermo Surveyor 
HPLC pump system, nanospray source, and Xcalibur 2.0 instrument control using 
standard data-dependent methods. Tandem MS data were analyzed with the Sequest 
algorithm against the IPI human database (135,674 entries, October 2007 release) 
including a concatenated reverse database for calculating false-discovery rate. 
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Figure 24. The SDS-PAGE analysis for the final elautes from the purification 
followed by Colloidal Blue staining. The final eluates from LNCaP FoxA1 cells 
and LNCaP control cells were separated in 10% SDS-PAGE gel. The protein bands 
were visualized by Colloidal blue staining. Protein bands from LNCaP FoxA1 cells 
were cut for trypsin digestion and LC-MS/MS analysis. The corresponding regions 
from control cells were also processed to identify non-specific bindings. 
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Identify FoxA1 binding partners by LC-MS/MS analysis 
The proteins from the complex have been identified according to the established 
procedures of the Vanderbilt MSRC. At least two peptides from two separate runs were 
used as the criteria for a positive hit. After screening and elimination of false positives, 
we identified a total of 16 proteins that appear to interact with Foxa1 (Table 2). Of 16 
proteins meeting the “hit” criteria, 7 have been previously reported to directly interact 
with AR, or an indirect link can be established. Three groups of nuclear proteins that were 
identified: 1) alter AR activity (7 proteins) while no reports exist on DNA binding protein, 
TOX HMG family # 4; 2) control protein structure/stability (2 proteins); and 3) involved 
in RNA processing (6 proteins). None of these nuclear proteins were reported by Kivinen 
et al., when they did affinity purification of nuclear proteins using a fragment of the 
probasin TS-1 sequence (Kivinen et al., 2004).  
 
The Nuclear Factor I (NFI) family of TFs contains four genes (NFIa, NFIb, NFIc, 
NFIx), that bind to the consensus DNA sequesnce TTGGCN5GCCAA (Green et al., 
1998). Knockout studies of individual NFI genes in mice result in a non-redundant 
phenotypes implying that NFI TFs are involved in tissue-specific expression (Wong et al., 
2007; Grunder et al., 2002; Steele-Perkins et al., 2003; Driller et al., 2007; Campbell et 
al., 2008). NFIx knockout mice display an agenesis of corpus callosum and a 
hydrocephalus and normally die 21 to 28 days after birth (Driller et al., 2007; Campbell 
et al., 2008). A deformation of the spine is also observed in NFIx-/- mice (Driller et al., 
2007). Embryonically, the hindgut gives rise to the prostate, bladder, rectum, and 
intestine. Since a phenotype in the intestine is reported in the NFIx-/-, it may be expected 
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that the loss of NFIx will show phenotypes in these embryonically related organs. 
Interestingly, each isoform of NFI has different specificity for estrogen receptor 
regulation of mammary gland specific differentiation markers (Murtagh et al., 2003), but 
no one has reported on the examination of the individual isoforms in terms of AR action. 
 
Nucleostemin (NS) expression is largely restricted to nucleoli of pluripotent 
embryonic stem cells, tissue stem cells, and a number of cancers including prostate 
cancer, but it absent in most adult tissues (Tsai and McKay, 2002; Liu et al., 2008). 
Traditionally, the nucleolus is recognized as the site of rRNA synthesis but now the 
nucleolus has also been linked to expression of tumor suppressor and oncogenes, cell 
senescence, and the modulation of telomerase function (Fox et al., 2002). NS is found to 
interact with Nucleophosmin (NPM) and NPM has been shown to interact with AR (Ma 
and Pederson, 2008; Leotoing et al., 2008). Guanine nucleotide binding protein-like 
3-like (GNL3L), a member of NS family, interacts with ERRgamma and can inhibit the 
transcriptional activities of ERR genes by reducing the steroid receptor coactivator 
binding (Rosen et al., 1980). An independent study recently shows that the inhibition of 
ERRgamma activity promotes growth of DU145 prostate cancer cells (Yu et al., 2007), 
and knockdown of NS in PC-3 cells decreased xenograft growth (Liu et al., 2008), 
suggesting a role of NS in prostate cancer progression. Although NS is absence in most 
adult differentiated cells, we find that NS is expressed in the normal adult mouse prostate 
tissue (unpublished data). 
 
Paraspeckle Protein 1 (PSP1) is an identified component protein of paraspeckles, a 
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nuclear body (Myojin et al., 2004). The protein contains a Drosophila Behavior Human 
Splicing (DBHS) motif that is also found in polypyrimidine tract-binding 
protein-associated splicing factor (PSF), p54nrb, and Non-POU-domain-containing 
octamer binding protein (NonO) (Myojin et al., 2004). The DBHS-containing proteins 
were known to play important roles in DNA replication, transcription, and mRNA 
processing (Myojin et al., 2004). PSP1 and PSF are reported to interact with AR and 
functions as AR coactivators to activate androgen receptor-mediated transcription 
together with other DBHS-containing proteins (Ishitani et al., 2003; Kuwahara et al., 
2006). The inner nuclear matrix structural protein Matrin 3 is found to form a complex 
with p54nrb and PSF and to play a role in controlling the export of edited mRNAs 
(Zhang and Carmichael, 2001). By interacting with PSF, Matrin 3 may indirectly interact 
with AR. 
 
DNA-dependent protein kinase (DNADPK), a member of the phosphatidylinositol 
3-kinase family, can phosphorylate the glucocorticoid receptor (Giffin et al., 1996; Giffin 
et al., 1997). The Ku subunits of DNADPK are reported to bind to PSA promoter acting 
as an AR coactivator (Mayeur et al., 2005). DNADPK is also found to regulate AR export 
through phosphorylation (Shank et al., 2008). Importantly, DNADPK has been shown to 
phosphorylate FoxA2, a forkhead protein closely related to FoxA1 (Nock et al., 2009). 
The phosphorylation of FoxA2 enhances its ability to bind to DNA (Nock et al., 2009). It 
would be reasonable to postulate that DNADPK then functions to downregulate AR 
binding to the DNA but to enhance binding of FoxA1. By enhancing FoxA1, this would 
allow the chromatin confirmation to remain accessible for re-activation by the AR. 
 88
 
Two of the proteins identified in Table 2, NFIx and NS, have been priorized for 
further study. 
 
 
 
Table 2: FOXA1 binding partners identified by tandem affinity purification 
followed by LC-MS/MS 
 
Protein kDa Function Accession # Comment 
 
Known or Potential AR Co-Regulators 
 
◊ Nuclear factor 
Ix (NFIx) 
50 Transcription 
Factor 
EAW84339 Tissue specific & NFI 
acts as AR co-regulator 
(Murtagh et al., 2003; 
Driller et al., 2007; 
Campbell et al., 2008; 
Driller et al., 2007; 
Campbell et al., 2008) 
*Para-speckle 
protein 1 α 
60 Located at nuclear 
para-speckles 
NP_00103587
9 
Interacts with 
AR(Ishitani et al., 
2003) Enhances AR 
action (Kuwahara et al., 
2006) 
◊ Nucleostemin 
(NS) 
70 Cell cycle AAV74413 Stem cell marker 
expressed in PCa (Tsai 
and McKay, 2002; Liu 
et al., 2008; Liu et al., 
2008) 
TOX HMG 
family # 4 
70 DNA binding 
protein 
NP_055643 High mobility group 
protein 
* PSF 75 Co-activator/repre
ssor 
NM_005066 Interacts with AR 
(Dong et al., 2007). AR 
co-regulator (Kuwahara 
et al., 2006). Interacts 
with Matrin-3 (Zhang 
and Carmichael, 2001) 
◊ Matrin-3 95 Nuclear matrix NP_061322 Interacts with PSF 
(Zhang and 
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Carmichael, 2001) 
*BRG-1 
associated 
factor 
180 DNA access Q86U86 Allows for AR access 
(Lemon et al., 2001) 
* DNADPK 360 Kinase NP_00107510
9 
Phosphorylates AR 
(Shank et al., 2008) 
 
Protein Stability 
 
PPCTI-4 57 PPIase EAW47800 Protein folding 
Heat shock 
cognate 
70 Protein stability BAD96505 Chaperone 
 
RNA processing 
 
Splicing factor 
3b 
25 RNA splicing Q6NT18 Nuclear protein 
HNRP 60 RNA splicing P14866 Nuclear protein 
CPASF-6 68 RNA processing Q16630 Nuclear protein 
DEAD/H BOX 
15 
90 RNA splicing EAW92821 Nuclear protein 
RNA binding 
protein 10 
100 Unknown P98175 Nuclear protein 
TAF4 RNA pol 
II 
90 Transcription NM_001358.2 Nuclear protein 
 
Table Key: * = Identified protein directly interacts with AR; ◊ =Potential of direct or 
indirect interaction with AR based upon the literature. Thus, 7/16 nuclear factors 
identified can be implicated in AR action. 
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CHAPTER V 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
Discussion 
The promoter of the rat PB gene has been extensively characterized and a small 
fragment of the PB promoter (-426 to +28 bp) has been shown to specifically target 
transgenes to mouse prostate (Greenberg et al., 1994). The testing of deletion constructs 
of the promoter fragment showed that an androgen response region (ARR: -244 to -96 bp) 
resided in this promoter (Zhang J et al., 2000). The ARR contains two strong AR binding 
sites termed ARBS1 (-236 to -223 bp) and ARBS2 (-140 to -117 bp) that function 
together in a co-operative manner (Kasper et al., 1994). Using the -244 to -96 bp 
fragment placed adjacent to -286 to +28 bp PB promoter, a new construct (ARR2PB) was 
shown to target high levels of androgen regulated gene expression specifically to the 
prostate (Zhang J et al., 2000). These studies indicated that the -286/+28 sequences 
contain the information necessary to regulate prostate-specific gene expression (Zhang J 
et al., 2000).  In order to define the minimal PB DNA sequences necessary for 
prostate-specific gene expression, a series of deletion constructs were tested in transgenic 
mice. These experiments defined that the sequences between -244 to -96 bp contained the 
necessary information to target transgene expression to the prostate (Zhang J-F et al., 
2010).  Using promoter mutagenesis analysis, EMSA assays, and transgenic mouse 
studies, we have identified key cis-acting elements in this region, including several 
transcriptional factors (Oct-1, c-jun, and NFI) and two tissue-specific elements (TS1 and 
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TS2) that bind AR, FoxA1 and USF2, which are critical for PB tissue-specific expression 
(Zhang J-F et al., 2010). 
 
Oct-1 has been reported to play an important role in androgen-regulated SLP gene 
expression in vivo (Scarlett and Robins, 1995; Scheller et al., 1996) and to be required for 
mouse mammary tumor virus (MMTV) transactivation (Prefontaine et al., 1998). Oct-1 
can directly interact with steroid receptors through its conserved POU domain 
(Prefontaine et al., 1999; Kallio et al., 1995) suggesting a conserved functional 
mechanism of action. The binding site of Oct-1 (-218/-206 bp) is located immediately 
downstream to ARBS-1 (Zhang J-F et al., 2010). The interaction between Oct-1 and AR 
on the SLP gene may occur on the PB promoter in a similar manner. Mutagenesis studies 
indicated that binding of Oct-1 in the PB promoter is important for promoter activation 
both in prostatic and and non-prostatic cells (Zhang J-F et al., 2010). 
 
Studies have demonstrated that c-jun can positively regulate AR transactivation in a 
dose-dependent manner through a direct interaction with the AR DNA-binding 
domain/hinge region (Bubulya et al., 1996). Further, c-jun promotes AR activity by 
enhancing AR DNA-binding and facilitating the ligand-dependent interaction between 
the AR amino- and carboxyl-terminals regions (Bubulya et al., 1996; Bubulya et al., 2001; 
Wise et al., 1998). On the PB promoter, the c-jun binding site (-108/-94 bp) is adjacent to 
the ARBS2 binding site (-140/-117 bp) (Zhang J-F et al., 2010).  Disruption of c-jun 
DNA-binding site dramatically decreases the PB promoter activity (Zhang J-F et al., 
2010), which suggests the transcriptional activity is modulated by cooperation between 
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AR and c-jun.  
 
The NFI family of proteins (Murtagh et al., 2003) are known to be involved in the 
regulation of several androgen dependent genes (Darne et al., 1997; Verrijdt et al., 1999). 
The in vivo glucocorticoid receptor (GR) induction of MMTV promoter involves a 
functional co-regulation between GR and NFI (Chavez and Beato, 1997). More recently, 
an unidentified NFI family member was shown to be essential for both GR-induced 
MMTV expression on naked DNA, and the recruitment of the chromatin remodeling 
enzyme BRG-1 (Hebbar and Archer, 2003) to regulatory sequence. A recent report 
indicates that NFI binding sites are significantly associated with FoxA1 binding sites in 
regions of acetylated DNA, which correlates with our finding that NFIx and FoxA1 are 
binding partners (Table 2). Linker mutagenesis, ChIP, and DNA sequence analysis 
revealed a critical NFI binding site (-88/-70 bp) in PB promoter (Zhang J-F et al., 2010). 
Mutation in NFI binding site results in a significant loss of PB promoter activity (Zhang 
J-F et al., 2010), which is consistent with a previous report showing that the binding of 
NFI to PB promoter is androgen-independent prostate cell specific (Yeung et al., 2003). 
However, our transgenic studies demonstrated that -244 to -96 bp of PB fragment is 
sufficient for the prostate specific gene expression, suggesting that the promoter binding 
by NFI is required for optimal PB gene activation in prostate cells or tissues, but not 
absolutely required for the prostatic-specific expression of the PB gene. 
 
Using linker mutation and transgenic studies, two tissue-specific DNA elements have 
been identified, which are fundamentally important for androgen-regulated 
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prostatic-specific PB promoter activation (Zhang J-F et al., 2010). The transgenic mice 
experiments demonstrated that mutation of TS1 dramatically decreased the transgene 
expression in prostate lobes whereas mutation of TS2 almost completely abolished the 
transgene activities in the transgenic mouse prostate (Zhang J-F et al., 2010). These data 
suggests that TS1 and TS2 work cooperatively to control PB gene expression in the 
prostate. Both TS1 and TS2 are adjacently positioned to ARBS1 and ARBS2 (Zhang J-F 
et al., 2010), respectively, suggesting that a fixed binding site organization maybe 
conserved due to functionally importance. The ARR2PB promoter duplicates the ARR 
region, containing four ARBS and three tissue-specific elements (one TS1 plus two TS2) 
that function cooperatively as a strong prostatic-specific promoter in vitro and in vivo 
(Farmer et al., 2001). Interestingly, TS1 and TS2 are interchangeable in biological 
function further suggesting the bind either identical or very similar factors (Zhang J-F et 
al., 2010). Southwestern experiments using 2×TS2 as probes identified two proteins that 
bind at this region (Gao et al., 2003). One protein is about 52 kDa, another is about 45 
kDa (Gao et al., 2003). The 52 kDa protein has been confirmed as FoxA1, a forkhead 
transcription factor (Gao et al., 2003). FoxA1 and AR have been identified to bind 
adjacent to each other at both ARBS1 and ARBS2 (Gao et al., 2003). FoxA1 is expressed 
in human and mouse prostate epithelium,  and FoxA1 expression is important not only 
in prostate-specific gene regulation but also in prostate development (Gao et al., 2003; 
Gao et al., 2005b). The prostates rescued from FoxA1-deficient mice display a severely 
disrupted ductal pattern resembling primitive epithelial cords, with an expansion of the 
basal cell population, and a lack of epithelial differentiation and PB expression, as well as 
other molecular alterations (Gao et al., 2005b). Interestingly, adjacently positioned 
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forkhead and AREs have also been identified in several key regulatory regions of other 
prostatic genes, including PSA core enhancer, SBP promoter, PAP promoter, etc., 
suggesting a fundamental role for FoxA1 in prostatic-specific gene expression (Gao et al., 
2003). A direct interaction between FoxA1 and AR has been observed in these promoters, 
indicating that both transcription factors cooperatively participate in the expression of 
these androgen-regulated prostate specific genes (Gao et al., 2005a). 
 
FoxA proteins activate transcription by displacing linker histones from nucleosomes 
and opening chromatin, making the local DNA region more accessible for other 
transcription factors (Cirillo et al., 1998). However, the molecular mechanisms by which 
FoxA proteins control transcription has only been partially characterized and little 
information exists on corresponding co-regulators that mediate the crosstalk of FoxA1 
with components of the general transcription machinery. FoxA1 binding sites are 
associated with glucocorticoid receptor binding sites (O'Brien et al., 1995) and are now 
recognized to be a common co-regulator with androgen receptor and estrogen receptor 
regulated genes (Gao et al., 2003; Laganiere et al., 2005; Carroll et al., 2005; DeGraff et 
al., 2009; Yu et al., 2005; Yu et al., 2006; Wang et al., 2007; Jia et al., 2008). 
Chromosome wide mapping analysis has shown that GATA2 and Oct-1 binding sites are 
also commonly associated with binding sites for AR and FoxA1 (Wang et al., 2007), and 
more recent data has identified that NFI binding sites are also commonly associated in 
this complex (Jia et al., 2008). The fact that FoxA binding sites are found adjacent to 
these other transcription factor binding sites suggests that FoxA proteins are capable of 
interacting with these proteins to control the activity of cis regulatory elements.  
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FoxA1 expression is detected early in prostate development and FoxA1 gene 
expression is necessary for normal prostate development as well as being implicated in 
the androgen regulation of prostate cancer (DeGraff et al., 2009). Thus, FoxA1 must 
regulate genes involved in development and differentiation of the prostatic luminal cells 
and androgen regulation of the growth of prostate cancer. Recent publications have 
shown that AR and adjacent FoxA1 sites are found on multiple promoters in prostatic 
cells (Jia et al., 2008; Lupien and Brown, 2009). Identifying the intermolecular 
interactions between FoxA1 and AR as well as other transcription factors as they regulate 
prostatic gene expression is necessary to understand the mechanism that results in failure 
of prostate cancer patients to androgen ablation therapy. 
 
One of the two proteins, which were identified from the Southwestern analysis with 
molecular weight about 45 kDa, we have confirmed to be USF2 protein (Sun et al., 2009). 
The present study has also identified USF2 as a novel FoxA1 interacting partner (Sun et 
al., 2009). USF2 is an E-box site binding protein which belongs to the 
basic-helix-loop-helix-leucine-zipper (bHLH-zip) family of transcription factors (Sirito et 
al., 1992). Studies suggest that USF2 functions as a tumor suppressor and can down 
regulate c-myc expression (Chen et al., 2006; Moriuchi et al., 1999; Luo and Sawadogo, 
1996). USF2 knockout mice demonstrate prostate hyperplasia indicating that USF2 plays 
an important role in prostate differentiation (Chen et al., 2006). 
 
Using the probasin GAAAATATGATA (-250 to -239 bp) sequence that overlaps with 
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ARBS1, affinity purification of transcription factors was performed and USF2 was shown 
to bind within this sequence (Kivinen et al., 2004). We confirm that USF2 does indeed 
bind to the PB promoter and that the DNA binding domains of USF2 and FoxA1 directly 
interact (Sun et al., 2009). FoxA1 binding sites exist on the PSA and SBP promoters, and 
we also show that USF2 binds to the PSA and SBP promoters (Sun et al., 2009). This 
indicates that functional binding sites for FoxA1 and USF2 are co-localized on these 
prostate-specific promoters (Sun et al., 2009). Whole-genomic mapping studies for USF1 
and USF2 binding sites show that these two transcription factors have distinct 
determinants for binding to DNA (Rada-Iglesias et al., 2008). Further, the analysis 
showed that a subset of 240 regions bound only USF2 (Rada-Iglesias et al., 2008). 
Consensus FoxA binding sites were the most abundant sites associated with these USF2 
unique sites, and FoxA binding sites were not significantly associated with USF1 binding 
sites (Rada-Iglesias et al., 2008). Furthermore, seven out of eight regions that were 
perfect matches for FoxA sites were confirmed to bind both FoxA and USF2 
(Rada-Iglesias et al., 2008). In addition, a recent study using a oligonucleotide-based 
assay to identify novel factors that bind to the ARE1 oligonucleotide from the PSA gene 
promoter indicate both FoxA1 and USF2 are bound to the region (Wong et al., 2009). In 
the present study, EMSA experiments confirmed the binding site of USF2 in the PSA 
core enhancer and show that USF1 fails to bind this region (Sun et al., 2009), in spite of 
the fact that USF2 and USF1 share a highly conserved C-terminal DNA binding domain 
(Sirito et al., 1994). These results indicate that the binding of USF2 in the PSA core 
enhancer is specific. Furthermore, USF2 binding sites were confirmed by ChIP assay on 
PB, SBP, and PSA regulatory regions, suggesting USF2 plays an important role in 
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prostate-specific promoters (Sun et al., 2009). Our studies and others (Rada-Iglesias et al., 
2008) now confirm that FoxA1 and USF2 binding sites often co-exist on multiple 
promoters.  
 
While the AR requires the presence of hormone to bind to functional cis regulatory 
sequence, FoxA1 and USF2 bind to the PB and SBP promoter both in the presence and 
absence of androgen (Sun et al., 2009). The PSA promoter contains low levels of USF2 
as measured by real-time PCR and the binding can be seen in Figure 11, where the USF2 
band shows up after 31 PCR cycles in the absence of androgens (Sun et al., 2009). The 
USF2 consensus DNA sequence is CANNTG and the matches found in PB is CAATTT, 
SBP is CAAAGT, and PSA is CAAATC. These differences between the three promoters 
may cause the differences in binding affinity of USF2.  FoxA1 plays an essential role in 
the “pioneering” of gene regulatory elements, allowing for the recruitment of additional 
factors required for gene regulation (Cirillo et al., 1998), and our data suggests that USF2 
cooperates with FoxA1 to regulate promoter activity. Changes in USF2 binding with or 
without AR activation were minimal. Thus, our results could not determine if USF2 
association is changed or unchanged by the binding of AR. As USF2 knockout mice 
develop prostate hyperplasia (Chen et al., 2006), and our data indicates that USF2 
cooperates with FoxA1 to regulate gene expression that is associated with normal 
differentiation in the prostate.  
 
As previously reported, down-regulation of FoxA1 had a limited effect on promoter 
activity following transient transfection (Carroll et al., 2005). This appears to be true for 
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USF2 as well, since down regulation USF2 expression in LNCaP cells failed to cause a 
dramatic change in ARR2PB or PSA promoter activity following transient transfection 
(Sun et al., 2009). This may be explained by the fact that in transient transfected DNA 
studies, the DNA remains naked and normal nucleosome structures do not form (Cirillo et 
al., 1998). Therefore, even though FoxA1 and USF2 knockout mice exhibit significant 
prostate phenotypes, it is reasonable to expect a limited impact of FoxA1 and USF2 
knockdown on promoter activity following transient transfection. However, the 
endogenous PSA mRNA levels slightly increased in LNCaP cells when USF2 levels were 
decreased. Even though the change of the PSA level was not statistically significant, it 
may suggest that USF2 is affecting chromatin structure of the PSA promoter that is 
absent on transient transfected DNA. 
 
Our previous studies have shown that androgen induced AR binding is adjacent to 
bound FoxA1 and that the DNA binding domain of the AR interacts with the DNA 
binding domain of FoxA1 (Gao et al., 2003). We show that USF2 is bound in a complex 
on DNA; whether FoxA1 and USF2 are bound to the same promoter at the same time or 
independent of each other we could not determined. Since FoxA1 has been reported as a 
common co-regulator of AR and ER (Gao et al., 2003; Laganiere et al., 2005; Carroll et 
al., 2005; DeGraff et al., 2009; Yu et al., 2005; Yu et al., 2006; Wang et al., 2007; Jia et al., 
2008) and USF2 can bind to the same/similar DNA sequence as FoxA1 (Rada-Iglesias et 
al., 2008), (Zhao et al., 2001) (Schuur et al., 2001; Kivinen et al., 2004)it is highly likely 
that our observation that USF2 is a co-regulator for these three androgen regulated and 
prostate-specific genes will also extend to a larger list of AR/FoxA1 (DeGraff et al., 2009) 
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as well as ER/FoxA1 regulated genes. We show that USF2 interacts with FoxA1 (Sun et 
al., 2009), and although a weak interaction of USF2 with AR has been reported (Kivinen 
et al., 2004), we could not detect the interaction of USF2 with AR (data not shown). Thus, 
USF2 may exist in a complex with the AR and other steroid receptors, but it is likely that 
the main interaction of USF2 is with FoxA1, suggesting FoxA1 acts as a bridge between 
USF2 and the AR, as well as other steroid hormone receptors. By ChIP assays, it is 
possible that we are detecting promoter sequences either bound with FoxA1 or USF2 but 
not both FoxA1 and USF2 at the same time. Also, it seems contrary that two transcription 
factors can bind to the DNA at the same site at the same time but it is possible to envision 
that the DNA is sandwiched between the these two factors. Since FoxA1 and USF2 
directly interact at the protein level via their DNA binding domains, we would expect 
protein to protein contact as well as protein to DNA contact would occur with both 
factors bound to the DNA at the same time. We have used ChIP on ChIP assay to examine 
whether the two proteins bind to the DNA the same time or not, the method could not be 
established due to the poor quality of the USF2 antibody. 
 
Working with Dr. Jonathan H Sheehan and Dr. Jarrod A Smith (Vanderbilt 
University), we have generated a computational model of protein-protein interactions that 
predicts the interaction of AR, FoxA1, and USF2 bound to probasin, a prostate specific 
promoter (Figure 25). The 3-D model is assembled manually by optimal 3-D alignment 
of the DNA oligos from the protein X-ray crystal structures with the NAB-generated 
structure of the PB promoter region using the molecular visualization program called 
UCSF Chimera (http://www.cgl.ucsf.edu/chimera) (Pettersen et al., 2004). This 3-D 
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model can mimic the binding of AR, FoxA1, and USF2 to PB promoter. Our data 
demonstrated that AR and FoxA1 bound to DNA at adjacent sites and the USF2 bound to 
the same binding site as FoxA1. Using existing X-ray crystal structures of the DNA 
binding region of AR, FoxA3, and USF1 (the X-ray crystal structure of FoxA1 and USF2 
is not available) bound to DNA, Dr. Sheehan and Smith created a model that predicted an 
interface between the AR DNA binding domain and the FoxA1 DNA binding domain. 
USF2 is predicted to binding at the same DNA site as FoxA1 but forming a clothes pin 
structure that helps secure both FoxA1 and AR to their binding sites. 
 
 
 
 
 
Figure 25. Computational modeling of AR, FoxA1, and USF2 protein interacting 
with PB promoter. The blue DNA represents the PB sequences of the prostate specific 
promoter. The red, yellow, and green proteins represent AR, FoxA1, and USF2 
respectively (see details in material and methods).  
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Using the 3-D molecular model, which is based on the experimental X-ray crystal 
structures of AR and FoxA3 bound to DNA, we have identified the interface between 
these two proteins. Within seven animo acids in the DNA binding domain of AR interface 
identified, point mutations of two amino acids (L574P and T575A) occurs in 
castrate-resistant prostate cancer and point mutation of two amino acids occurs in 
androgen insensitivity syndrome (AIS). Our lab has demonstrated that the two mutations 
found in AIS inactivate the AR. However, DHT induced AR activity was enhanced only 
in the presents of FoxA1 by 32% with the L574P mutation and 72% with the T575A 
mutation (DeGraff, unpublished data). Since this increase in AR activity only occurred 
when FoxA1 was expressed, this suggests that an increase in binding between AR and 
FoxA1 fosters an increased sensitivity to low dose androgens. This could account for 
continued AR action even when androgens are blocked in the CRPC patients. Thus, 
designing drugs to interfere with AR activity by blocking AR-FoxA1 protein interactions 
provides an achievable and unique approach to inhibit the growth of prostate cancer.  
Since we have shown that USF2 interacts with FoxA1 and binds to the same DNA site 
(Sun et al., 2009), a drug that targeted AR-FoxA1 likely would disruption of the 
AR/FoxA1/USF2 complex. In addition to AR/FoxA1/USF2, we have shown that Oct-1, 
c-jun, NFI, and other unidentified TFs are bind to the proximal PB DNA region (Zhang 
J-F et al., 2010), suggesting a large protein complex forms together to regulate 
prostate-specific gene expression. Identifying additional proteins that may also enter into 
the transcriptional complex with FoxA1 and AR can help us to discover the critical 
transcription factors that control cell type specific gene expression and provide a more 
complete understanding of prostate development. New drugs and therapies for prostate 
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cancer patients could be developed to target the key transcription factors that control AR 
activity. 
 
To identify novel FoxA1 binding partners, FLAG and 6-His tagged human FoxA1 
protein stably expressed in the LNCaP cell line was established. The LNCaP cell line is 
androgen-dependent and AR positive cell line that contains endogenous FoxA1. This cell 
line serves as a good model to study FoxA1 binding partners. The tagged FoxA1 was 
highly expressed in LNCaP cells when compared to the endogenous level of FoxA1 
(Figure 20). The high expression level of the tagged FoxA1 can reduce the DNA binding 
or protein-protein binding of the endogenous FoxA1. However, the high level of tagged 
FoxA1 expression may not reflect the true FoxA1 level in biological systems; therefore, 
some false positive binding partners may be pulled down. To avoid the false positive 
binding, the identified FoxA1 binding proteins need to be subjected for further 
protein-protein interaction studies to confirm the interactions are real. 
 
After the tandem purification of the tagged FoxA1 protein complex, LC-MS/MS 
analysis has detected 16 proteins that appear to interact with FoxA1. AR was shown to be 
pulled down together with FoxA1 (Figure 23) by western blot, but AR was not identified 
by LC-MS/MS analysis, which may be due to the low sensitivity of LC-MS/MS 
compared with western blot or immunoprecipitation. USF2 could not be identified either 
by this study, this may be due to the relatively low expression level of USF2 or low 
binding affinity with FoxA1. Of the 16 identified proteins, 7 have been previously 
reported to directly interact with AR, or an indirect link can be established. Three groups 
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of nuclear proteins that were identified: 1) alter AR activity (7 proteins) while no reports 
exist on DNA binding protein, TOX HMG family # 4; 2) control protein 
structure/stability (2 proteins); and 3) involved in RNA processing (6 proteins). None of 
these nuclear proteins were reported by Kivinen et al., when they did affinity purification 
of nuclear proteins using a fragment of the probasin that contains the TS-1 sequence and 
the AR/FoxA1 binding site (Kivinen et al., 2004). 
 
The seven proteins that co purified with FoxA1 that have been shown to associate 
with AR are most interesting. NFI TFs are involved in tissue-specific expression (Wong 
et al., 2007; Grunder et al., 2002; Steele-Perkins et al., 2003; Driller et al., 2007; 
Campbell et al., 2008), which may act in concert with AR and FoxA1 to modulate 
prostate-specific gene expression. NS is reported to involved in tumorigenesis and cell 
senescence (Fox et al., 2002) and is absent in most adult differentiated cells (Tsai and 
McKay, 2002; Liu et al., 2008); however, NS is expressed in the normal adult mouse 
prostate tissue (unpublished data), which indicates that interaction of NS with FoxA1 and 
AR suggests that NS is involved in the regulation of prostate specific gene expression. 
PSP1 is known to play important roles in DNA replication, transcription, and mRNA 
processing, suggesting that the interaction of this protein with FoxA1 may have several 
important consequences (Myojin et al., 2004). Most interestingly, Matrin 3 has been 
shown to be a major component of the nuclear matrix, suggesting that FoxA1 subnuclear 
localization is maintained by this important protein. The fact that Matrin 3 has also been 
shown to play a role in controlling the export of edited mRNAs (Zhang and Carmichael, 
2001), suggests that the interaction of FoxA1 with Matrin 3 may have important 
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consequences for the splicing of FoxA1 regulated transcripts. It is also important to note 
that the DNADPK that co-purified with FoxA1 has been shown to phosphorylate FoxA2, 
a forkhead protein closely related to FoxA1 (Nock et al., 2009). The phosphorylation of 
FoxA2 enhances its ability to bind to DNA (Nock et al., 2009). It would be reasonable to 
postulate that DNADPK then functions to downregulate AR binding to the DNA but to 
enhance binding of FoxA1. By enhancing FoxA1 binding, this would allow the chromatin 
confirmation to remain accessible for re-activation by the AR. 
 
In summary, we report a novel FoxA1 interacting partner USF2 which shares the 
same binding sites as FoxA1 in multiple prostate specific promoters. Since FoxA1 plays a 
major role in modifying chromatin structure and USF2 interacts with FoxA1 at the same 
DNA binding site, we would predict the USF2 is involved in FoxA1 regulation of 
chromatin structure. Whole-genomic mapping studies for USF1 and USF2 binding sites 
show that USF2 binding sites, but not USF1, are frequently associated with consensus 
FoxA binding sites (Rada-Iglesias et al., 2008). This supports the conclusion that the 
functional interaction between USF2 and FoxA1 is not limited to AR regulated genes and 
that this interaction play a fundamental role in FoxA1 role as a “pioneer factor”. 
 
FoxA1 functions in a cell type-specific manner to attract lineage-specific 
transcription factors. Together with the methylation of histone H3, FoxA1 forms part of 
the epigenetic signature that alters chromatin structure allowing for lineage-specific gene 
regulation (Lupien et al., 2008). This is consistent with the role of FoxA1 to serve as a 
“pioneer factor” that displaces linker histones from nucleosomes, causing an unfolding of 
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chromatin and allowing the accessibility of DNA regulation region to other TFs (Cirillo 
et al., 2002). This fundamental function of FoxA1 should play a critical role in 
chromosome organization in response to AR signaling. Prostate epithelium requires AR 
for differentiation, FoxA1 interacts directly with AR, and prostate tissue rescued from 
FoxA1 null mice exhibits abnormal histology and fails to express differentiation markers 
such as probasin (DeGraff et al., 2009). This indicated that FoxA1 expression is required 
for AR action.  
 
Transcriptional regulation not only depends on the interactions between DNA and 
binding partners, but also on the interactions among the protein-protein interactions. 16 
FoxA1 binding partners have been identified by using tandem purification followed by 
LC-MS/MS analysis. Transcriptional factor NFIx is shown to also interact with AR 
(DeGraff, unpulished data) and NS is reported to indirectly interact with AR. Both of the 
proteins are involved in prostate development and prostate cancer. A recent study using 
formaldehyde assisted isolation of regulatory elements monitored the chromatin structure 
at FoxA1 binding sites chromosome-wide and found out that a significant portion of 
FoxA1-bound sites represent a relatively closed chromatin conformation and are not 
correlated with gene expression in a certain cell type (Eeckhoute et al., 2009). 
Interestingly, the same FoxA1-bound regulatory sites are inactive in one cell type, but 
functional in another cellular context, suggesting that FoxA1 binding is required, but not 
sufficient, for a functional activity of bound enhancers in a given cell type (Eeckhoute et 
al., 2009). These findings provide evidence that other interacting partners of FoxA1 are 
necessary to define the cell-type-specific expression. 
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Future Direction 
 
We have identified some of the binding partners of FoxA1 in LNCaP cells. The same 
experimental approach will be applied to HeLa FoxA1 / HeLa E cells and HeLa AR 
FoxA1 / HeLa AR E cells. Comparing the binding partners for FoxA1 in LNCaP cells 
with that from HeLa cells will reveal which binding partners are important in prostate 
cancer cells and which are common to a non-prostatic cells. Also, by using HeLa-AR 
cells, the purification of proteins by a tagged FoxA1 may form a complex with AR that 
will identify transcription factors not seen in HeLa cells alone. 
 
Further study on the identified FoxA1 binding transcription factors will be 
performed: 
 
1. To confirm the binding between FoxA1 and the binding partners which have been 
identified by LC-MS/MS. After the identification of the FoxA1 binding partners, they 
will be assigned into classes of function, if possible. Only transcription factors identified 
as FoxA1 binding partners will be pursued at this time. Clones will be obtained, if 
necessary by PCR cloning. Confirmation of the binding between FoxA1 and these 
binding partners will be performed to avoid the false positive results by the following 
approaches: 
a) In vitro GST pull-down assay or co-IP followed with Western blot will be used to 
confirm the binding. 
b) Confocal fluorescent microscopy will be performed for colocalization, if 
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antibodies are available. 
 
2. Function analysis of the FoxA1 binding partners. After the confirmation of the 
binding between FoxA1 and other transcription factors, we will further analyze the 
function of this complex to androgen regulated gene expression. The identified 
transcription factors will be placed in an expression vector. The following experiments 
will be performed: 
a) Using the PSA-Luc and PB-Luc reporter described above, transient transfection 
with FoxA1, AR, and expression vectors for the identified transcription factors will be 
performed to test the biological activity of the FoxA1 binding partners. 
b) Since FoxA1 interacts in a complex of proteins, the newly identified binding 
partners will be characterized not only for there ability to bind to FoxA1 but also to AR 
and USF2.  
c) EMSA and supershifts using specific antibodies against the transcription factors 
will be performed using a radiolabeled oligonucleotide containing both FoxA1 and ARE 
of the human PSA core enhancer 
(5’-CCTACTCTGGAGGAACATATTGTATTGATTGTCCTTGACAGTAAACAAATCT
GTT-3’, 55bp). These experiments will test if the transcription factor binds to the DNA 
and interact with FoxA1 or if they bind by protein-protein interactions. 
d) ChIP will be performed to investigate the in vivo association of the transcription 
factors with human PSA enhancer and PB promoter. Specific antibodies against the 
transcription factors, FoxA1, and AR will be used for immunoprecipitation of 
antigen-bound transcription factors to genomic DNA fragments from LNCaP cell lysate 
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(treated with DHT or maintained in androgen-depleted medium). The DNA precipitated 
down by the antibodies will be amplified by PCR using specific primers spanning the 
tested regions. 
e) Transcription factors identified to have the greatest effect on FoxA1 activity will 
be up or down regulated by siRNA in LNCaP cells and androgen regulation of both PSA 
by Western and RT-PCR will be monitored. Further, cell proliferation will be monitored.  
In summary, by a combination of approaches, the functional importance in AR action 
of the transcription factors identified as FoxA1 binding partners will be determined. This 
information will help decipher the mechanism of AR action in controlling 
prostate-specific gene expression as well as proliferation of prostatic cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 109
REFERENCES 
 
Abate-Shen,C. and Shen,M.M. (2000). Molecular genetics of prostate cancer. Genes Dev. 
14, 2410-2434. 
Alberts,B., Bray,D., Lewis,J., Raff,M., Roberts,K., Watson,J.D., and eds (1994). Control 
of Gene Expression: Combinatorial Gene Control Is the Norm in Eucaryotes. New York 
and London. Garland Publishing, Inc. Molecular Biology of the Cell 445-453. 
Andriani,F., Nan,B., Yu,J., Li,X., Weigel,N.L., McPhaul,M.J., Kasper,S., Kagawa,S., 
Fang,B., Matusik,R.J., Denner,L., and Marcelli,M. (2001). Use of the probasin promoter 
arr(2)pb to express bax in androgen receptor-positive prostate cancer cells. J. Natl. 
Cancer Inst. 93, 1314-1324. 
Arnold,H.H. and Winter,B. (1998). Muscle differentiation: more complexity to the 
network of myogenic regulators. Curr. Opin. Genet. Dev. 8, 539-544. 
Arnone,M.I. and Davidson,E.H. (1997). The hardwiring of development: organization 
and function of genomic regulatory systems. Development 124, 1851-1864. 
Aumueller,G., Seitz,J., and Riva,A. (1994). Functional Morphology of Prostate Gland., 
A.Riva, F.Testa Riva, and P.M.Motta, eds. Kluwer Academic Publishers), pp. 61-112. 
Aumuller,G. and Seitz,J. (1990). Protein secretion and secretory processes in male 
accessory sex glands. Int. Rev. Cytol. 121, 127-231. 
Ayer,D.E., Kretzner,L., and Eisenman,R.N. (1993). Mad: a heterodimeric partner for Max 
that antagonizes Myc transcriptional activity. Cell 72, 211-222. 
Beckmann,H., Su,L.K., and Kadesch,T. (1990). TFE3: a helix-loop-helix protein that 
activates transcription through the immunoglobulin enhancer muE3 motif. Genes Dev. 4, 
167-179. 
Bhatia-Gaur,R., Donjacour,A.A., Sciavolino,P.J., Kim,M., Desai,N., Young,P., 
Norton,C.R., Gridley,T., Cardiff,R.D., Cunha,G.R., Abate-Shen,C., and Shen,M.M. 
(1999). Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 13, 966-977. 
Bieberich,C.J., Fujita,K., He,W.W., and Jay,G. (1996). Prostate-specific and 
androgen-dependent expression of a novel homeobox gene. J. Biol. Chem. 271, 
31779-31782. 
Blackwell,T.K., Kretzner,L., Blackwood,E.M., Eisenman,R.N., and Weintraub,H. (1990). 
Sequence-specific DNA binding by the c-Myc protein. Science 250, 1149-1151. 
Blackwood,E.M. and Eisenman,R.N. (1991). Max: a helix-loop-helix zipper protein that 
forms a sequence-specific DNA-binding complex with Myc. Science 251, 1211-1217. 
 110
Bodner,M., Castrillo,J.L., Theill,L.E., Deerinck,T., Ellisman,M., and Karin,M. (1988). 
The pituitary-specific transcription factor GHF-1 is a homeobox-containing protein. Cell 
55, 505-518. 
Brewster,S.F. and Simons,J.W. (1994). Gene therapy in urological oncology: principles, 
strategies and potential. Eur. Urol. 25, 177-182. 
Brivanlou,A.H. and Darnell,J.E., Jr. (2002). Signal transduction and the control of gene 
expression. Science 295, 813-818. 
Brookes,D.E., Zandvliet,D., Watt,F., Russell,P.J., and Molloy,P.L. (1998). Relative 
Activity and Specificity of Promoters from Prostate-expressed Genes. The Prostate 35, 
18-26. 
Brown,T.R., Lubahn,D.B., Wilson,E.M., French,F.S., Migeon,C.J., and Corden,J.L. 
(1990). Functional characterization of naturally occurring mutant androgen receptors 
from subjects with complete androgen insensitivity. Molecular Endocrinology 4, 
1759-1772. 
Bubulya,A., Chen,S.Y., Fisher,C.J., Zheng,Z., Shen,X.Q., and Shemshedini,L. (2001). 
c-Jun potentiates the functional interaction between the amino and carboxyl termini of the 
androgen receptor. J. Biol. Chem. 276, 44704-44711. 
Bubulya,A., Wise,S.C., Shen,X.Q., Burmeister,L.A., and Shemshedini,L. (1996). c-Jun 
can mediate androgen receptor-induced transactivation. J. Biol. Chem. 271, 24583-24589. 
Bungert,J., Kober,I., During,F., and Seifart,K.H. (1992). Transcription factor eUSF is an 
essential component of isolated transcription complexes on the duck histone H5 gene and 
it mediates the interaction of TFIID with a TATA-deficient promoter. J. Mol. Biol. 223, 
885-898. 
Campbell,C.E., Piper,M., Plachez,C., Yeh,Y.T., Baizer,J.S., Osinski,J.M., Litwack,E.D., 
Richards,L.J., and Gronostajski,R.M. (2008). The transcription factor Nfix is essential for 
normal brain development. BMC. Dev. Biol. 8, 52. 
Carey,M. (1998). The enhanceosome and transcriptional synergy. Cell 92, 5-8. 
Carr,C.S. and Sharp,P.A. (1990). A helix-loop-helix protein related to the 
immunoglobulin E box-binding proteins. Mol. Cell Biol. 10, 4384-4388. 
Carroll,J.S., Liu,X.S., Brodsky,A.S., Li,W., Meyer,C.A., Szary,A.J., Eeckhoute,J., 
Shao,W., Hestermann,E.V., Geistlinger,T.R., Fox,E.A., Silver,P.A., and Brown,M. (2005). 
Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation 
requiring the forkhead protein FoxA1. Cell 122, 33-43. 
Carthew,R.W., Chodosh,L.A., and Sharp,P.A. (1985). An RNA polymerase II 
transcription factor binds to an upstream element in the adenovirus major late promoter. 
Cell 43, 439-448. 
 111
Carthew,R.W., Chodosh,L.A., and Sharp,P.A. (1987). The major late transcription factor 
binds to and activates the mouse metallothionein I promoter. Genes Dev. 1, 973-980. 
Celis,L., Claessens,F., Peeters,B., Heyns,W., Verhoeven,G., and Rombauts,W. (1993). 
Proteins interacting with an androgen-responsive unit in the C3(1) gene intron. Mol. Cell 
Endocrinol. 94, 165-172. 
Chang,L.S., Shi,Y., and Shenk,T. (1989). Adeno-associated virus P5 promoter contains an 
adenovirus E1A-inducible element and a binding site for the major late transcription 
factor. J. Virol. 63, 3479-3488. 
Chavez,S. and Beato,M. (1997). Nucleosome-mediated synergism between transcription 
factors on the mouse mammary tumor virus promoter. Proc. Natl. Acad. Sci. U. S. A 94, 
2885-2890. 
Chen,H., Nandi,A.K., Li,X., and Bieberich,C.J. (2002). NKX-3.1 interacts with 
prostate-derived Ets factor and regulates the activity of the PSA promoter. Cancer Res 62, 
338-340. 
Chen,N., Szentirmay,M.N., Pawar,S.A., Sirito,M., Wang,J., Wang,Z., Zhai,Q., Yang,H.X., 
Peehl,D.M., Ware,J.L., and Sawadogo,M. (2006). Tumor-suppression function of 
transcription factor USF2 in prostate carcinogenesis. Oncogene 25, 579-587. 
Chodosh,L.A., Carthew,R.W., Morgan,J.G., Crabtree,G.R., and Sharp,P.A. (1987). The 
adenovirus major late transcription factor activates the rat gamma-fibrinogen promoter. 
Science 238, 684-688. 
Cirillo,L.A., Lin,F.R., Cuesta,I., Friedman,D., Jarnik,M., and Zaret,K.S. (2002). Opening 
of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and 
GATA-4. Mol. Cell 9, 279-289. 
Cirillo,L.A., McPherson,C.E., Bossard,P., Stevens,K., Cherian,S., Shim,E.Y., Clark,K.L., 
Burley,S.K., and Zaret,K.S. (1998). Binding of the winged-helix transcription factor 
HNF3 to a linker histone site on the nucleosome. EMBO J. 17, 244-254. 
Clark,K.L., Halay,E.D., Lai,E., and Burley,S.K. (1993). Co-crystal structure of the 
HNF-3/fork head DNA-recognition motif resembles histone H5. Nature 364, 412-420. 
Cleutjens,K.B., van der Korput,H.A., van Eekelen,C.C., van Rooij,H.C., Faber,P.W., and 
Trapman,J. (1997). An androgen response element in a far upstream enhancer region is 
essential for high, androgen-regulated activity of the prostate- specific antigen promoter. 
Mol. Endocrinol. 11, 148-161. 
Coffey,D.S., and Pienta,K.J. (1987). New concepts in studying the control of normal and 
cancer growth of the prostate. Prog. Clin. Biol. Res. 239, 1-73 
Cooney,K.A., Wetzel,J.C., Consolino,C.M., and Wojno,K.J. (1996). Identification and 
characterization of proximal 6q deletions in prostate cancer. Cancer Res. 56, 4150-4153. 
 112
Cunha,G.R. (1994). Role of mesenchymal-epithelial interactions in normal and abnormal 
development of the mammary gland and prostate. Cancer 74, 1030-1044. 
Cunha,G.R., Chung,L.W., Shannon,J.M., and Reese,B.A. (1980). Stromal-epithelial 
interactions in sex differentiation. Biol. Reprod. 22, 19-42. 
Cunha,G.R., Donjacour,A.A., Cooke,P.S., Mee,S., Bigsby,R.M., Higgins,S.J., and 
Sugimura,Y. (1987). The endocrinology and developmental biology of the prostate. 
Endocr. Rev. 8, 338-362. 
Cunha,G.R. and Lung,B. (1978). The possible influence of temporal factors in androgenic 
responsiveness of urogenital tissue recombinants from wild-type and androgen- 
insensitive (Tfm) mice. J. Exp. Zool. 205, 181-193. 
Cunningham,J.M., Shan,A., Wick,M.J., McDonnell,S.K., Schaid,D.J., Tester,D.J., Qian,J., 
Takahashi,S., Jenkins,R.B., Bostwick,D.G., and Thibodeau,S.N. (1996). Allelic imbalance 
and microsatellite instability in prostatic adenocarcinoma. Cancer Research. 56, 
4475-4482. 
Darne,C.H., Morel,L., Claessens,F., Manin,M., Fabre,S., Veyssiere,G., Rombauts,W., and 
Jean,C.L. (1997). Ubiquitous transcription factors NF1 and Sp1 are involved in the 
androgen activation of the mouse vas deferens protein promoter. Mol. Cell Endocrinol. 
132, 13-23. 
Day,R.N. and Maurer,R.A. (1989). The distal enhancer region of the rat prolactin gene 
contains elements conferring response to multiple hormones. Mol. Endocrinol. 3, 3-9. 
De Marzo,A.M., Platz,E.A., Sutcliffe,S., Xu,J., Gronberg,H., Drake,C.G., Nakai,Y., 
Isaacs,W.B., and Nelson,W.G. (2007). Inflammation in prostate carcinogenesis. Nat. Rev. 
Cancer 7, 256-269. 
Debes,J.D. and Tindall,D.J. (2004). Mechanisms of androgen-refractory prostate cancer. 
N. Engl. J. Med. 351, 1488-1490. 
DeGraff,D.J., Yu,X., Sun,Q., Mirosevich,J., Jin,R.J., Wang,Y.-Q., Gupta,A., Nandana,S., 
Case,T.C., Paul,M., Huang,H.-Y., Shapiro,E., Logan,S.K., Suzuki,K., Orgebin-Crist,M.C., 
and Matusik,R.J. (2009). The role of Foxa proteins in the regulation of the androgen 
receptor activity. In Androgen Action in Prostate Cancer, D.J.Tindall and J.L.Mohler, eds. 
(New York: Springer Science and Business Media), p. 587-615. 
Doane,A.S., Danso,M., Lal,P., Donaton,M., Zhang,L., Hudis,C., and Gerald,W.L. (2006). 
An estrogen receptor-negative breast cancer subset characterized by a hormonally 
regulated transcriptional program and response to androgen. Oncogene. 
Dong,X., Sweet,J., Challis,J.R., Brown,T., and Lye,S.J. (2007). Transcriptional activity of 
androgen receptor is modulated by two RNA splicing factors, PSF and p54nrb. Mol. Cell 
Biol. 27, 4863-4875. 
 113
Donjacour,A.A. and Cunha,G.R. (1993). Assessment of prostatic protein secretion in 
tissue recombinants made of urogenital sinus mesenchyme and urothelium from normal 
or androgen-insensitive mice. Endocrinology 132, 2342-2350. 
Driller,K., Pagenstecher,A., Uhl,M., Omran,H., Berlis,A., Grunder,A., and Sippel,A.E. 
(2007). Nuclear factor I X deficiency causes brain malformation and severe skeletal 
defects. Mol. Cell Biol. 27, 3855-3867. 
Du,G. and Prestwich,G.D. (1995). Protein structure encodes the ligand binding specificity 
in pheromone binding proteins. Biochemistry 34, 8726-8732. 
Eeckhoute,J., Lupien,M., Meyer,C.A., Verzi,M.P., Shivdasani,R.A., Liu,X.S., and 
Brown,M. (2009). Cell-type selective chromatin remodeling defines the active subset of 
FOXA1-bound enhancers. Genome Res. 19 , 372-380. 
Ellwood-Yen,K., Graeber,T.G., Wongvipat,J., Iruela-Arispe,M.L., Zhang,J.-F., 
Matusik,R.J., Thomas,G.V., and Sawyers,C.L. (2003). Myc-driven murine prostate cancer 
shares molecular features with human prostate tumors. Cancer Cell 4, 223-238. 
Elo,J.P., Kvist,L., Leinonen,K., Isomaa,V., Henttu,P., Lukkarinen,O., and Vihko,P. (1995). 
Mutated human androgen receptor gene detected in a prostatic cancer patient is also 
activated by estradiol. J. Clin. Endocrinol. Metab. 80, 3494-3500. 
Espinas,M.L., Roux,J., Pictet,R., and Grange,T. (1995). Glucocorticoids and protein 
kinase A coordinately modulate transcription factor recruitment at a 
glucocorticoid-responsive unit. Mol. Cell Biol. 15, 5346-5354. 
Farmer,G., Connolly,E.S., Jr., Mocco,J., and Freedman,L.P. (2001). Molecular analysis of 
the prostate-specific antigen upstream gene enhancer. Prostate 46, 76-85. 
Feldman,B.J. and Feldman,D. (2001). The development of androgen-independent 
prostate cancer. Nat. Rev. Cancer 1, 34-45. 
Fox,A.H., Lam,Y.W., Leung,A.K., Lyon,C.E., Andersen,J., Mann,M., and Lamond,A.I. 
(2002). Paraspeckles: a novel nuclear domain. Curr. Biol. 12, 13-25. 
Fry,C.J. and Peterson,C.L. (2002). Transcription. Unlocking the gates to gene expression. 
Science 295, 1847-1848. 
Fujimoto,N., Yeh,S., Kang,H.Y., Inui,S., Chang,H.C., Mizokami,A., and Chang,C. (1999). 
Cloning and characterization of androgen receptor coactivator, ARA55, in human 
prostate. J. Biol. Chem. 274, 8316-8321. 
Gann,P.H. (2002). Risk factors for prostate cancer. Rev. Urol. 4 Suppl 5, S3-S10. 
Gao,N., Ishii,K., Mirosevich,J., Kuwajima,S., Oppenheimer,S., Roberts,R.L., Jiang,M., 
Yu,X., Shappell,S., Caprioli,R.M., Stoffel,M., Hayward,S.W., and Matusik,R.J. (2005a). 
Forkhead Box A1 Regulates Prostate Ductal Morphogenesis and Promotes Epithelial Cell 
 114
Maturation. Development 132, 3431-3443. 
Gao,N., Ishii,K., Mirosevich,J., Kuwajima,S., Oppenheimer,S.R., Roberts,R.L., Jiang,M., 
Yu,X., Shappell,S.B., Caprioli,R.M., Stoffel,M., Hayward,S.W., and Matusik,R.J. (2005b). 
Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell 
maturation. Development 132, 3431-3443. 
Gao,N., Zhang,J., Rao,M.A., Case,T.C., Mirosevich,J., Wang,Y., Jin,R., Gupta,A., 
Rennie,P.S., and Matusik,R.J. (2003). The role of hepatocyte nuclear factor-3 alpha 
(Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. 
Mol. Endocrinol. 17, 1484-1507. 
Ghadersohi,A. and Sood,A.K. (2001). Prostate epithelium-derived Ets transcription factor 
mRNA is overexpressed in human breast tumors and is a candidate breast tumor marker 
and a breast tumor antigen. Clin. Cancer Res 7, 2731-2738. 
Gierer,A. (1974). Molecular models and combinatorial principles in cell differentiation 
and morphogenesis. Cold Spring Harb. Symp. Quant. Biol. 38, 951-961. 
Giffin,W., Kwast-Welfeld,J., Rodda,D.J., Prefontaine,G.G., Traykova-Andonova,M., 
Zhang,Y., Weigel,N.L., Lefebvre,Y.A., and Hache,R.J. (1997). Sequence-specific DNA 
binding and transcription factor phosphorylation by Ku Autoantigen/DNA-dependent 
protein kinase. Phosphorylation of Ser-527 of the rat glucocorticoid receptor. J. Biol. 
Chem. 272, 5647-5658. 
Giffin,W., Torrance,H., Rodda,D.J., Prefontaine,G.G., Pope,L., and Hache,R.J. (1996). 
Sequence-specific DNA binding by Ku autoantigen and its effects on transcription. 
Nature 380, 265-268. 
Gourdji,D. and Laverriere,J.N. (1994). The rat prolactin gene: a target for tissue-specific 
and hormone-dependent transcription factors. Mol. Cell Endocrinol. 100, 133-142. 
Greaves,R.F. and O'Hare,P. (1991). Sequence, function, and regulation of the Vmw65 
gene of herpes simplex virus type 2. J. Virol. 65, 6705-6713. 
Green,J.E., Greenberg,N.M., Ashendel,C.L., Barrett JC, Boone,C.W., Getzenberg,R.H., 
Henkin,J., Matusik,R.J., Janus,T.J., and Scher,H.I. (1998). Transgenic and Reconstitution 
Models of Prostate Cancer. The Prostate 36, 59-63. 
Greenberg,N.M., DeMayo,F.J., Finegold,M.J., Medina,D., Tilley,W.D., Aspinall,J.O., 
Cunha,G.R., Donjacour,A.A., Matusik,R.J., and Rosen,J.M. (1995). Prostate cancer in a 
transgenic mouse. Proc Natl Acad Sci U S A 92, 3439-3443. 
Greenberg,N.M., DeMayo,F.J., Sheppard,P.C., Barrios,R., Lebovitz,M., Finegold,M., 
Angelopoulou,R., Dodd,J.G., Duckworth,M.L., Rosen,J.M., and Matusik,R.J. (1994). The 
rat probasin gene promoter directs hormonally and developmentally regulated expression 
of a heterologous gene specifically to the prostate in transgenic mice. Molecular 
Endocrinology 8, 230-239. 
 115
Greenlee,R.T., Hill-Harmon,M.B., Murray,T., and Thun,M. (2001). Cancer statistics, 
2001. CA Cancer J. Clin. 51, 15-36. 
Gregor,P.D., Sawadogo,M., and Roeder,R.G. (1990). The adenovirus major late 
transcription factor USF is a member of the helix-loop-helix group of regulatory proteins 
and binds to DNA as a dimer. Genes Dev. 4, 1730-1740. 
Grossmann,M.E., Huang,H., and Tindall,D.J. (2001). Androgen receptor signaling in 
androgen-refractory prostate cancer. J. Natl. Cancer Inst. 93, 1687-1697. 
Grunder,A., Ebel,T.T., Mallo,M., Schwarzkopf,G., Shimizu,T., Sippel,A.E., and 
Schrewe,H. (2002). Nuclear factor I-B (Nfib) deficient mice have severe lung hypoplasia. 
Mech. Dev. 112, 69-77. 
Gutierrez-Hartmann,A., Siddiqui,S., and Loukin,S. (1987). Selective transcription and 
DNase I protection of the rat prolactin gene by GH3 pituitary cell-free extracts. Proc. Natl. 
Acad. Sci. U. S. A 84, 5211-5215. 
Halazonetis,T.D. and Kandil,A.N. (1991). Determination of the c-MYC DNA-binding 
site. Proc. Natl. Acad. Sci. U. S. A 88, 6162-6166. 
Hayashi,N., Cunha,G.R., and Parker,M. (1993). Permissive and instructive induction of 
adult rodent prostatic epithelium by heterotypic urogenital sinus mesenchyme. Epithelial. 
Cell Biol. 2, 66-78. 
Hebbar,P.B. and Archer,T.K. (2003). Nuclear factor 1 is required for both 
hormone-dependent chromatin remodeling and transcriptional activation of the mouse 
mammary tumor virus promoter. Mol. Cell Biol. 23, 887-898. 
Heinlein,C.A. and Chang,C. (2004). Androgen receptor in prostate cancer. Endocr. Rev. 
25, 276-308. 
Hua,V.N. and Schaeffer,A.J. (2004). Acute and chronic prostatitis. Med. Clin. North Am. 
88, 483-494. 
Huang,W., Shostak,Y., Tarr,P., Sawyers,C., and Carey,M. (1999). Cooperative Assembly 
of Androgen Receptor into a Nucleoprotein Complex That Regulates the Prostate-specific 
Antigen Enhancer. J. Biol. Chem. 274, 25756-25768. 
Huggins,C. and Hodges,C.V. (1941). The Effect of Castration, of Estrogen and of 
Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate. 
Cancer Res. 1, 293-297. 
Ingraham,H.A., Chen,R.P., Mangalam,H.J., Elsholtz,H.P., Flynn,S.E., Lin,C.R., 
Simmons,D.M., Swanson,L., and Rosenfeld,M.G. (1988). A tissue-specific transcription 
factor containing a homeodomain specifies a pituitary phenotype. Cell 55, 519-529. 
Isaacs,J.T. and Coffey,D.S. (1989). Etiology and disease process of benign prostatic 
 116
hyperplasia. Prostate Suppl 2, 33-50. 
Ishitani,K., Yoshida,T., Kitagawa,H., Ohta,H., Nozawa,S., and Kato,S. (2003). p54nrb 
acts as a transcriptional coactivator for activation function 1 of the human androgen 
receptor. Biochem. Biophys. Res. Commun. 306, 660-665. 
Jackson,S.M., Keech,C.A., Williamson,D.J., and Gutierrez-Hartmann,A. (1992). 
Interaction of basal positive and negative transcription elements controls repression of the 
proximal rat prolactin promoter in nonpituitary cells. Mol. Cell Biol. 12, 2708-2719. 
Jia,L., Berman,B.P., Jariwala,U., Yan,X., Cogan,J.P., Walters,A., Chen,T., Buchanan,G., 
Frenkel,B., and Coetzee,G.A. (2008). Genomic androgen receptor-occupied regions with 
different functions, defined by histone acetylation, coregulators and transcriptional 
capacity. PLoS. ONE. 3, e3645. 
Kaestner,K.H., Hiemisch,H., Luckow,B., and Schutz,G. (1994). The HNF-3 gene family 
of transcription factors in mice: gene structure, cDNA sequence, and mRNA distribution. 
Genomics 20, 377-385. 
Kaestner,K.H., Hiemisch,H., and Schutz,G. (1998). Targeted disruption of the gene 
encoding hepatocyte nuclear factor 3gamma results in reduced transcription of 
hepatocyte-specific genes. Mol. Cell Biol. 18, 4245-4251. 
Kaestner,K.H., Katz,J., Liu,Y., Drucker,D.J., and Schutz,G. (1999). Inactivation of the 
winged helix transcription factor HNF3alpha affects glucose homeostasis and islet 
glucagon gene expression in vivo. Genes Dev. 13, 495-504. 
Kaestner,K.H., Knochel,W., and Martinez,D.E. (2000). Unified nomenclature for the 
winged helix/forkhead transcription factors. Genes Dev. 14, 142-146. 
Kallio,P.J., Poukka,H., Moilanen,A., Janne,O.A., and Palvimo,J.J. (1995). Androgen 
receptor-mediated transcriptional regulation in the absence of direct interaction with a 
specific DNA element. Mol. Endocrinol. 9, 1017-1028. 
Kang,H.Y., Yeh,S., Fujimoto,N., and Chang,C. (1999). Cloning and characterization of 
human prostate coactivator ARA54, a novel protein that associates with the androgen 
receptor. J. Biol. Chem. 274, 8570-8576. 
Kasper,S. and Matusik,R.J. (2000). Rat Probasin: Structure and Function of an Outlier 
Lipocalin. Biochim. Biophys. Acta 1482 , 249-258. 
Kasper,S., Rennie,P.S., Bruchovsky,N., Lin,L., Cheng,H., Snoek,R., Dahlman-Wright,K., 
Gustafsson,J.A., Shui,R., Sheppard,P.C., and Matusik,R.J. (1999). Selective activation of 
the probasin androgen responsive region by steroid hormones. Journal of Molecular 
Endocrinology 22, 313-325. 
Kasper,S., Rennie,P.S., Bruchovsky,N., Sheppard,P.C., Cheng,H., Lin,L., Shiu,R.P.C., 
Snoek,R., and Matusik,R.J. (1994). Cooperative binding of androgen receptors to two 
 117
DNA sequences is required for androgen induction of the probasin gene. J. Biol. Chem. 
269, 31763-31769. 
Kasper,S., Sheppard,P.C., Yan,Y., Pettigrew,N., Borowsky,A.D., Prins,G.S., Dodd,J.G., 
Duckworth,M.L., and Matusik,R.J. (1998). Development, Progression And 
Androgen-Dependence of Prostate Tumors in Transgenic: A Model For Prostate Cancer. 
Laboratory Investigation 78, 319-334. 
Kaufmann,E. and Knochel,W. (1996). Five years on the wings of fork head. Mech. Dev. 
57, 3-20. 
Kazemi-Esfarjani,P., Beitel,L., Trifiro,M., Kaufman,M., Rennie,P.S., Sheppard,P.C., 
Matusik,R.J., and Pinsky,L. (1993). Substitution of valine 865 by methionine or leucine 
causes complete or partial androgen insensitivity, respectively with distinct androgen 
receptor phenotypes. Molecular Endocrinology 7, 37-46. 
Kim,J.Y., Kim,H.J., Kim,K.T., Park,Y.Y., Seong,H.A., Park,K.C., Lee,I.K., Ha,H., 
Shong,M., Park,S.C., and Choi,H.S. (2004). Orphan nuclear receptor small heterodimer 
partner represses hepatocyte nuclear factor 3/Foxa transactivation via inhibition of its 
DNA binding. Mol. Endocrinol. 18, 2880-2894. 
Kivinen,A., Patrikainen,L., Kurkela,R., Porvari,K., and Vihko,P. (2004). USF2 is 
connected to GAAAATATGATA element and associates with androgen 
receptor-dependent transcriptional regulation in prostate. Prostate 59, 190-202. 
Klezovitch,O., Chevillet,J., Mirosevich,J., Roberts,R.L., Matusik,R.J., and Vasioukhin,V. 
(2004). Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 6, 
185-195. 
Kops,G.J. and Burgering,B.M. (1999). Forkhead transcription factors: new insights into 
protein kinase B (c-akt) signaling. J. Mol. Med.  77, 656-665. 
Kote-Jarai,Z., Leongamornlert,D., Tymrakiewicz,M., Field,H., Guy,M., Al Olama,A.A., 
Morrison,J., O'Brien,L., Wilkinson,R., Hall,A., Sawyer,E., Muir,K., Hamdy,F., 
Donovan,J., Neal,D., Easton,D., and Eeles,R. (2010). Mutation analysis of the MSMB 
gene in familial prostate cancer. Br. J. Cancer 102, 414-418. 
Krongrad,A. and Droller,M.J. (1993). Anatomy of the prostate. In Prostate Diseases, 
H.Lepor and R.K.Lawson, eds. (Philadelphia: W.B Saunders Company), pp. 17-27. 
Kumar,A.S., Gonzales,L.W., and Ballard,P.L. (2000). Transforming growth factor-beta(1) 
regulation of surfactant protein B gene expression is mediated by protein 
kinase-dependent intracellular translocation of thyroid transcription factor-1 and 
hepatocyte nuclear factor 3. Biochim. Biophys. Acta  1492, 45-55. 
Kumar,V.L. and Majumder,P.K. (1995). Prostate gland: structure, functions and 
regulation. Int. Urol. Nephrol. 27, 231-243. 
 118
Kuwahara,S., Ikei,A., Taguchi,Y., Tabuchi,Y., Fujimoto,N., Obinata,M., Uesugi,S., and 
Kurihara,Y. (2006). PSPC1, NONO, and SFPQ are expressed in mouse Sertoli cells and 
may function as coregulators of androgen receptor-mediated transcription. Biol. Reprod. 
75, 352-359. 
Laganiere,J., Deblois,G., Lefebvre,C., Bataille,A.R., Robert,F., and Giguere,V. (2005). 
From the Cover: Location analysis of estrogen receptor alpha target promoters reveals 
that FOXA1 defines a domain of the estrogen response. Proc. Natl. Acad. Sci. U. S. A 
102, 11651-11656. 
Lai,E., Prezioso,V.R., Smith,E., Litvin,O., Costa,R.H., and Darnell,J.E., Jr. (1990). 
HNF-3A, a hepatocyte-enriched transcription factor of novel structure is regulated 
transcriptionally. Genes Dev. 4, 1427-1436. 
Lai,E., Prezioso,V.R., Tao,W.F., Chen,W.S., and Darnell,J.E., Jr. (1991). Hepatocyte 
nuclear factor 3 alpha belongs to a gene family in mammals that is homologous to the 
Drosophila homeotic gene fork head. Genes Dev. 5, 416-427. 
Latil,A., Baron,J.C., Cussenot,O., Fournier,G., Soussi,T., Boccon-Gibod,L., Le Duc,A., 
Rouesse,J., and Lidereau,R. (1994). Genetic alterations in localized prostate cancer: 
identification of a common region of deletion on chromosome arm 18q. Genes 
Chromosomes. Cancer 11, 119-125. 
Latil,A., Cussenot,O., Fournier,G., Driouch,K., and Lidereau,R. (1997). Loss of 
heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three 
independent regions. Cancer Res 57, 1058-1062. 
Lee,J., Demissie,K., Lu,S.E., and Rhoads,G.G. (2007). Cancer incidence among 
Korean-American immigrants in the United States and native Koreans in South Korea. 
Cancer Control 14, 78-85. 
Lemaigre,F.P., Courtois,S.J., Lafontaine,D.A., and Rousseau,G.G. (1989). Evidence that 
the upstream stimulatory factor and the Sp1 transcription factor bind in vitro to the 
promoter of the human-growth-hormone gene. Eur. J. Biochem. 181, 555-561. 
Lemon,B., Inouye,C., King,D.S., and Tjian,R. (2001). Selectivity of 
chromatin-remodelling cofactors for ligand-activated transcription. Nature 414, 924-928. 
Leotoing,L., Meunier,L., Manin,M., Mauduit,C., Decaussin,M., Verrijdt,G., Claessens,F., 
Benahmed,M., Veyssiere,G., Morel,L., and Beaudoin,C. (2008). Influence of 
nucleophosmin/B23 on DNA binding and transcriptional activity of the androgen receptor 
in prostate cancer cell. Oncogene 27, 2858-2867. 
Liu,R.L., Zhang,Z.H., Zhao,W.M., Wang,M., Qi,S.Y., Li,J., Zhang,Y., Li,S.Z., and Xu,Y. 
(2008). Expression of nucleostemin in prostate cancer and its effect on the proliferation 
of PC-3 cells. Chin Med. J. (Engl. ) 121, 299-304. 
Lowe,S.L., Rubinchik,S., Honda,T., McDonnell,T.J., Dong,J.Y., and Norris,J.S. (2001). 
 119
Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis 
in LNCaP prostate cancer cells. Gene Ther. 8, 1363-1371. 
Luo,X. and Sawadogo,M. (1996). Antiproliferative properties of the USF family of 
helix-loop-helix transcription factors. Proc. Natl. Acad. Sci. U. S. A 93, 1308-1313. 
Lupien,M. and Brown,M. (2009). Cistromics of hormone-dependent cancer. Endocr. 
Relat Cancer 16, 381-389. 
Lupien,M., Eeckhoute,J., Meyer,C.A., Wang,Q., Zhang,Y., Li,W., Carroll,J.S., Liu,X.S., 
and Brown,M. (2008). FoxA1 translates epigenetic signatures into enhancer-driven 
lineage-specific transcription. Cell 132, 958-970. 
Lyon,M.F. and Hawkes,S.G. (1970). X-linked gene for testicular feminization in the 
mouse. Nature 227, 1217-1219. 
Ma,H. and Pederson,T. (2008). Nucleophosmin Is a Binding Partner of Nucleostemin in 
Human Osteosarcoma Cells. Mol. Biol. Cell. 
Macke T. and Case D.A. (1998). Modeling unusual nucleic acid structures. In Molecular 
Modeling of Nucleic Acids, N.B. Leontes and J. SantaLucia, Jr., eds. Washington, DC: 
American Chemical Society, 379-393 
Matuo,Y., Nishi,N., Negi,T., Tanaka,Y., and Wada,F. (1982). Isolation and 
characterization of androgen-dependent non-histone chromosomal protein from 
dorsolateral prostate of rats. Biochem. Biophys. Res. Commun. 109, 334-340. 
Matusik,R.J., Jin,R.J., Sun,Q., Wang,Y.-Q., Yu,X., Gupta,A., Nandana,S., Case,T.C., 
Paul,M., Mirosevich,J., Oottamasathien,S., and Thomas,J. (2008). Prostate Epithelial Cell 
Fate. Differentiation 76, 682-698. 
Maurer,R.A. and Notides,A.C. (1987). Identification of an estrogen-responsive element 
from the 5'-flanking region of the rat prolactin gene. Mol. Cell Biol. 7, 4247-4254. 
Mayeur,G.L., Kung,W.J., Martinez,A., Izumiya,C., Chen,D.J., and Kung,H.J. (2005). Ku 
is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer 
cells. J. Biol. Chem. 280, 10827-10833. 
Mirosevich,J., Gao,N., Gupta,A., Shappell,S., Jove,R., and Matusik,R.J. (2005a). The 
expression and role of Foxa proteins in prostate cancer. Prostate In Press. 
Mirosevich,J., Gao,N., and Matusik,R.J. (2005b). Expression of foxa transcription factors 
in the developing and adult murine prostate. The Prostate 62, 339-352. 
Miyamoto,N.G., Moncollin,V., Egly,J.M., and Chambon,P. (1985). Specific interaction 
between a transcription factor and the upstream element of the adenovirus-2 major late 
promoter. EMBO J. 4, 3563-3570. 
 120
Moriuchi,M., Moriuchi,H., Margolis,D.M., and Fauci,A.S. (1999). USF/c-Myc enhances, 
while Yin-Yang 1 suppresses, the promoter activity of CXCR4, a coreceptor for HIV-1 
entry. J. Immunol. 162, 5986-5992. 
Murre,C., McCaw,P.S., and Baltimore,D. (1989). A new DNA binding and dimerization 
motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell 
56, 777-783. 
Murtagh,J., Martin,F., and Gronostajski,R.M. (2003). The Nuclear Factor I (NFI) gene 
family in mammary gland development and function. J. Mammary. Gland. Biol. 
Neoplasia. 8, 241-254. 
Myojin,R., Kuwahara,S., Yasaki,T., Matsunaga,T., Sakurai,T., Kimura,M., Uesugi,S., and 
Kurihara,Y. (2004). Expression and functional significance of mouse paraspeckle protein 
1 on spermatogenesis. Biol. Reprod. 71, 926-932. 
Newcomer,M.E. (1995). Retinoid-binding proteins: structural determinants important for 
function. FASEB J. 9, 229-239. 
Nock,A., Ascano,J.M., Jones,T., Barrero,M.J., Sugiyama,N., Tomita,M., Ishihama,Y., and 
Malik,S. (2009). Identification of DNA-dependent protein kinase as a cofactor for the 
forkhead transcription factor FoxA2. J. Biol. Chem. 284, 19915-19926. 
O'Brien,R.M., Noisin,E.L., Suwanichkul,A., Yamasaki,T., Lucas,P.C., Wang,J.C., 
Powell,D.R., and Granner,D.K. (1995). Hepatic nuclear factor 3- and hormone-regulated 
expression of the phosphoenolpyruvate carboxykinase and insulin-like growth 
factor-binding protein 1 genes. Mol. Cell Biol. 15, 1747-1758. 
Oettgen,P., Finger,E., Sun,Z., Akbarali,Y., Thamrongsak,U., Boltax,J., Grall,F., Dube,A., 
Weiss,A., Brown,L., Quinn,G., Kas,K., Endress,G., Kunsch,C., and Libermann,T.A. 
(2000). PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with 
the androgen receptor and activates prostate-specific antigen gene expression. J. Biol. 
Chem. 275, 1216-1225. 
Pani,L., Overdier,D.G., Porcella,A., Qian,X., Lai,E., and Costa,R.H. (1992). Hepatocyte 
nuclear factor 3 beta contains two transcriptional activation domains, one of which is 
novel and conserved with the Drosophila fork head protein. Mol. Cell Biol. 12, 
3723-3732. 
Pettersen,E.F., Goddard,T.D., Huang,C.C., Couch,G.S., Greenblatt,D.M., Meng,E.C., and 
Ferrin,T.E. (2004). UCSF Chimera--a visualization system for exploratory research and 
analysis. J. Comput. Chem. 25, 1605-1612. 
Philip,R., Brunette,E., Kilinski,L., Murugesh,D., McNally,M.A., Ucar,K., Rosenblatt,J., 
Okarma,T.B., and Lebkowski,J.S. (1994). Efficient and sustained gene expression in 
primary T lymphocytes and primary and cultured tumor cells mediated by 
adeno-associated virus plasmid DNA complexed to cationic liposomes. Mol. Cell Biol. 
14, 2411-2418. 
 121
Pinsky,L., Trifiro,M., Kaufman,M., Beitel,L.K., Mhatre,A., Kazemi-Esfarjani,P., 
Sabbaghian,N., Lumbroso,R., Alvarado,C., Vasiliou,M., and et al (1992). Androgen 
resistance due to mutation of the androgen receptor. Clinical & Investigative Medicine - 
Medecine Clinique Et Experimentale 15, 456-472. 
Potter,J.J., Cheneval,D., Dang,C.V., Resar,L.M., Mezey,E., and Yang,V.W. (1991). The 
upstream stimulatory factor binds to and activates the promoter of the rat class I alcohol 
dehydrogenase gene. J. Biol. Chem. 266, 15457-15463. 
Prefontaine,G.G., Lemieux,M.E., Giffin,W., Schild-Poulter,C., Pope,L., LaCasse,E., 
Walker,P., and Hache,R.J. (1998). Recruitment of octamer transcription factors to DNA 
by glucocorticoid receptor. Mol. Cell Biol. 18, 3416-3430. 
Prefontaine,G.G., Walther,R., Giffin,W., Lemieux,M.E., Pope,L., and Hache,R.J. (1999). 
Selective binding of steroid hormone receptors to octamer transcription factors 
determines transcriptional synergism at the mouse mammary tumor virus promoter. J. 
Biol. Chem. 274, 26713-26719. 
Prendergast,G.C., Lawe,D., and Ziff,E.B. (1991). Association of Myn, the murine 
homolog of max, with c-Myc stimulates methylation-sensitive DNA binding and ras 
cotransformation. Cell 65, 395-407. 
Prendergast,G.C. and Ziff,E.B. (1991). Methylation-sensitive sequence-specific DNA 
binding by the c-Myc basic region. Science 251, 186-189. 
Qian,X. and Costa,R.H. (1995). Analysis of hepatocyte nuclear factor-3 beta protein 
domains required for transcriptional activation and nuclear targeting. Nucleic Acids Res 
23, 1184-1191. 
Quigley,C.A., De Bellis,A., Marschke,K.B., el Awady,M.K., Wilson,E.M., and French,F.S. 
(1995). Androgen receptor defects: historical, clinical, and molecular perspectives. 
Endocr. Rev. 16, 271-321. 
Rada-Iglesias,A., Ameur,A., Kapranov,P., Enroth,S., Komorowski,J., Gingeras,T.R., and 
Wadelius,C. (2008). Whole-genome maps of USF1 and USF2 binding and histone H3 
acetylation reveal new aspects of promoter structure and candidate genes for common 
human disorders. Genome Res 18, 380-392. 
Reisman,D. and Rotter,V. (1993). The helix-loop-helix containing transcription factor 
USF binds to and transactivates the promoter of the p53 tumor suppressor gene. Nucleic 
Acids Res. 21, 345-350. 
Rennie,P.S., Bruchovsky,N., Leco,K.J., Sheppard,P.C., McQueen,S.A., Cheng,H., 
Block,M.E., MacDonald,B.S., Nickel,B.E., Chang,C., Liao,S., Cattini,P.A., and 
Matusik,R.J. (1993). Characterization of two cis-acting elements involved in the 
androgen regulation of the probasin gene. Molecular Endocrinology 7, 23-36. 
Riccio,A., Pedone,P.V., Lund,L.R., Olesen,T., Olsen,H.S., and Andreasen,P.A. (1992). 
 122
Transforming growth factor beta 1-responsive element: closely associated binding sites 
for USF and CCAAT-binding transcription factor-nuclear factor I in the type 1 
plasminogen activator inhibitor gene. Mol. Cell Biol. 12, 1846-1855. 
Rivero,V.E., Motrich,R.D., Maccioni,M., and Riera,C.M. (2007). Autoimmune etiology 
in chronic prostatitis syndrome: an advance in the understanding of this pathology. Crit 
Rev. Immunol. 27, 33-46. 
Robyr,D., Gegonne,A., Wolffe,A.P., and Wahli,W. (2000). Determinants of vitellogenin 
B1 promoter architecture. HNF3 and estrogen responsive transcription within chromatin. 
J. Biol. Chem. 275, 28291-28300. 
Rosen,J.M., Matusik,R.J., Richards,D.A., Gupta,P., and Rodgers,J.R. (1980). 
Multihormonal regulation of casein gene expression at the transcriptional and 
posttransciptional levels in the mammary gland. Recent Progress In Hormone Research 
36, 157-193. 
Roy,A.K., Lavrovsky,Y., Song,C.S., Chen,S., Jung,M.H., Velu,N.K., Bi,B.Y., and 
Chatterjee,B. (1999). Regulation of androgen action. Vitam. Horm. 55:309-52, 309-352. 
Saric,T., Brkanac,Z., Troyer,D.A., Padalecki,S.S., Sarosdy,M., Williams,K., Abadesco,L., 
Leach,R.J., and O'Connell,P. (1999). Genetic pattern of prostate cancer progression. Int. J. 
Cancer 81, 219-224. 
Sasaki,H. and Hogan,B.L. (1993). Differential expression of multiple fork head related 
genes during gastrulation and axial pattern formation in the mouse embryo. Development 
118, 47-59. 
Sato,M., Ishizawa,S., Yoshida,T., and Shibahara,S. (1990). Interaction of upstream 
stimulatory factor with the human heme oxygenase gene promoter. Eur. J. Biochem. 188, 
231-237. 
Sawadogo,M. and Roeder,R.G. (1985). Interaction of a gene-specific transcription factor 
with the adenovirus major late promoter upstream of the TATA box region. Cell 43, 
165-175. 
Sawadogo,M., Van Dyke,M.W., Gregor,P.D., and Roeder,R.G. (1988). Multiple forms of 
the human gene-specific transcription factor USF. I. Complete purification and 
identification of USF from HeLa cell nuclei. J. Biol. Chem. 263, 11985-11993. 
Scarlett,C.O. and Robins,D.M. (1995). In vivo footprinting of an androgen-dependent 
enhancer reveals an accessory element integral to hormonal response. Mol. Endocrinol. 9, 
413-423. 
Scheller,A., Scheinman,R.I., Thompson,E., Scarlett,C.O., and Robins,D.M. (1996). 
Contextual dependence of steroid receptor function on an androgen-responsive enhancer. 
Mol. Cell Endocrinol. 121, 75-86. 
 123
Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, and Henderson DR 
(1996). Prostate-specific antigen expression is regulated by an upstream enhancer. 
Journal of Biological Chemistry 7043-7051. 
Schuur,E.R., Loktev,A.V., Sharma,M., Sun,Z., Roth,R.A., and Weigel,R.J. (2001). 
Ligand-dependent interaction of estrogen receptor-alpha with members of the forkhead 
transcription factor family. J. Biol. Chem. 276, 33554-33560. 
Scotto,K.W., Kaulen,H., and Roeder,R.G. (1989). Positive and negative regulation of the 
gene for transcription factor IIIA in Xenopus laevis oocytes. Genes Dev. 3, 651-662. 
Shank,L.C., Kelley,J.B., Gioeli,D., Yang,C.S., Spencer,A., Allison,L.A., and Paschal,B.M. 
(2008). Activation of the DNA-dependent protein kinase stimulates nuclear export of the 
androgen receptor in vitro. J. Biol. Chem. 283, 10568-10580. 
Simardi,L.H., Tobias-MacHado,M., Kappaz,G.T., Taschner,G.P., Potts,J.M., and 
Wroclawski,E.R. (2004). Influence of asymptomatic histologic prostatitis on serum 
prostate-specific antigen: a prospective study. Urology 64, 1098-1101. 
Sirito,M., Lin,Q., Maity,T., and Sawadogo,M. (1994). Ubiquitous expression of the 43- 
and 44-kDa forms of transcription factor USF in mammalian cells. Nucleic Acids Res. 22, 
427-433. 
Sirito,M., Walker,S., Lin,Q., Kozlowski,M.T., Klein,W.H., and Sawadogo,M. (1992). 
Members of the USF family of helix-loop-helix proteins bind DNA as homo- as well as 
heterodimers. Gene Expr. 2, 231-240. 
Sornson,M.W., Wu,W., Dasen,J.S., Flynn,S.E., Norman,D.J., O'Connell,S.M., 
Gukovsky,I., Carriere,C., Ryan,A.K., Miller,A.P., Zuo,L., Gleiberman,A.S., Andersen,B., 
Beamer,W.G., and Rosenfeld,M.G. (1996). Pituitary lineage determination by the Prophet 
of Pit-1 homeodomain factor defective in Ames dwarfism. Nature 384, 327-333. 
Spence,A.M., Sheppard,P.C., Davie,J.R., Matuo,Y., Nishi,N., McKeehan,W.L., Dodd,J.G., 
and Matusik,R.J. (1989). Regulation of a bifunctional mRNA results in synthesis of 
secreted and nuclear probasin. Proceedings of the National Academy of Sciences of the 
United States of America 86, 7843-7847. 
Stafford,J.M., Wilkinson,J.C., Beechem,J.M., and Granner,D.K. (2001). Accessory 
factors facilitate the binding of glucocorticoid receptor to the phosphoenolpyruvate 
carboxykinase gene promoter. J. Biol. Chem. 276, 39885-39891. 
Steele-Perkins,G., Butz,K.G., Lyons,G.E., Zeichner-David,M., Kim,H.J., Cho,M.I., and 
Gronostajski,R.M. (2003). Essential role for NFI-C/CTF transcription-replication factor 
in tooth root development. Mol. Cell Biol.  23, 1075-1084. 
Sugimura,Y., Cunha,G.R., Donjacour,A.A., Bigsby,R.M., and Brody,J.R. (1986). 
Whole-mount autoradiography study of DNA synthetic activity during postnatal 
development and androgen-induced regeneration in the mouse prostate. Biol. Reprod. 34, 
 124
985-995. 
Sun,Q., Yu,X., DeGraff,D.J., and Matusik,R.J. (2009). Upstream stimulatory factor 2, a 
novel FoxA1-interacting protein, is involved prostate specific gene expression. Molecular 
Endocrinology 23, 2038-2047. 
Takahashi,S., Shan,A.L., Ritland,S.R., Delacey,K.A., Bostwick,D.G., Lieber,M.M., 
Thibodeau,S.N., and Jenkins,R.B. (1995). Frequent loss of heterozygosity at 7q31.1 in 
primary prostate cancer is associated with tumor aggressiveness and progression. Cancer 
Res. 55, 4114-4119. 
Taplin,M.E., Bubley,G.J., Shuster,T.D., Frantz,M.E., Spooner,A.E., Ogata,G.K., 
Keer,H.N., and Balk,S.P. (1995). Mutation of the androgen-receptor gene in metastatic 
androgen- independent prostate cancer. N. Engl. J. Med. 332, 1393-1398. 
Tsai,R.Y. and McKay,R.D. (2002). A nucleolar mechanism controlling cell proliferation 
in stem cells and cancer cells. Genes Dev. 16, 2991-3003. 
Vallet,V., Antoine,B., Chafey,P., Vandewalle,A., and Kahn,A. (1995). Overproduction of 
a truncated hepatocyte nuclear factor 3 protein inhibits expression of liver-specific genes 
in hepatoma cells. Mol. Cell Biol. 15, 5453-5460. 
Verrijdt,G., Schoenmakers,E., Alen,P., Haelens,A., Peeters,B., Rombauts,W., and 
Claessens,F. (1999). Androgen specificity of a response unit upstream of the human 
secretory component gene is mediated by differential receptor binding to an essential 
androgen response element. Mol. Endocrinol. 13, 1558-1570. 
Virkkunen,P., Hedberg,P., Palvimo,J.J., Birr,E., Porvari,K., Ruokonen,M., Taavitsainen,P., 
Janne,O.A., and Vihko,P. (1994). Structural comparison of human and rat 
prostate-specific acid phosphatase genes and their promoters: identification of putative 
androgen response elements. Biochem. Biophys. Res. Commun. 202, 49-57. 
Wakao,H., Schmitt-Ney,M., and Groner,B. (1992). Mammary gland-specific nuclear 
factor is present in lactating rodent and bovine mammary tissue and composed of a single 
polypeptide of 89 kDa. J. Biol. Chem. 267, 16365-16370. 
Wang,J.C., Stromstedt,P.E., O'Brien,R.M., and Granner,D.K. (1996). Hepatic nuclear 
factor 3 is an accessory factor required for the stimulation of phosphoenolpyruvate 
carboxykinase gene transcription by glucocorticoids. Mol. Endocrinol. 10, 794-800. 
Wang,Q., Li,W., Liu,X.S., Carroll,J.S., Janne,O.A., Keeton,E.K., Chinnaiyan,A.M., 
Pienta,K.J., and Brown,M. (2007). A hierarchical network of transcription factors governs 
androgen receptor-dependent prostate cancer growth. Mol. Cell 27, 380-392. 
Wang,X., Yeh,S., Wu,G., Hsu,C.L., Wang,L., Chiang,T., Yang,Y., Guo,Y., and Chang,C. 
(2001). Identification and characterization of a novel androgen receptor coregulator 
ARA267-alpha in prostate cancer cells. J. Biol. Chem. 276, 40417-40423. 
 125
Wang,Y., Kasper,S., Yuan,J., Jin,R.J., Zhang,J., Ishii,K., Wills,M.L., Hayward,S.W., and 
Matusik,R.J. (2006). Androgen-dependent prostate epithelial cell selection by targeting 
ARR(2)PBneo to the LPB-Tag model of prostate cancer. Lab Invest 86, 1074-1088. 
Waterman,M.L., Adler,S., Nelson,C., Greene,G.L., Evans,R.M., and Rosenfeld,M.G. 
(1988). A single domain of the estrogen receptor confers deoxyribonucleic acid binding 
and transcriptional activation of the rat prolactin gene. Mol. Endocrinol. 2, 14-21. 
Weigel,D. and Jackle,H. (1990). The fork head domain: a novel DNA binding motif of 
eukaryotic transcription factors? Cell 63 , 455-456. 
Wen,Y., Giri,D., Yan,D.H., Spohn,B., Zinner,R.G., Xia,W., Thompson,T.C., Matusik,R.J., 
and Hung,M.C. (2003). Prostate-specific antitumor activity by probasin 
promoter-directed p202 expression. Mol. Carcinog. 37, 130-137. 
Wiener,J.S., Teague,J.L., Roth,D.R., Gonzales,E.T., Jr., and Lamb,D.J. (1997). Molecular 
biology and function of the androgen receptor in genital development. J. Urol. 157, 
1377-1386. 
Wise,S.C., Burmeister,L.A., Zhou,X.F., Bubulya,A., Oberfield,J.L., Birrer,M.J., and 
Shemshedini,L. (1998). Identification of domains of c-Jun mediating androgen receptor 
transactivation. Oncogene 16, 2001-2009. 
Wong,H.Y., Demmers,J.A., Bezstarosti,K., Grootegoed,J.A., and Brinkmann,A.O. (2009). 
DNA dependent recruitment of DDX17 and other interacting proteins by the human 
androgen receptor. Biochim. Biophys. Acta 1794, 193-198. 
Wong,Y.W., Schulze,C., Streichert,T., Gronostajski,R.M., Schachner,M., and Tilling,T. 
(2007). Gene expression analysis of nuclear factor I-A deficient mice indicates delayed 
brain maturation. Genome Biol. 8, R72. 
Wu,L., Matherly,J., Smallwood,A., Adams,J.Y., Billick,E., Belldegrun,A., and Carey,M. 
(2001). Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene 
therapy vectors. Gene Ther. 8, 1416-1426. 
Xie,X., Zhao,X., Liu,Y., Zhang,J., Matusik,R.J., Slawin,K.M., and Spencer,D.M. (2001). 
Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death 
switch for the treatment of prostate cancer. Cancer Res. 61, 6795-6804. 
Xu,Q., Nakanishi,T., Sekimizu,K., and Natori,S. (1994). Cloning and identification of 
testis-specific transcription elongation factor S-II. J. Biol. Chem. 269, 3100-3103. 
Yamamoto,M., Gao,F., Furuichi,M., Ichiyoshi,Y., and Endo,H. (1989). A LINE 1 
sequence interrupts the rat alpha 2u globulin gene. Biochim. Biophys. Acta 1008, 
322-328. 
Yan,Y., Sheppard,P.C., Kasper,S., Lin,L., Hoare,S., Kapoor,A., Dodd,J.G., 
Duckworth,M.L., and Matusik,R.J. (1997). A large fragment of the probasin promoter 
 126
targets high levels of transgene expression to the prostate of transgenic mice. The 
Prostate 32, 129-139. 
Yeh,S. and Chang,C. (1996). Cloning and characterization of a specific coactivator, 
ARA70, for the androgen receptor in human prostate cells. Proceedings. of. the. National. 
Academy. of. Sciences. of. the. United. States. of. America. 93, 5517-5521. 
Yeh,S., Tsai,M.Y., Xu,Q., Mu,X.M., Lardy,H., Huang,K.E., Lin,H., Yeh,S.D., 
Altuwaijri,S., Zhou,X., Xing,L., Boyce,B.F., Hung,M.C., Zhang,S., Gan,L., and Chang,C. 
(2002). Generation and characterization of androgen receptor knockout (ARKO) mice: an 
in vivo model for the study of androgen functions in selective tissues. Proc. Natl. Acad. 
Sci. U. S. A 99, 13498-13503. 
Yeung,L.H., Read,J.T., Sorenson,P., Nelson,C.C., Jia,W., and Rennie,P.S. (2003). 
Identification and characterization of a prostate-specific androgen-independent 
protein-binding site in the probasin promoter. Biochem. J. 371, 843-855. 
Yu,D.C., Chen,Y., Seng,M., Dilley,J., and Henderson,D.R. (1999). The addition of 
adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor 
xenografts [In Process Citation]. Cancer Res. 59, 4200-4203. 
Yu,S., Wang,X., Ng,C.F., Chen,S., and Chan,F.L. (2007). ERRgamma suppresses cell 
proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate 
cancer cells and its implication as a therapeutic target for prostate cancer. Cancer Res. 67, 
4904-4914. 
Yu,X., Gupta,A., Wang,Y.-Q., Suzuki,K., Mirosevich,J., Orgebin-Crist,M.C., and 
Matusik,R.J. (2005). Foxa1 and Foxa2 interact with the androgen receptor to regulate 
prostate and epididymal genes differentially. Annals New York Academy of Sciences 
1061, 77-93. 
Yu,X., Suzuki,K., Wang,Y., Gupta,A., Jin,R., Orgebin-Crist,M.C., and Matusik,R. (2006). 
The role of forkhead box A2 to restrict androgen-regulated gene expression of lipocalin 5 
in the mouse epididymis. Mol. Endocrinol. 20, 2418-2431. 
Zaret,K. (1999). Developmental competence of the gut endoderm: genetic potentiation by 
GATA and HNF3/fork head proteins. Dev. Biol. 209, 1-10. 
Zenklusen,J.C., Thompson,J.C., Troncoso,P., Kagan,J., and Conti,C.J. (1994). Loss of 
heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene 
at 7q31.1. Cancer Res. 54, 6370-6373. 
Zervos,A.S., Gyuris,J., and Brent,R. (1993). Mxi1, a protein that specifically interacts 
with Max to bind Myc-Max recognition sites. Cell 72, 223-232. 
Zhang J-F, Gao,N., DeGraff,D.J., Yu,X., Sun,Q., Case,T.C., and Matusik,R.J. (2010). 
Characterization of cis-elements of the probasin promoter necessary for prostate-specific 
probasin gene expression. The Prostate Mar 5. 
 127
Zhang J, Thomas,T.Z., Kasper,S., and Matusik,R.J. (2000). A small composite probasin 
promoter confers high levels of prostate-specific gene expression through regulation by 
androgens and glucocorticoid in vitro and in vivo. Endocrinology 141, 4698-4710. 
Zhang,J., Thomas,T.Z., Kasper,S., and Matusik,R.J. (2000). A small composite probasin 
promoter confers high levels of prostate-specific gene expression through regulation by 
androgens and glucocorticoids in vitro and in vivo. Endocrinology 141, 4698-4710. 
Zhang,Z. and Carmichael,G.G. (2001). The fate of dsRNA in the nucleus: a 
p54(nrb)-containing complex mediates the nuclear retention of promiscuously A-to-I 
edited RNAs. Cell 106, 465-475. 
Zhao,H.H., Herrera,R.E., Coronado-Heinsohn,E., Yang,M.C., Ludes-Meyers,J.H., 
Seybold-Tilson,K.J., Nawaz,Z., Yee,D., Barr,F.G., Diab,S.G., Brown,P.H., Fuqua,S.A., 
and Osborne,C.K. (2001). Forkhead homologue in rhabdomyosarcoma functions as a 
bifunctional nuclear receptor-interacting protein with both coactivator and corepressor 
functions. J. Biol. Chem. 276, 27907-27912. 
Zhou,Y.B., Gerchman,S.E., Ramakrishnan,V., Travers,A., and Muyldermans,S. (1998). 
Position and orientation of the globular domain of linker histone H5 on the nucleosome. 
Nature 395, 402-405. 
Zwartkruis,F., Hoeijmakers,T., Deschamps,J., and Meijlink,F. (1991). Characterization of 
the murine Hox-2.3 promoter: involvement of the transcription factor USF (MLTF). 
Mech. Dev. 33, 179-190. 
 
